,id,ticker,title,category,content,date,provider,url,article_id
129277,350792,ACAD,After Hours Gainers   Losers  08 08 2018 ,news,Top Gainers  YELP  11 3   SAIL  10 3   CVNA  9 8   MFIN  9 4   ROKU  9 2  Top Losers  AKBA  12 5   TLGT  12 3   ELF  10 3   ACAD  8 7   ENBL  8 3  Now read ,2018-08-08,Seeking Alpha,https://www.investing.com/news/stock-market-news/after-hours-gainers--losers-08082018-1566638,1566638
129281,350796,ACAD,Acadia Pharma finance chief bids adieu,news,ACADIA Pharmaceuticals   NASDAQ ACAD  EVP and Chief Financial Officer Todd Young will leave the company on October 31 to accept a position at another healthcare company SVP  Investor Relations Elena Ridloff  CFA will serve as interim CFO Now read ,2018-10-29,Seeking Alpha,https://www.investing.com/news/stock-market-news/acadia-pharma-finance-chief-bids-adieu-1664738,1664738
129306,350821,ACAD,ACADIA  ACAD  Up More Than 100  In The Past Year  Here s Why,opinion,Shares of ACADIA Pharmaceuticals Inc    NASDAQ ACAD   have skyrocketed 111 4  in the past year versus the  decrease of 2 8  The company s sole marketed drug Nuplazid  pimavanserin  is the first and the only FDA approved treatment for hallucinations and delusions associated with Parkinson s disease psychosis In the first nine months of 2019  Nuplazid recorded sales of  240 8 million  reflecting a surge of 46 6  year over year Following a strong performance during the third quarter of 2019  ACADIA raised its full year 2019 net sales guidance for Nuplazid to  330  340 million from the earlier projection of  320  330 million Several additional studies on Nuplazid targeting different types of neurological and psychiatric disorders are currently ongoing  The drug is being evaluated in the phase III HARMONY study for treating dementia related psychosis  DRP   Other studies include the phase III ENHANCE study for schizophrenia inadequate response  the phase II ADVANCE study for addressing schizophrenia negative symptoms and the phase III CLARITY study as an adjunctive treatment of major depressive disorder Notably  in September 2019  Nuplazid met the primary endpoint in the phase III HARMONY study by showing statistically significant superiority over placebo in increasing the time to relapse of dementia related psychosis  ACADIA is planning to meet the FDA authorities for discussing a possible submission of a supplemental new drug application for Nupalzid to treat DRP in the first half of 2020 In November 2019  ACADIA announced positive top line results from the phase II ADVANCE study  which met its primary goal A potential approval for any of the above indications will be a significant boost to the company Meanwhile  ACADIA initiated a phase III study on its investigational candidate trofinetide in October 2019 for the treatment of Rett syndrome  a rare neurodevelopmental congenital CNS disorder for treating girls aged between five and 20 years Currently  ACADIA has no approved product in its portfolio other than Nupalzid  Therefore  the company s sole dependence on a single drug is a concern  Thus  any regulatory setback for Nupalzid could hurt sales significantly for ACADIA  Moreover  competition from other companies  such as Axsome Therapeutics   NASDAQ AXSM   which has four CNS product candidates  is a headwind ACADIA Pharmaceuticals Inc  Price   Zacks Rank   Stocks to ConsiderACADIA currently carries a Zacks Rank  3  Hold   Better ranked stocks in the biotech sector include Repligen Corporation   NASDAQ RGEN   and Epizyme  Inc    NASDAQ EPZM    both sporting a Zacks Rank  1  Strong Buy   You can see  Repligen s earnings estimates have moved 0 9  north for 2020 over the past 60 days  The stock has soared 71 2  in the past year Epizyme s loss per share estimates have narrowed 1  for 2020 over the past 60 days  The stock has surged 167 1  in the past year 7 Best Stocks for the Next 30 DaysJust released  Experts distill 7 elite stocks from the current list of 220 Zacks Rank  1 Strong Buys  They deem these tickers  Most Likely for Early Price Pops  Since 1988  the full list has beaten the market more than 2X over with an average gain of  24 6  per year  So be sure to give these hand picked 7 your immediate attention ,2020-01-16,Zacks Investment Research,https://www.investing.com/analysis/acadia-acad-up-more-than-100-in-the-past-year-heres-why-200499647,200499647
129307,350822,ACAD,ACADIA up 18  on Q2 beat,news,ACADIA Pharmaceuticals   ACAD  17 5   heads north on more than double normal volume on the heels of its Q2 results released after the close yesterday Nuplazid sales continue to ramp  up almost 100  sequentially  includes  3 6M associated with the change in accounting treatment to sell in revenue recognition from sell through method  and up 154  since Q4 2016 Previously  ACADIA Pharma beats by  0 17  beats on revenue  Aug  8 Now read ,2017-08-09,Seeking Alpha,https://www.investing.com/news/stock-market-news/acadia-up-18-on-q2-beat-516556,516556
129308,350823,ACAD,Healthcare   Top 5 Gainers   Losers as of 11 00 am,news,Gainers  NTRA  27   ACHN  26   ACAD  18   IPXL  15   CBLI  13  Losers  SGRY  38   TBPH  18   PGNX  16   BLCM  15   NSTG  11  Now read ,2017-08-09,Seeking Alpha,https://www.investing.com/news/stock-market-news/healthcare--top-5-gainers--losers-as-of-1100-am-516576,516576
129309,350824,ACAD,ACADIA launches late stage study of Nuplazid in dementia related psychosis  shares ahead 4  after hours,news,ACADIA Pharmaceuticals   NASDAQ ACAD  is up 4  after hours on robust volume on the heels of its announcement of the start of a Phase 3 clinical trial  HARMONY  assessing NUPLAZID  pimavanserin  for the treatment of hallucinations and delusions associated with dementia related psychosis  a Breakthrough Therapy tagged indication HARMONY will have a 12 week open label stabilization period during which participants will receive a daily dose of 34 mg  20 mg if clinically justified  of pimavanserin  Afterward  those who meet prespecified criteria for treatment response will be randomized to continue to receive daily pimavanserin  34 mg or 20 mg  or placebo for up to 26 weeks  The primary endpoint is time to relapse in the double blind period NUPLAZID is currently approved in the U S  to treat hallucinations and delusions associated with Parkinson s disease psychosis The company will host a conference call today at 5 00 pm ET to discuss the study Previously  Acadia giving up gains as investors realize the  successful  mid stage of pimavanserin failed to achieve the primary endpoint  Dec  20  2016 Now read ,2017-10-04,Seeking Alpha,https://www.investing.com/news/stock-market-news/acadia-launches-latestage-study-of-nuplazid-in-dementiarelated-psychosis-shares-ahead-4-after-hours-536990,536990
129310,350825,ACAD,Mid stage study of Acadia s pimavanserin hits primary endpoint  but fails on key secondaries  shares down 7 ,news,ACADIA Pharmaceuticals   ACAD  6 9   slumps on almost double normal volume in response to final results from a Phase 2 clinical trial  the  019 Study  assessing NUPLAZID  pimavanserin  for the treatment of Alzheimer s disease psychosis  The data were presented at the 10th Clinical Trials on Alzheimer s Disease meeting in Boston The study met its primary endpoint demonstrating a statistically significant treatment effect versus placebo as measured by a scale called NPI NH Psychosis score at week 6 Pimavanserin failed to statistically separate from placebo on key secondary endpoints measured by two scales  ADCS CGIC and CMAI SF and on the exploratory endpoints of change of NPI NH Psychosis score at week 12 or a scale measuring daily activities called ADCS ADL A Phase 3 study  HARMONY  assessing pimavanserin for the treatment of hallucinations and delusions associated with dementia related psychosis is underway with an estimated completion date of March 2020  The primary endpoint is the time to relapse up to week 26  but the specific metric is not provided Previously  Acadia giving up gains as investors realize the  successful  mid stage of pimavanserin failed to achieve the primary endpoint  Dec  20  2016 Now read ,2017-11-06,Seeking Alpha,https://www.investing.com/news/stock-market-news/midstage-study-of-acadias-pimavanserin-hits-primary-endpoint-but-fails-on-key-secondaries-shares-down-7-820352,820352
129311,350826,ACAD,Premarket Losers as of 9 05 am  2 28 2018 ,news,FTR  24  on Q4 earnings ELF  10  on Q4 earnings ATRA  9  on negative analyst action ACAD  9  on Q4 earnings LOW  8  on Q4 earnings MNKD  8  ZSAN  6  CELG  6  on ozanimod fumble PZZA  5  on Q4 earnings EOG  5  on Q4 earnings  Now read ,2018-02-28,Seeking Alpha,https://www.investing.com/news/stock-market-news/premarket-losers-as-of-905-am-2282018-1316943,1316943
129312,350827,ACAD,Healthcare   Top 5 Gainers   Losers as of 11 00 am  2 28 2018 ,news,Gainers  ECYT  27   FPRX  14   IVTY  13   AHPI  13   HSKA  12  Losers  ZSAN  22   ACAD  16   CYH  16   GNMK  13   TSRO  12  Now read ,2018-02-28,Seeking Alpha,https://www.investing.com/news/stock-market-news/healthcare--top-5-gainers--losers-as-of-1100-am-2282018-1317295,1317295
129313,350828,ACAD,ACADIA down 17  after Q4 Nuplazid sales disappoint,news,ACADIA Pharmaceuticals   ACAD  16 6   slumps on over triple normal volume after it posted Q4 results yesterday after the close  Revenue of  43 6M was a bit shy of consensus   0 72M  NUPLAZID  pimavanserin  accounted for all sales  Its Q4 tally was up 263  yoy  The company expects NUPLAZID to generate  255M   270M in sales this year  Consensus view is currently   260M  Q1 sales should be  45M   48M  up  7  sequentially  midpoint  Now read ,2018-02-28,Seeking Alpha,https://www.investing.com/news/stock-market-news/acadia-down-17-after-q4-nuplazid-sales-disappoint-1317291,1317291
129340,350855,ACAD,Teladoc  TDOC  To Report Q3 Earnings  What s In The Cards ,opinion,"Teladoc Health  Inc    NYSE TDOC    the global leader in virtual care  will release third quarter 2019 results on Oct 30  2019  after market close The Zacks Consensus Estimate stands at a loss of 40 cents per share  The company had reported loss of 34 cents in the year ago quarter  The consensus mark for revenues is pegged at  136 18 million  indicating 23  increase from the year ago period reported figure In the last reported quarter  Teladoc Health sustained a loss of 41 cents per share  which was a penny wider than the Zacks Consensus Estimate of a loss of 40 cents per share   The loss can be attributed to higher operating expenses than revenues Higher visit revenues  which are attributable to increased adoption of virtual care and benefits from the company s diversification strategy  are likely to have aided the company s third quarter performance The acquisition of Advance Medical  made last year  is likely to have benefited the company s revenues by increasing membership in the quarter under review Teladoc s Behavioral Health business is likely to have been one of the strongest drivers of visit growth in the third quarter  The company might have witnessed increased engagement in its business to business service in terms increased number of visits In its Health Plan business  the company is likely to have witnessed growth in terms of new distribution and penetration of existing relationships in the to be reported quarter  This area continues to diversify with wins in new lines of business  population and geographies both commercial and government programs   Teladoc recently expanded its relationship with a major Blues plan and continued to increase penetration into its largest client s books of business  where its sales velocity is healthy and on track with expectations  This is likely to have benefited the company s performance in the to be reported quarter Teladoc is likely to have witnessed higher visit fee revenue driven by increase in U S  paid membership visits as well as individuals with visit fee only access in the third quarter  The U S  paid membership visits include revenues from general medical visits as well as other specialty visits primarily comprised of expert medical and commercial behavioral health services  The balance of visit fee revenue is primarily comprised of the company s visit fee only access Operating expenses are likely to have increased in the third quarter as the company continued to gain from operating leverage Company s GuidanceFor the third quarter of 2019  the company expects total revenues between  135 million and  138 million and an EBITDA loss in the range of  10 5  12 5 million  Adjusted EBITDA is projected between  7 million and  9 million  total U S  paid membership is expected in the range of 28 5 million to 29 5 million and visit fee only access to be available to approximately 10 million individuals Total visit is expected between 800 000 and 900 000 in the quarter and net loss per share between a loss of  0 40 and  0 42  based on 72 3 million weighted average shares outstanding Earnings Surprise HistoryThe company boasts an attractive earnings surprise history  having surpassed estimates in three of the four reported quarters with an average positive surprise of 4 4   This is depicted in the graph below Teladoc Health  Inc  Price and EPS Surprise    What Our Model SaysOur proven model does not conclusively predict an earnings beat for Teladoc this season  The combination of a positive  and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  increases the odds of an earnings beat  But that s not the case here Earnings ESP  Earnings ESP  which represents the difference between the Most Accurate Estimate and the Zacks Consensus Estimate  is  0 69   You can uncover the best stocks to buy or sell before they re reported with our  Zacks Rank  Currently  the company carries a Zacks Rank  3 Stocks Worth a LookHere are a few healthcare stocks worth considering as these have the right combination of elements to beat on earnings in the upcoming quarterly results Amgen Inc    NASDAQ AMGN   has an Earnings ESP of  0 04  and a Zacks Rank of 3 
You can see  
ACADIA Pharmaceuticals Inc    NASDAQ ACAD   has an Earnings ESP of  5 44  and a Zacks Rank 3 Mednax Inc    NYSE MD   has an Earnings ESP of  1 1  and carries a Zacks  3 Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ",2019-10-27,Zacks Investment Research,https://www.investing.com/analysis/teladoc-tdoc-to-report-q3-earnings-whats-in-the-cards-200479117,200479117
129341,350856,ACAD,Cigna  CI  To Report Q3 Earnings  What s In The Offing ,opinion,"Cigna Corp    NYSE CI   will release third quarter 2019 results on Oct 31  before market open The Zacks Consensus Estimate for the company s earnings per share is pegged at  4 37  indicating an increase of 13 8  from the year ago quarter reported figure  The consensus mark for revenues is pegged at  34 1 billion  suggesting an increase of 198  from the year ago quarter reported figure In the last reported quarter  Cigna s earnings of  4 3 per share beat the Zacks Consensus Estimate by 15 3  and grew 10 5  year over year  led by accretion from Express Scripts  NASDAQ ESRX  acquisition Factors at PlayCigna s Integrated Medical segment is likely to have driven revenues on customer growth  deepening of customer relationships  premium growth reflecting underlying cost trends  and the inclusion of Express Scripts and Medicare Part D business  The segment is likely to have seen an increase in global medical customers  led by growth in select and middle market segments In the company s Health Services segment  earnings are likely to have benefited from organic growth due to the addition of new pharmacy customers  strong volumes of adjusted pharmacy scripts fulfilled and continued improvement in specialty pharmacy The company s International business is expected to have benefited from business growth and strong margins  partially offset by unfavorable foreign currency impacts Group Disability and Life business is likely to have witnessed growth owing to solid performance in disability and life Overall third quarter earnings are likely to have gained from strong medical and specialty contributions and continued effective medical cost management Medical cost ratio  MCR   which measures cost to revenues  is likely to have increased year over year in the quarter under review  driven by the inclusion of Express Scripts and Medicare Part D business  the pricing effect due to the suspension of health insurance tax  and a higher MCR in its individual business Cigna s debt levels are likely to have declined in the third quarter  as it prioritizes to repay debt that was taken to fund the purchase of Express Scripts  Share repurchases made by the company during the third quarter are likely to have aided the bottom line Earnings SurpriseThe company boasts an attractive earnings surprise history  having surpassed estimates in three of the four reported quarters with an average positive surprise of 7 02   This is depicted in the graph below Cigna Corporation Price and EPS Surprise     
What Our Model SaysOur proven model does not conclusively predict an earnings beat for Cigna this season  The combination of a positive  and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  increases the odds of an earnings beat  But that s not the case here Earnings ESP  Earnings ESP  which represents the difference between the Most Accurate Estimate and the Zacks Consensus Estimate  is  0 82   You can uncover the best stocks to buy or sell before they re reported with our Zacks Rank  Currently  the company carries a Zacks Rank  3 Stocks Worth a LookHere are a few healthcare stocks worth considering as these have the right combination of elements to beat on earnings in the upcoming quarterly results Amgen Inc    NASDAQ AMGN   has an Earnings ESP of  0 04  and a Zacks Rank of 3 
You can see  
ACADIA Pharmaceuticals Inc    NASDAQ ACAD   has an Earnings ESP of  5 44  and a Zacks Rank 3 Mednax Inc    NYSE MD   has an Earnings ESP of  1 1  and carries a Zacks  3 Breakout Biotech Stocks with Triple Digit Profit PotentialThe biotech sector is projected to surge beyond  775 billion by 2024 as scientists develop treatments for thousands of diseases  They re also finding ways to edit the human genome to literally erase our vulnerability to these diseases Zacks has just released Century of Biology  7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance  Our recent biotech recommendations have produced gains of  98    119  and  164  in as little as 1 month  The stocks in this report could perform even better ",2019-10-29,Zacks Investment Research,https://www.investing.com/analysis/cigna-ci-to-report-q3-earnings-whats-in-the-offing-200479399,200479399
129342,350857,ACAD,ACADIA And Dynavax Shares Set To Move Higher,opinion,"Stock Charts To Watch 
Applied Optoelectronics  Inc   AAOI 
  Applied Opt   NASDAQ AAOI  popped out in Sept  I put a swing on it that didn t work  it backed off  popped out  pulled back  and had a nice day on Monday  jumping 1 27  or 12   to 12 15  with a high of 12 58  on 1 9 million shares on Monday  It looks like it broke out of a base  Watch for a run that tests the 12 3 4 13 as early as Tuesday  If it takes that out  you might see something in the 14 1 2 3 4 zone  and then the secondary target is up at 18  It looks like it might be turning around 
 ACADIA Pharmaceuticals Inc   ACAD ACADIA  NASDAQ ACAD  broke out of a coil on Monday or at least the wedge that I pointed out over the weekend  with a pop of 2 63  or 6 17   to 45 24  reaching 45 87  on 2 6 million shares  Breaking out of that range now tells me that it s headed to 51  and then 54 55 
Dynavax Technologies Corporation  DVAX 
Dynavax Technologies  NASDAQ DVAX  popped 40 cents  or 7 6   to 5 66  with a high of 5 69  on 1 1 million shares on Monday  I put a swing target on this stock in Sept  it rolled back  expanded the base  broke out  flagged  popped  retested  and popped again on Monday  It looks like this is going higher  Targets are 6 1 2 and 8  going forward 
 InMode  INMD InMode  NASDAQ INMD  had another explosive day on Monday  and popped 4 97  or 12 29   to 45 41  with a high of 46 24  on 1 9 million shares  The volume doubled  You can see the top of the angle of ascent is 49  which is the target  and may happen as early as Tuesday  as well 
Nektar Therapeutics  NKTR 
 Nektar Therapeutics   NASDAQ NKTR  popped  pulled back  got up to 22 48 on Monday  before pulling back  It jumped 94 cents  or 4 69   to 20 98  on 7 15 million shares  Sometimes  as I said  they break out  get into a gap  pull back and extend  That s exactly what NKTR did  Targets are 24 5  28  and 31 going forward 
ShockWave Medical  Inc   SWAV 
 Shockwave Medical   NASDAQ SWAV  may be going  with a big reversal downward on Friday  and then back up again on Monday  jumping 2 08  or 6 11   to 36 14  with a high of 35 53  on 321 557 shares traded  I like it s chances  Targets are 38 1 2 and 43 1 2 
Stocks on the long sideApplied Optoelectronics  Inc   AAOI   ACADIA Pharmaceuticals Inc   ACAD   Adverum Biotechnologies  Inc   ADVM   Agenus Inc   AGEN   Digital Turbine  Inc   APPS   Aquestive Therapeutics  Inc   AQST   Constellation Pharmaceuticals  Inc   CNST   Corcept Therapeutics Incorporated  CORT   Dynavax Technologies Corporation  DVAX   Entercom Communications Corp   ETM   Gravity Co   Ltd   GRVY  InMode Ltd   INMD   Jounce Therapeutics  Inc   JNCE   Kodiak Sciences Inc   KOD   Repro Med Systems  Inc   KRMD   Nektar Therapeutics  NKTR   Invitae Corporation  NVTA   ShockWave Medical  Inc   SWAV   and TechTarget  Inc   TTGT  ",2019-11-11,Harry Boxer,https://www.investing.com/analysis/acadia-and-dynavax-shares-set-to-move-higher-200484433,200484433
129343,350858,ACAD,Medtronic  MDT  To Report Q2 Earnings  What s In Store ,opinion,Medtronic plc   NYSE MDT   is scheduled to report second quarter fiscal 2020 results on Nov 19  before the opening bell In the last reported quarter  the company s earnings beat the Zacks Consensus Estimate by 6 8   Moreover  the bottom line outpaced estimates in the trailing four quarters  the average being 5 8  Let s see how things are shaping up prior to this announcement Key CatalystsWe are upbeat about Medtronic s successful execution of growth strategies  such as therapy innovation  globalization and increase in economic value  Combined with the demographics of an aging population  these positives opened up wide opportunities for the company  which might get reflected in the upcoming quarterly results The therapy innovation space has been seeing multiple developments  Under Cardiac and Vascular Group  CVG   new therapies are helping the company gain traction from the rapidly growing MedTech market for left ventricular assist device  transcatheter aortic valve replacement  drug coated balloons  atrial fibrillation ablation and insertable diagnostics Medtronic PLC Price and EPS Surprise   There has been a gradually stabilizing trend in the global cardiac rhythm and heart failure  CRHF  market  In the fiscal second quarter  the company is expected to have registered strong growth in its ICD  implantable cardioverter defibrillator  and CRT  cardiac resynchronization therapy  product lines within the scope of CRHF  banking on product launch and creation of meaningful markets Strong demand for the company s Micra transcatheter pacing system  Valiant Navion thoracic stent graft  VenaSeal Closure System  TYRX absorbable antibacterial envelope  Reveal LINQ product lines and a robust performance in TAVR franchise are steadily driving Medtronic s revenues within this niche  Further  following CMS  final TAVR NCD memo published in June  many new TAVR centers in the United States are entering into partnerships with Medtronic  This is also expected to have positively contributed to Medtronic s top line in the fiscal second quarter However  in the to be reported quarter  this growth is likely to have been offset by weakened sales of left ventricular assist device  LVAD  as a result of market share loss  due to the regulatory approval of Abbott s competitive product HeartMate 3  and certain unfavorable changes in the heart transplant guideline  This apart  sales might have taken a hit as the company is in its CRM replacement cycle Overall  the Zacks Consensus Estimate for CVG revenues in the fiscal second quarter is pegged at  2 87 billion  indicating a 0 4  dip from the year ago reported number Within Restorative Therapies Group  RTG   the company is again projected to have seen solid progress  particularly in Brain   Pain divisions despite challenges in the Spine market Medtronic s integrated robotics and navigation platform Mazor X Stealth is expected to have driven growth in Neurosurgery business along with creating demand for the core spine implants The Zacks Consensus Estimate for RTG revenues in the fiscal second quarter stands at  2 07 billion  implying a 3  improvement from the last reported figure Within Minimally Invasive Therapies Group  MITG   the company is once again expected to have delivered higher revenues  banking on sturdy sales of Advanced Stapling and Advanced Energy products  Innovations within its Tri Staple and LigaSure franchises including new EEA circular stapler with Tri Staple technology and Ligasure Exact dissector might have aided growth The Zacks Consensus Estimate for MITG revenues in the fiscal second quarter is pegged at  2 14 billion  suggesting a 1 8  slip from the last reported quarter Within Diabetes  Medtronic is likely to have sustained U S  patient demand for its MiniMed 670G hybrid closed loop system in the fiscal second quarter  Outside the United States  the company is witnessing buoyant demand for 640G system  It is continuing with the launch of MiniMed 670G in several international markets  which in turn  is expected to have consistently boosted its international diabetes revenues The Zacks Consensus Estimate for Diabetes revenues is pegged at  596 million  indicating a 2 2  increase from the prior year reported figure Here s What the Quantitative Model PredictsPer our proven model  a stock needs to have a positive and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  to deliver a positive earnings surprise  This is not the case here as you will see below Earnings ESP  Medtronic has an Earnings ESP of 0 00   You can uncover the best stocks to buy or sell before they re reported with our  Zacks Rank  Medtronic carries a Zacks Rank  3  Stocks Worth a LookHere are a few medical stocks worth considering with the right combination of elements to beat on earnings in the to be reported quarter ACADIA Pharmaceuticals Inc    NASDAQ ACAD   has an Earnings ESP of  0 26  and a Zacks Rank  2 Exact Sciences Corporation   NASDAQ EXAS   has an Earnings ESP of  1 27  and a Zacks Rank of 2 Jazz Pharmaceuticals plc   NASDAQ JAZZ   has an Earnings ESP of  4 48  and a Zacks Rank of 1  You can see  7 Best Stocks for the Next 30 DaysJust released  Experts distill 7 elite stocks from the current list of 220 Zacks Rank  1 Strong Buys  They deem these tickers  Most Likely for Early Price Pops  Since 1988  the full list has beaten the market more than 2X over with an average gain of  24 5  per year  So be sure to give these hand picked 7 your immediate attention ,2019-11-17,Zacks Investment Research,https://www.investing.com/analysis/medtronic-mdt-to-report-q2-earnings-whats-in-store-200486056,200486056
129344,350859,ACAD,ACADIA launches mid stage study of NUPLAZID as adjunctive therapy in patients with negative symptoms of schizophrenia,news,ACADIA Pharmaceuticals   ACAD  1 4   initiates a Phase 2 clinical trial  ADVANCE  assessing NUPLAZID  pimavanserin  for adjunctive treatment of patients with negative symptoms of schizophrenia  There are no currently approved drugs for this population  representing as many as half of schizophrenia sufferers ADVANCE is a 26 week  double blind  placebo controlled study that will randomize  380 subjects to receive either pimavanserin or placebo  once daily  in addition to their ongoing antipsychotic therapy  The starting dose of pimavanserin at baseline will be 20 mg but may be adjusted down to 10 mg or up to 34 mg during the first eight weeks of treatment  The primary endpoint is the change from baseline to week 26 in the total score of a scale called Negative Symptom Assessment 16  NSA 16   Following the trial  participants will be eligible to enroll in a 52 week open label extension study Schizophrenia patients are characterized by having positive or negative symptoms  Positive symptoms include hallucinations  delusions and disorganized speech  Negative symptoms include flat effect  loss of interest  emotional withdrawal and cognitive impairment NUPLAZID is a non dopaminergic antipsychotic that acts as a selective serotonin inverse agonist that preferentially targets 5 HT2A receptors while avoiding activity at common targets like dopamine  The FDA approved it in April for the treatment of Parkinson s disease psychosis ,2016-11-15,Seeking Alpha,https://www.investing.com/news/stock-market-news/acadia-launches-mid-stage-study-of-nuplazid-as-adjunctive-therapy-in-patients-with-negative-symptoms-of-schizophrenia-440988,440988
129345,350860,ACAD,Trump corporate tax plans may spur U S  drug maker M As ,news,Investing com   Trump s plan to encourage U S  firms to repatriate overseas cash piles could spark M As among drug makers Trump proposes a 10  tax rate rather than 35  on firms bring home cash Cash may be used to buy smaller firms with potential blockbusters rather than risk investment in R D Top 5 U S  pharmas estimated to hold about  250 bn in overseas cash Valuations of potential biotech acquisition targets close to historic lows Potential buyers   NYSE Pfizer    NYSE Merck    NYSE Johnson   Johnson    NASDAQ Amgen    NYSE Eli Lilly Potential targets   NYSE Bristol Myers Squibb    NASDAQ Incyte    NASDAQ Acadia  ,2016-12-06,Investing.com,https://www.investing.com/news/stock-market-news/trump-corporate-tax-plans-may-spur-u.s.-drug-maker-m-as-445941,445941
129346,350861,ACAD,ACADIA Q1 results in line  shares slip 9  on expectations of revenue beat,news,ACADIA Pharmaceuticals   ACAD  9 2   Q1 results   M   Revenues  NUPLAZID sales   15 3   27 5  sequentially   Deferred product revenue  4 1   57 7  sequentially  Net Loss   87 8    76 3    Loss Share   0 72    60 0   Results were in line with expectations  Q2 consensus  loss share of   0 73  on revenues of  20 2M Phase 3 assessing NUPLAZID in Alzheimer s disease psychosis to commence in H2 Now read ,2017-05-10,Seeking Alpha,https://www.investing.com/news/stock-market-news/acadia-q1-results-in-line;-shares-slip-9-on-expectations-of-revenue-beat-482492,482492
129347,350862,ACAD,Takeover rumors de jour  Pfizer taking out Bristol Myers  ACADIA Pharma,news,For investors who enjoy the rumor mill   Pfizer   PFE  1   is mulling a takeout of Bristol Myers Squibb  BMY  0 2   and  ACADIA Pharmaceuticals   ACAD  3 4   is in the crosshairs of an unnamed suitor Now read ,2017-06-21,Seeking Alpha,"https://www.investing.com/news/stock-market-news/takeover-rumors-de-jour:-pfizer-taking-out-bristol-myers,-acadia-pharma-497821",497821
129372,350887,ACAD,Palatin s  PTN  To Report Q4 Earnings  What s In The Cards ,opinion,"Palatin Technologies  Inc    NYSE PTN   will focus on the commercialization of Vyleesi in the fourth quarter of fiscal 2019 Shares of the company have rallied 23 9  year to date against the  s decline of 3 0  In the last reported quarter  the company witnessed a negative earnings surprise of 50 00   Moreover  Palatinsurpassed earnings estimates in one of the trailing four quarters  the average positive surprise being 37 50  Let s see how things are shaping up prior to the upcoming results Factors Likely to Impact Q4 ResultsIn June 2019  the FDA granted marketing approval to AMAG Pharmaceuticals  Inc  s   NASDAQ AMAG   new drug application  NDA  for Vyleesi   bremelanotide injection   a melanocortin receptor agonist developed by Palatin  indicated for the treatment of premenopausal women with acquired  generalized hypoactive sexual desire disorder  HSDD   The FDA s approval of the NDA triggers a  60 million milestone payment to Palatin under its North American license agreement with AMAG  In the second quarter  we expect Palatin to provide commercialization updates on the drug The company should also provide updates on its pipeline candidates during the quarter Palatin s new product development activities primarily focus on melanocortin receptor 1   MC1r   agonists  with potential to treat a number of inflammatory and autoimmune diseases such as dry eye disease  also known as keratoconjunctivitis sicca   uveitis  diabetic retinopathy and inflammatory bowel disease The company has also designed and is developing potential NPR candidates that are selective for one or more different natriuretic peptide receptors  NPR   including natriuretic peptide receptor A   NPR A    natriuretic peptide receptor B   NPR B   and natriuretic peptide receptor C   NPR C   PL 3994 is an NPR A agonist  which has completed phase I clinical safety studies  It has potential in the treatment of several cardiovascular diseases  including genetic and orphan diseases resulting from a deficiency of endogenous active NPR A  The company has ongoing academic collaborations with several institutions for PL 3994 PL 5028  a dual NPR A and NPR C agonist  is in preclinical development for cardiovascular diseases to reduce cardiac hypertrophy and fibrosis  The company has ongoing academic collaborations with several institutions for PL 5028 and seeks to enter a development partnership for the same by the end of calendar year 2019 What Does the Zacks Model Unveil Our proven model does not conclusively show an earnings beat for Palatin in the to be reported quarter  This is because a stock needs to have both a positive  and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  to be able to beat estimates  But that is not the case here  as you will see below Earnings ESP  Palatin has an Earnings ESP of 0 00   This is because both the Most Accurate Estimate and the Zacks Consensus Estimate are pegged at a loss of 2 cents  You can uncover the best stocks to buy or sell before they re reported with our  Zacks Rank  The company currently has a Zacks Rank  2  which increases the predictive power of ESP  However  we need to have a positive Earnings ESP to be confident of an earnings beat Note that Sell rated stocks  Zacks Rank  4 or 5  going into the earnings announcement are best avoided  Palatin Technologies  Inc  Price and Consensus
    Stocks That Warrant a LookHere are some drug biotech stocks you may want to consider  as our model shows that these have the right combination of elements to post an earnings beat this quarter Acadia Pharmaceuticals Inc    NASDAQ ACAD   has an Earnings ESP of  0 49  and a Zacks Rank  2  You can see  Celgene Corporation   NASDAQ CELG   has an Earnings ESP of  0 27  and a Zacks Rank  3 Today s Best Stocks from Zacks Would you like to see the updated picks from our best market beating strategies  From 2017 through 2018  while the S P 500 gained  15 8   five of our screens returned  38 0    61 3    61 6    68 1   and  98 3   This outperformance has not just been a recent phenomenon  From 2000   2018  while the S P averaged  4 8  per year  our top strategies averaged up to  56 2  per year ",2019-08-15,Zacks Investment Research,https://www.investing.com/analysis/palatins-ptn-to-report-q4-earnings-whats-in-the-cards-200455877,200455877
129373,350888,ACAD,Vanda Receives CRL From FDA For SNDA Of Jet Lag Treatment,opinion,Vanda Pharmaceuticals Inc     NASDAQ VNDA   received a Complete Response Letter  CRL  from the FDA for the supplemental New Drug Application  sNDA  of Hetlioz  tasimelteon  to treat Jet Lag Disorder  JLD  Hetlioz is already approved in the United States and Europe for the treatment of non 24 hour sleep wake disorder   a serious  rare and chronic circadian rhythm disorder Shares of the company have slumped 41 3  year to date against the  s growth of 0 6  The company submitted the regulatory filing based on a study  which showed that JLD patients slept nearly three hours longer during the three nights  following their transatlantic trip  when treated with Hetlioz than they did when they were untreated  The results were consistent with Vanda s jet lag simulation studies  according to the company The CRL stated that the measures demonstrating improved sleep were of unclear clinical significance  The FDA made additional observations on various aspects of Vanda s sNDA Vanda intends to consider each observation as it plans for continued engagement with the FDA on this matter    To date  there are no treatments approved by the FDA for JLD  a public health issue experienced by millions of people every year  JLD sufferers attempt to treat the condition with unapproved remedies  which do not address either the symptoms or the underlying cause of the disorder The label expansion of the drug would have boosted sales  Vanda Pharmaceuticals Inc  Price    Zacks Rank   Other Stocks to ConsiderVanda currently carries a Zacks Rank  2  Buy  Some other top ranked stocks are Acorda Therapeutics Inc    NASDAQ ACOR    CSL Limited   OTC CSLLY   and ACADIA Pharmaceuticals Inc    NASDAQ ACAD    While Acorda and CSL Limited sport a Zacks Rank  1  Strong Buy   ACADIA carries a Zacks Rank  2  You can see  Acorda s loss per share estimates have narrowed from  3 59 to  2 74 for 2019 in the past 60 days  The company delivered a positive earnings surprise in the trailing four quarters  the average being 69 68  CSL Limited s earnings per share estimates have increased from  1 75 to  2 46 for 2019 and from  1 96 to  2 75 for 2020 in the past 60 days  Shares of the company have rallied 20 9  year to date ACADIA s loss per share estimates have narrowed from  1 90 to  1 78 for 2019 in the past 60 days  Shares of the company have surged 80 8  year to date Legalizing THIS Could Be Even Bigger than Marijuana Americans spend an estimated  150 billion in this industry every year  more than twice as much as they spend on marijuana  Now that 8 states have fully legalized it  with several more states following close behind   Zacks has identified 5 stocks that could soar in response to the powerful demand  One industry insider described the future as  mind blowing    and early investors can still get in ahead of the surge ,2019-08-20,Zacks Investment Research,https://www.investing.com/analysis/vanda-receives-crl-from-fda-for-snda-of-jet-lag-treatment-200456646,200456646
129374,350889,ACAD,ACADIA Enters Oversold Territory,opinion,ACADIA Pharmaceuticals Inc    NASDAQ ACAD   has been on a bit of a cold streak lately  but there might be light at the end of the tunnel for this overlooked stock  And for technical investors there is some hope when looking at ACAD given that  according to its RSI reading of 27 73  it is now in oversold territory What is RSI  RSI stands for  Relative Strength Index  and it is a popular indicator used by technically focused investors  It compares the average of gains in days that closed up to the average of losses in days that closed down  readings above 70 suggest an asset is overbought  while an RSI below 30 suggests undervalued conditions are present Other FactorsYet ACAD s low RSI value isn t the only reason to have some optimism over a coming turnaround  as there has been plenty of positive earnings estimate revision activity as of late  This is especially true when investors take a deep dive into some of these estimate revision stats and recent changes to ACADIA Pharmaceuticals  earnings consensus Over the past two months  investors have seen 8 earnings estimate revision move higher  compared with none lower  at least when looking at the key current year time frame  And the consensus estimate for ACAD has also been on an upward trend over the past 60 days  as estimates have risen by 6 8  over the last two months If this wasn t enough ACADIA Pharmaceuticals also has a Zacks Rank  2  Buy  which puts it into rare company among its peers  So  given all of these factors  investors may want to consider getting in on this stock now  or holding on   as there are some favorable trends that could bubble up for this stock before long  You can see  Today s Best Stocks from ZacksWould you like to see the updated picks from our best market beating strategies  From 2017 through 2018  while the S P 500 gained  15 8   five of our screens returned  38 0    61 3    61 6    68 1   and  98 3  This outperformance has not just been a recent phenomenon  From 2000   2018  while the S P averaged  4 8  per year  our top strategies averaged up to  56 2  per year ,2019-09-08,Zacks Investment Research,https://www.investing.com/analysis/acadia-enters-oversold-territory-200462913,200462913
129375,350890,ACAD,Stocks To Watch  ACAD  ITI  MAXR  NKTR  OSTK  SIEN,opinion,"ACADIA Pharmaceuticals 
ACAD made a monster move on Monday on good news and then pulled back  On Tuesday  it was up 2 37  or 6   to 41 22  on 7 4 million shares  I think it s going to go higher  I m looking for 50 51 
 Iteris  
ITI has a beautiful inverse head and shoulders  a base  a breakout  a retest  consolidate  and go  It s four waves up and I think the fifth one has started  It was up 26 cents  or 5   to 5 69  or 236 025 shares traded on Tuesday  I think it will go to 6 1 2  7 1 4  and 8 
Maxar Technologies
MAXR had a swing put on it that didn t work  it came down and retest for six more weeks  and then popped out on Tuesday  It was a big day  jumping 1 35  or 19 2   to 8 38  on 5 4 million shares  Look for it to test 10  The top of the channel may be tested as well at about 12 and maybe 12 3 4 
 Nektar Therapeutics  
NKTR which I love the chart and the company  popped 2 05  or 11 1 2   to 19 91  on 4 3 million shares on Tuesday  It s at the bottom of the long term channel  but it s telling me that it may have a big move coming up  Halfway into the gap is 24  and then 28 are the targets 
Overstock com  
OSTK is doing well on a big comeback  It s been up five days in a row  and on Tuesday  it popped another 1 85  or 9 5   to 21 32  on 5 7 million shares  The volume was the best in two weeks  I think it s immediately going to test the zone in the 22 3 4 23 1 2 area  If it gets through that  I expect it to get to 26 27 
Sientra
SIEN looks like it s ready for a reversal day  perhaps  On Tuesday  it advanced 46 cents  or 7   to 7 08  on 1 million shares  If this can get through 7 33  35  then 8 1 2 and 10 are the targets 
Stocks on the long side
ACADIA Pharmaceuticals Inc   ACAD   Akebia Therapeutics  Inc   AKBA   AMAG Pharmaceuticals  Inc   AMAG   Endo International plc  ENDP   Francesca s Holdings Corporation  FRAN   G1 Therapeutics  Inc   GTHX   At Home Group Inc   HOME   Iteris  Inc   ITI   LSB Industries  Inc   LXU   Maxar Technologies Inc   MAXR   Mesoblast Limited  MESO   The Michaels Companies  Inc   MIK    Mallinckrodt   NYSE MNK  Public Limited Company  MNK   Nektar Therapeutics  NKTR   Owens   Minor  Inc   OMI   Orion Group Holdings  Inc   ORN    Overstock com    Inc   NASDAQ OSTK   Puma Biotechnology  Inc   PBYI   Pier 1 Imports  Inc   PIR   Pieris Pharmaceuticals  Inc   PIRS   Sientra  Inc   SIEN   and Tenneco Inc   TEN  ",2019-09-11,Harry Boxer,https://www.investing.com/analysis/stocks-to-watch-acad-iti-maxr-nktr-ostk-sien-200463525,200463525
129396,350911,ACAD,5 Trade Ideas  ACAD  BEN  GPK  TEAM  WU,opinion,"ACADIA Pharma  Ticker   ACAD

ACADIA Pharmaceuticals Inc  NASDAQ ACAD  started higher in December and met resistance into April  It pulled back slightly and has consolidated there since  Friday saw it try to push over resistance with the RI rising to the bullish zone and the MACD positive and moving higher  Look for a pushover resistance to participate 
Franklin Resources  Ticker   BEN

Franklin Resources  NYSE BEN  finally broke out of a broad consolidation when it made a higher high in April  The pullback from there found support at the 200 day SMA and it reversed back higher  It is now approaching the April high with the RSI rising in the bullish zone and then MACD positive and moving higher  Look for a push over the April high to participate 
Graphic Packaging  Ticker   GPK

Graphic Packaging GPK cleared a double bottom in February and then shifted to a sideways consolidation  In April it broke that to the upside and gapped up to find resistance in May  After a pullback to the 200 day SMA it reversed and ran to a higher high into June  Another pullback  to a higher low  and it reversed again  It sits at the prior high with the RSI rising in the bullish zone and the MACD crossed up and rising  Look for a new high to participate 
Atlassian  Ticker   TEAM

Atlassian Corp Plc  NASDAQ TEAM  has been moving higher since October  There have been a couple of pauses and pullbacks along the way and it is consolidating in one now  The RSI is rising in the bullish zone with the MACD crossing up and positive  Look for a push up out of consolidation to participate 
Western Union  Ticker   WU

Western Union Company  NYSE WU  started higher in December and paused as it moved into February  The price held over the 50 day SMA on a pullback and then started higher in March  It flattened out again in April and continued sideways until the beginning of June  It rose and found resistance again then pulled back to the 50 day SMA  A reversal sees it back at the prior high with the RSI rising in the bullish zone and the MACD crossed up and rising  Look for a pushover resistance to participate 
Elsewhere look for Gold to pause in its uptrend  holding around 1400  while Crude Oil pauses in the pullback  The US Dollar Index looks to reverse higher in consolidation while US Treasuries pullback in their uptrend  The Shanghai Composite looks to continue the messy uptrend while Emerging Markets stall in their move higher 
Volatility looks to remain very low keeping the bias higher for the equity index ETF s SPY  IWM and QQQ  Their short term charts are all positive looking for more upside  But on the longer timeframe  the SPY and QQQ are decidedly more bullish  triggering patterns with very big potential moves  while the IWM remains stuck in a range  Use this information as you prepare for the coming week and trad em well 
Disclaimer  The information in this blog post represents my own opinions and does not contain a recommendation for any particular security or investment  I or my affiliates may hold positions or other interests in securities mentioned in the Blog  please see my Disclaimer page for my full disclaimer 
Original Post",2019-07-08,Gregory W. Harmon,https://www.investing.com/analysis/5-trade-ideas-for-monday-acadia-franklin-resources-graphic-packaging-atlassian-200437482,200437482
129397,350912,ACAD,ACADIA Pharmaceuticals Inc   ACAD  Shares March Higher  Can It Continue  ,opinion,As of late  it has definitely been a great time to be an investor in ACADIA Pharmaceuticals Inc    NASDAQ ACAD    The stock has moved higher by 5 7  in the past month  while it is also above its 20 Day SMA too  This combination of strong price performance and favorable technical  could suggest that the stock may be on the right path We certainly think that this might be the case  particularly if you consider ACAD s recent earnings estimate revision activity  From this look  the company s future is quite favorable  as ACAD has earned itself a Zacks Rank  2  Buy   meaning that its recent run may continue for a bit longer  and that this isn t the top for the in focus company  You can see  The Hottest Tech Mega Trend of All                 Last year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ,2019-08-06,Zacks Investment Research,https://www.investing.com/analysis/acadia-pharmaceuticals-inc-acad-shares-march-higher-can-it-continue-200451322,200451322
129419,350934,ACAD,What s In The Cards For Bausch Health  BHC  Q4 Earnings ,opinion,"Bausch Health Companies Inc    NYSE BHC   is scheduled to report fourth quarter and full year 2018 results on Feb 20 
In the last reported quarter  the company s earnings beat estimates by 32 2   Bausch s earnings track record has been pretty decent so far  Over the last four quarters  the company beat earnings expectations thrice  delivering average positive earnings surprise of 83 2  
Bausch s stock has gained 19 5  in the past six months compared to  a 22 2  decline for the  
 
 
Factors Likely to Impact Results
Bausch conducts its business in four operating segments   the Bausch   Lomb International segment  the Salix segment  the Ortho Dermatologics segment and the Diversified Products segment 
The Bausch   Lomb International segment primarily comprises products with a focus on the vision care  surgical  consumer and ophthalmology Rx products  The Salix segment consists of sales of gastrointestinal products 
The Ortho Dermatologics segment consists of sales of Ortho Dermatologics  dermatological  products in the United States and global sales of Solta medical dermatological devices 
The Diversified Products segment comprises sales of pharmaceutical products in the areas of neurology and certain other therapeutic classes in the United States  generic products  and dentistry products 
Approximately 75  of the company s total third quarter revenues was generated by the Bausch   Lomb International and the Salix segments  Hence  the focus will be on these two segments in the fourth quarter  Revenues in 2018 are expected between  8 15 billion and  8 35 billion  The company expects R D expenses of  415 million in 2018 
The Salix business continues to drive growth and contribute to the top line  In particular  increased sales of Xiaflex and Relistor are boosting the segment  In August  Bausch launched Lucemrya for the mitigation of withdrawal symptoms to facilitate abrupt discontinuation of opioids in adults 
The company also entered into an exclusive agreement with Dova Pharmaceuticals  Inc  to co promote Doptelet in the United States for the treatment of thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo a procedure  Bausch also launched Plenvu  a one liter PEG bowel cleansing preparation for colonoscopies  in the United States 
Meanwhile  investors are expected to focus on pipeline development  apart from the regular top and bottom line numbers  Bausch has narrowed its focus on seven recently launched or expected to be launched products pending completion of testing and receipt of FDA approval  The products include Vyzulta  Siliq  Bryhali  psoriasis   Lumify  Duobrii  Relistor and SiHy Daily 
Bausch also obtained FDA approval for Vyzulta  a treatment option for glaucoma  The FDA also approved Lumify  the over the counter eye drop with low dose brimonidine for the treatment of eye redness  The approval of new drugs should boost the top line  The company successfully launched Lumify 
The FDA also approved Altreno  IDP 121   an acne treatment in lotion form  The company launched Bryhali lotion  a topical treatment for plaque psoriasis  following the receipt of final FDA approval  The FDA accepted the resubmission of the NDA for Duobrii Lotion for the topical treatment of plaque psoriasis with a PDUFA action date of Feb 15  2019  The phase III studies for IDP 120 are expected to begin shortly and the company expects to submit an NDA for IDP 123 in the first half of 2019 
The focus will also be on the company s efforts to pay down debt  as it had been under the scanner for its huge levels of debt  During the third quarter  the company repaid  360 million of debt  Consequently  the company reduced debt by approximately  7 4 billion  since the first quarter of 2016  In January 2019  the company paid down an additional  100 million of its senior secured term loans using cash generated from operations 
Earnings Whispers
Our proven model does not conclusively show that Bausch will beat on earnings this quarter  That is because a stock needs to have both a positive  and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  to be able to beat estimates  Unfortunately  that is not the case here  as you will see below 
Earnings ESP  Earnings ESP for Bausch is 0 00   This is because both the Zacks Consensus Estimate and the Most Accurate Estimate is pegged at 88 cents  You can uncover the best stocks to buy or sell before they re reported with our  
Zacks Rank  Bausch carries a Zacks Rank  3  which is favorable  However  the 0 0  ESP makes surprise prediction difficult 
We caution against Sell rated stocks  Zacks Rank  4 or 5  going into the earnings announcement  especially when the company is seeing negative estimate revisions 
Stocks to Consider
Here are some companies you may consider  as our model shows that these have the right combination of elements to deliver a beat this quarter 
Mallinckrodt   NYSE MNK   has an Earnings ESP of  2 25  and a Zacks Rank  2  The company is scheduled to report results on Feb 26  You can see  
ACADIA Pharmaceuticals Inc    NASDAQ ACAD   has an Earnings ESP of  12 95  and a Zacks Rank  3  It is scheduled to release results on Feb 28 
Recro Pharma  Inc    NASDAQ REPH   has an Earnings ESP of  3 03  and a Zacks Rank  2  It is scheduled to report earnings on Feb 19 
Zacks  Top 10 Stocks for 2019
In addition to the stocks discussed above  wouldn t you like to know about our 10 finest buy and holds for the year 
From more than 4 000 companies covered by the Zacks Rank  these 10 were picked by a process that consistently beats the market  Even during 2018 while the market dropped  5 2   our Top 10s were up well into double digits  And during bullish 2012   2017  they soared far above the market s  126 3   reaching  181 9  
This year  the portfolio features a player that thrives on volatility  an AI comer  and a dynamic tech company that helps doctors deliver better patient outcomes at lower costs ",2019-02-15,Zacks Investment Research,https://www.investing.com/analysis/whats-in-the-cards-for-bausch-health-bhc-q4-earnings-200389004,200389004
129420,350935,ACAD,5 Trade Ideas For Monday  ACAD  LPSN  LSTR  WP  And ZEN,opinion,"ACADIA Pharmaceuticals  Ticker   ACAD

ACAD stared higher off of the December bottom  pausing when it had returned to the Fall highs  Then two weeks ago it jumped to a higher high before the digestive pullback last week  The strong move Friday  along with the RSI turning back up and MACD avoiding a cross down support another leg higher  Look for continuation to participate 
LivePerson  Ticker   LPSN

LPSN topped out in September and then started to move lower  It found support in December and started to move higher into the New Year  Two weeks ago it made a higher high and then pulled back  It ended last week moving back up toward that high  The RSI is also moving back higher in the bullish zone with the MACD flat and positive  Look for continuation to participate higher 
Landstar  Ticker   LSTR

LSTR started lower in early September  It found support at the end of October and reversed only to be stopped at the 200 day SMA at the end of November  It fell back from there to a lower low at the end of the month  Since then it rose back through the 200 day SMA to a higher high in February and has pulled back  Friday saw a strong move that may mark the bottom with the RSI turning back up but the MACD still falling  Look for continuation to participate   
Worldpay  Ticker   WP

WP topped in October and then began a drop that found support in late December  It has stepped higher since  adding a gap up 2 weeks ago  It has been digesting that gap and ended last week with a strong move that may indicate another leg beginning  The RSI is turning back up after retracting from an overbought condition while the MACD may be crossing down  Look for continuation to participate higher 
Zendesk  Ticker   ZEN

ZEN pulled back from a high in September  finding support in November  It confirmed a double bottom as it rose into 2019 and kept moving higher  It hit resistance last week and pulled back  By the end of the week  it was showing strength again  The RSI is turning back up but the MACD is falling  Look for continuation in the price to participate 
Up Next  Bonus Idea
Elsewhere look for Gold to pullback in its uptrend while Crude Oil marks time moving sideways  The U S  Dollar Index continues in broad consolidation but with a possible bullish reversal building while US Treasuries move higher in broad consolidation  The Shanghai Composite is making a digestive move in its uptrend while Emerging Markets are pulling back and possibly reversing lower 
Volatility looks to remain low but rising from extremes shifting the bias to lower for the equity index ETF s SPY  IWM and QQQ  Their charts all confirmed reversal patterns on the weekly timeframe and their first 5 day moves lower on the daily timeframe  No major damage to the uptrend has been done at this point  Use this information as you prepare for the coming week and trad em well 
Disclaimer 
The information in this blog post represents my own opinions and does not contain a recommendation for any particular security or investment  I or my affiliates may hold positions or other interests in securities mentioned in the Blog  please see my Disclaimer page for my full disclaimer 
Original post",2019-03-11,Gregory W. Harmon,https://www.investing.com/analysis/5-trade-ideas-for-monday-acadia-pharma-liveperson-landstar-worldpay-and-zendes-200396259,200396259
129436,350951,ACAD,MacroGenics Up On Lifting Of Partial Hold On Cancer Candidate,opinion,"MacroGenics  Inc    NASDAQ MGNX   announced that the FDA has lifted the partial clinical hold placed on phase I studies evaluating its antibody monoclonal candidate  MGD009  The company is developing the candidate as monotherapy and in combination therapies for treating various types of cancer Shares of MacroGenics closed 2 3  higher on Jan 25 following the news  The company s shares have declined 41 5  in the past six months compared with the  s fall of 5 1  The partial clinical hold was placed on the studies in December due to hepatic  liver related  adverse events reported by the company as observed in the clinical studies  While the restriction put by the regulatory authority denied enrollment of new patients to the studies  it allowed continuation of treatment for the previously enrolled patients with a pre assigned dose The company stated that it worked rapidly to provide a comprehensive response to the FDA by the end of December to avoid significant delay in the study  With the removal of the hold  the company will be able to enroll new patients MGD009 is a bispecific DART molecule  which redirects T cells to kill B7 H3 protein expressing cells involved in immune regulation  The candidate helps treat cancer as the targeted protein is over expressed on a wide variety of cancer cells We note that a phase I study is evaluating MGD009 monotherapy in unresectable or metastatic B7 H3 expressing tumors while another phase I study is evaluating the candidate in combination with the company s anti pd 1 antibody candidate  MGA012  in relapsed or refractory cancer with similar tumors Apart from MGD009  MacroGenics is also evaluating an antibody drug conjugate candidate  MGC018  in advanced solid tumors MacroGenics  Inc  Price
    Zacks Rank   Key PicksMacroGenics currently carries a Zacks Rank  2  Buy  Some other top ranked stocks fromthe pharma sector include Alder BioPharmaceuticals  Inc    NASDAQ ALDR    ACADIA Pharmaceuticals Inc    NASDAQ ACAD   and Five Prime Therapeutics  Inc    NASDAQ FPRX    All the three stocks carry a Zacks Rank  2  Buy   You can see  Alder BioPharma s loss estimates have narrowed from  4 63 to  4 57 for 2018 and from  3 50 to  3 41 for 2019 over the past 30 days  The company delivered positive earnings surprise in three of the four trailing quarters with the average beat being 4 22  ACADIA Pharma s loss estimates have narrowed from  2 00 to  1 99 for 2018 and from  1 77 to  1 72 for 2019 over the past 30 days  The company came up with a positive earnings surprise in three of the four trailing quarters with the average beat being 6 77  Five Prime s loss per share estimates narrowed from  4 32 to  4 30 for 2018 and from  5 26 to  5 06 for 2019 over the past 30 days  The company delivered a positive surprise in two of the four trailing quarters with the average beat being 1 61  Zacks  Top 10 Stocks for 2019In addition to the stocks discussed above  would you like to know about our 10 finest buy and holds for the year Who wouldn t  Our annual Top 10s have beaten the market with amazing regularity  In 2018  while the market dropped  5 2   the portfolio scored well into double digits overall with individual stocks rising as high as  61 5   And from 2012 2017  while the market boomed  126 3  Zacks  Top 10s reached an even more sensational  181 9  ",2019-01-27,Zacks Investment Research,https://www.investing.com/analysis/macrogenics-up-on-lifting-of-partial-hold-on-cancer-candidate-200379982,200379982
129437,350952,ACAD,Exelixis  EXEL  To Report Q4 Earnings  What s In Store ,opinion,"Exelixis  Inc    NASDAQ EXEL   is scheduled to report fourth quarter 2018 results on Feb 12  after the market closes 
Exelixis  shares have gained 7 6  in the past six months compared with the  decline of 13 5  

 
The company has an excellent earnings surprise history  surpassing expectations in all of the trailing four quarters with average beat of 83 43    In the last reported quarter  the company beat expectations by 115 79  
Let s see what is in store for this quarter 
Factors Likely to Impact Results
Strong Cabometyx sales boosted the company s third quarter results and we expect the momentum to continue in the fourth quarter  The company experienced 11  increase in Cabometyx s prescriber base in the third quarter as compared to that in the second quarter 
While the FDA approved Cabometyx tablets in April 2016 for the treatment of advanced renal cell carcinoma   RCC    the drug s label was also expanded in December 2017 for the treatment of previously untreated advanced RCC  Since the drug is now approved for first line RCC as well  the company can now cater to the entire patient population suffering from the disease 
In May 2018  Exelixis and partner Ipsen Biopharmaceuticals also obtained the European Commission  EC  approval for Cabometyx  20 mg  40 mg and 60 mg  in the first line treatment of adults with intermediate  or poor risk advanced RCC  The approval will broaden the geographic reach of the drug as the market potential is significant for the first line treatment of kidney cancer 
Moreover  Exelixis and partner Ipsen obtained EC approval for Cabometyx as a monotherapy for hepatocellular carcinoma  HCC  in adults who have previously been treated with Bayer s Nexavar  In January 2019  the FDA also approved Cabometyx for HCC 
In September 2018  Exelixis announced that the National Comprehensive Cancer Network  NCCN  has updated its Clinical Practice Guidelines to include new recommendations for lead drug Cabometyx  As a result of the update  Cabometyx is now recommended by the NCCN for the treatment of advanced RCC  regardless of patient risk status  favorable   intermediate  and poor risk  
We expect sales to get a further boost  with an increase in the eligible patient population for Cabometyx in the United States  However  competition has increased in the RCC market  with the approval of Opdivo combined with Yervoy for the treatment of poor and intermediate risk first line RCC 
Meanwhile  investors are expected to focus on pipeline development  In December 2018  Exelixis and Ipsen announced the initiation of a pivotal phase III study   COSMIC 312   to evaluate a Cabometyx combination therapy in treatment na ve advanced HCC  Moreover  an exploratory arm will also evaluate Cabometyx monotherapy in the first line setting for similar patients 
Exelixis is developing cabozantinib in a broad development program  comprising more than 45 clinical studies across multiple indications  Exelixis inked agreements with Bristol Myers   NYSE BMY   and Roche to develop cabozantinib in combination with immunotherapy agents 
Earlier  Exelixis announced encouraging results from the dose escalation stage of the phase Ib COSMIC 021 study of Cabometyx in combination with Tecentriq in previously untreated advanced RCC  The combination was well tolerated and showed promising anti tumor activity 
Exelixis expects total costs and operating expenses for 2018 to be  410  420 million 
Earnings Whispers
Our proven model does not conclusively show that Exelixis will beat on earnings this quarter  That is because a stock needs to have both a positive  and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  to be able to beat estimates  Unfortunately  that is not the case here  as you will see below 
Earnings ESP  Earnings ESP for Exelixis is  3 45   The Zacks Consensus Estimate is pegged at 25 cents  while the Most Accurate Estimate is pegged at 24 cents  You can uncover the best stocks to buy or sell before they re reported with our  
Zacks Rank  Exelixis carries a Zacks Rank  2  which is favorable  However  the negative ESP makes surprise prediction difficult 
We caution against Sell rated stocks  Zacks Rank  4 or 5  going into the earnings announcement  especially when the company is seeing negative estimate revisions Exelixis  Inc  Price  Consensus and EPS Surprise
 

   Stocks to Consider
Here are some companies you may consider  as our model shows that these have the right combination of elements to deliver a beat this quarter 
Mallinckrodt   NYSE MNK   has an Earnings ESP of  2 25  and a Zacks Rank  2  The company is scheduled to report results on Feb 26  You can see  
ACADIA Pharmaceuticals Inc    NASDAQ ACAD   has an Earnings ESP of  3 89  and a Zacks Rank  3 
Zacks  Top 10 Stocks for 2019
In addition to the stocks discussed above  wouldn t you like to know about our 10 finest buy and holds for the year 
From more than 4 000 companies covered by the Zacks Rank  these 10 were picked by a process that consistently beats the market  Even during 2018 while the market dropped  5 2   our Top 10s were up well into double digits  And during bullish 2012   2017  they soared far above the market s  126 3   reaching  181 9  
This year  the portfolio features a player that thrives on volatility  an AI comer  and a dynamic tech company that helps doctors deliver better patient outcomes at lower costs ",2019-02-07,Zacks Investment Research,https://www.investing.com/analysis/exelixis-exel-to-report-q4-earnings-whats-in-store-200385363,200385363
129438,350953,ACAD,Tilray  TLRY  To Report Q4 Earnings  What s In The Cards ,opinion,"Tilray  Inc    NASDAQ TLRY   is expected to release fourth quarter 2018 results on Feb 12 
In the last reported quarter  Tilray beat earnings expectations by 42 9   The company went public in July 2018 
Pipeline Progress in Focus
Tilray produces medical cannabis in Canada and Europe  In July 2018  Tilray completed its IPO  selling 10 350 000 shares of Class 2 common stock at  17 per share  C 22 45 per share   The company received net proceeds of  163 6 million  after deducting the underwriting discount 
The company has two product categories   dried cannabis  which includes whole flower and ground flower  and cannabis extracts  which includes full spectrum and purified oil drops and capsules  The company recorded 85 8  growth in revenues  driven by increased patient demand  bulk sales to other licensed producers and accelerated wholesale distribution in export markets  We expect the momentum to continue in the fourth quarter as well 
There is a global paradigm shift with regard to cannabis  As a result of this shift  the multi billion dollar cannabis industry is transforming from a state of prohibition to a state of legalization  Medical cannabis is now authorized at the national or federal level in 29 countries  Although the legal market for medical cannabis is still in its early stages  it represents huge potential  Recreational cannabis was legalized on Oct 17  2018  by the Federal Government 
In September 2018  Tilray announced that the U S  Drug Enforcement Administration  DEA  has approved an import pharmaceutical grade medical cannabis product produced by Tilray in the United States  for a clinical trial focused on Essential Tremor  ET   a neurological movement disorder  The drug will be imported from Canada for a clinical trial to be conducted at the University of California San Diego  UC San Diego  Center for Medicinal Cannabis Research  CMCR  to examine its safety  tolerability and efficacy for ET 
Tilray has been working to broaden its global footprint  In December 2018  Tilray announced that its subsidiary  Tilray Canada Ltd  has entered into a global framework agreement with the generic arm of Novartis   NYSE NVS    Sandoz AG  expanding the current collaboration  Under the new agreement  Tilray will collaborate with Sandoz to increase the availability of high quality medical cannabis products across the world  The company recently entered into a research partnership with world s leading brewer  Anheuser Busch InBev SA NV to research non alcohol beverages containing tetrahydrocannabinol and CBD 
The company recently entered into a marketing agreement with Authentic Brands Group  Both the companies have entered into a long term revenue sharing agreement to market and distribute a portfolio of consumer cannabis products within Authentic s brand portfolio  in jurisdictions where regulations permit 
In October 2018  Tilray acquired its existing Chile based import and distribution partner  Alef Biotechnology SpA  In December 2018  Tilray announced an investment in Qu bec based cannabis producer  ROSE LifeScience Inc   and an exclusive sale  supply  distribution and marketing agreement between High Park Farms Ltd   a wholly owned subsidiary of Tilray  and ROSE 
We expect investors to focus on other business updates from the company on the call  apart from the regular top and bottom line numbers 
Earnings Whispers
Our proven model does not conclusively show that Tilray will beat on earnings this quarter  That is because a stock needs to have both a positive  and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  to be able to beat estimates  Unfortunately  that is not the case here  as you will see below 
Earnings ESP  The Earnings ESP  which represents the difference between the Most Accurate Estimate and the Zacks Consensus Estimate  is  45 46   This is because the Most Accurate Estimate stands at   0 24 and the Zacks Consensus Estimate is   0 17  You can uncover the best stocks to buy or sell  before they re reported  with our  
Zacks Rank  Tilray currently carries a Zacks Rank  3  Hold   Note that we caution against stocks with a Zacks Rank  4 or 5  Strong Sell  going into the earnings announcement  especially when the company is seeing negative estimate revisions 
Share Price Performance
Tilray s stock has gained 257 2  after it went public  against the  s decline of 15 1  in the last twelve months 

 
Stocks to Consider
Here are some health care stocks you may want to consider  as our model shows that these have the right combination of elements to post an earnings beat this quarter 
Mallinckrodt   NYSE MNK   has an Earnings ESP of  2 25  and a Zacks Rank  2  The company is scheduled to report results on Feb 26  You can see  
ACADIA Pharmaceuticals Inc    NASDAQ ACAD   has an Earnings ESP of  3 89  and a Zacks Rank  3 
The Hottest Tech Mega Trend of AllLast year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ",2019-02-08,Zacks Investment Research,https://www.investing.com/analysis/tilray-tlry-to-report-q4-earnings-whats-in-the-cards-200385979,200385979
129441,350956,ACAD,Is A Disappointment In Store For Incyte  INCY  Q4 Earnings ,opinion,"Incyte Corporation   NASDAQ INCY   is scheduled to report fourth quarter 2018 results on Feb 14  before the market opens 
In the last reported quarter  the company missed estimates by 5 0   Incyte s earnings track record has been disappointing so far  Over the last four quarters  the company missed earnings expectations thrice  delivering average negative earnings surprise of 6 75  Incyte Corporation Price  Consensus and EPS Surprise
 

   Factors Driving Growth
Incyte s lead drug  Jakafi  ruxolitinib  is a first in class JAK1 JAK2 inhibitor  approved for the treatment of patients with polycythemia vera   PV    and those with intermediate or high risk myelofibrosis   MF    including primary MF  post PV MF and post essential thrombocythemia MF  While Incyte markets the drug in the United States  it is marketed by Novartis   NYSE NVS   as Jakavi outside the country 
Incyte continues to gain traction from Jakafi s performance  Jakafi revenues summed  1 0 billion in the first nine months of 2018  up 21  from the year ago timeframe  driven by strong patient demand 
We expect the trend to continue in the fourth quarter  The company updated its sales guidance with the third quarter results  The company expects Jakafi revenues of  1 370  1 400 million  previous guidance   1 350  1 400 million  
In order to expand patient population and increase commercial potential of the drug  the company is working toward expanding Jakafi s label  further 
We expect investors to also focus on the pipeline development efforts  given the recent setbacks 
The FDA recently extended the review period of the supplemental New Drug Application  sNDA  for Jakafi to treat patients with acute graft versus host disease  GVHD  who have had an inadequate response to corticosteroids   The sNDA was submitted in August 2018  and the FDA granted it both Priority Review and Breakthrough Therapy designation  
However  the FDA extended the action date by three months to review additional data submitted by Incyte in response to the FDA s information requests  The additional data has been determined by the FDA to constitute a major amendment to the sNDA  Hence  the new Prescription Drug User Fee Act  PDUFA  target action date is May 24  2019 
We remind investors that while Jakafi sales and royalties are key components of Incyte s revenue growth  Iclusig sales and Olumiant royalties are also contributing to the top line  Iclusig revenues are expected to be  80  85 million 
Earlier in the month  Incyte and partner Eli Lilly and Company  NYSE LLY  announced that Olumiant  baricitinib  met the primary endpoint in two phase III studies   BREEZE AD1 and BREEZE AD2   evaluating the efficacy and safety of Olumiant monotherapy for the treatment of adult patients with moderate to severe atopic dermatitis  AD   Olumiant is already approved for the treatment of moderately to severely active rheumatoid arthritis   RA   in patients with inadequate response or intolerant to TNF inhibitor therapies 
The company also updated its guidance along with third quarter results announcement  R D expenses are now expected to be  993  1 038 million  down from  1 008  1 103 million projected earlier  SG A expenses are expected to be  370  385 million compared with the previous guidance of  340  355 million 
Meanwhile  Incyte entered into a collaboration agreement with China based Innovent Biologics  Inc 
Both the companies have entered into the agreement through their respective subsidiaries  for the development of three clinical stage product candidates   pemigatinib  FGFR1 2 3 inhibitor   itacitinib  JAK1 inhibitor  and parsaclisib  PI3K  inhibitor   All the three candidates were discovered and developed by Incyte 
Share Price Performance
Incyte s stock has gained 24 1  in the past six months  worse than the  s decline of 14 4  

 
Earnings Whispers
Our proven model does not conclusively show that Incyte will beat on earnings this quarter  That is because a stock needs to have both a positive  and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  to be able to beat estimates  Unfortunately  that is not the case here  as you will see below 
Earnings ESP  For Incyte  Earnings ESP is  17 82   You can uncover the best stocks to buy or sell before they re reported with our  
Zacks Rank  Incyte currently carries a Zacks Rank  5  Strong Sell   While the company s positive ESP is favorable  an unfavorable rank makes surprise prediction difficult  Moreover  we caution against stocks with a Zacks Rank  4  Sell  or 5 going into the earnings announcement  especially when the company is seeing negative estimate revisions 
Stocks to Consider
Here are two health care stock worth considering with the right combination of elements to beat on earnings 
Mallinckrodt   NYSE MNK   has an Earnings ESP of  2 25  and a Zacks Rank  2  The company is scheduled to report results on Feb 26  You can see  
ACADIA Pharmaceuticals Inc    NASDAQ ACAD   has an Earnings ESP of  3 89  and a Zacks Rank  3 
Is Your Investment Advisor Fumbling Your Financial Future 
See how you can more effectively safeguard your retirement with a new Special Report   4 Warning Signs Your Investment Advisor Might Be Sabotaging Your Financial Future  ",2019-02-11,Zacks Investment Research,https://www.investing.com/analysis/is-a-disappointment-in-store-for-incyte-incy-q4-earnings-200386504,200386504
129442,350957,ACAD,Zoetis  ZTS  To Report Q4 Earnings  What s In The Cards ,opinion,"Zoetis Inc    NYSE ZTS   is gearing up to report fourth quarter 2018 results 
Zoetis  performance has been impressive  with the company surpassing expectations in all of the previous four quarters  the average positive earnings surprise being 6 98  
Zoetis  share price movement shows that the stock has outperformed the in the past year  The stock has rallied 19 4   against the industry s decline of 16 4  

 
Let s see how things are shaping up for this announcement 
Factors to Consider
Zoetis derives majority of its revenues from a diversified product portfolio of medicines and vaccines used to treat and protect livestock and companion animals  The company continues to strengthen its diverse product portfolio through lifecycle innovations  strong customer relationships  and access to new markets and technologies 
The company s companion animal business has been performing well  Apoquel and other product launches continue to drive growth in companion animal portfolio  Key dermatology products Apoquel and Cytopoint  new products such as Simparica and Stronghold Plus  and increased medicalization rates in key international markets such as China and Brazil should propel further growth 
Zoetis expects to generate more than  500 million in combined sales from Apoquel and Cytopoint in 2018  Oral parasite Simparica is expected to witness further growth  The company also expects to see more favorable conditions for livestock 
In July  Zoetis completed the acquisition of Caifornia based Abaxis to augment its presence in the animal health diagnostics market  which is a fast growing portion of the animal health industry  This is anticipated to boost sales  Further  updates on this acquisition are expected during fourth quarter conference call 
We expect the company to throw more light other pipeline updates 
What Our Model Indicates
Our proven model does not conclusively show that Zoetis is likely to beat earnings in the to be reported quarter  This is because the stock needs to have both a positive  and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  to be able to beat estimates  But that is not the case here  as you will see below 
Earnings ESP  Zoetis has an Earnings ESP of  1 52  as the Zacks Consensus Estimate is pegged at 77 cents  while the Most Accurate Estimate is pegged at 78 cents  You can uncover the best stocks to buy or sell before they re reported with our  
Zacks Rank  Zoetis carries a Zacks Rank  4 
Note that Sell rated stocks  Zacks Rank  4 or 5  going into an earnings announcement are best avoided Zoetis Inc  Price and EPS Surprise

    
Stocks That Warrant a Look
Here are some stocks you may want to consider as our model shows that these have the right combination of elements to post an earnings beat this quarter 
Acadia Pharmaceuticals Inc    NASDAQ ACAD   has an Earnings ESP of  3 89  and a Zacks Rank  3      
Aduro Biotech Inc    NASDAQ ADRO   has an Earnings ESP of  15 23  and a Zacks Rank  2 
Amicus Therapeutics Inc    NASDAQ FOLD   has an Earnings ESP of  10 07  and a Zacks Rank  3 
Is Your Investment Advisor Fumbling Your Financial Future  
See how you can more effectively safeguard your retirement with a new Special Report   4 Warning Signs Your Investment Advisor Might Be Sabotaging Your Financial Future  ",2019-02-11,Zacks Investment Research,https://www.investing.com/analysis/zoetis-zts-to-report-q4-earnings-whats-in-the-cards-200386525,200386525
129454,350969,ACAD,ACAD  NDRA  TWTR  TAL Stock Updates,opinion,"ACADIA Pharmaceuticals Inc   NASDAQ ACAD   one of our swings  came down hard to support and bounced on Thursday  jumping 2 03  or 10 1 2   to 21 27  on 2 1 million shares  That was a major bounce off the low  You have to stop it now under 19  191 4 is support  If you can get this through 23 1 2  we re looking at 26  and 27 1 2 
ENDRA Life Sciences Inc   NASDAQ NDRA  has a very interesting chart  It has big volume on the upside  and then a pullback because the volume lowered  On Thursday  it bounced 48 cents  or 12   to 4 36  with a volume increase to 925 958 shares traded  Technicals are also increasing and looking better  Since Jan  it formed a base  broke out  and pulled back in a falling wedge  Targets are 6  and then 8 
Twitter  Inc   NYSE TWTR   had a good day on Thursday  It popped out of a falling wedge in a breakaway gap above the 50  eking out 4 26  or 15   to 31 80  on 79 million shares  For me  that s a significant day  If it can hold 30 1 4  and come on again  we could see 36 15  which is the target 
TAL Education Group  NYSE TAL  in China broke back out and closed at the 50  jumping 3 24  or 14   to 25 98  on 15 million shares on Thursday  If it makes it through here  a major breakout above 27 1 4 will get it to 35 
Stocks on the long side included ACADIA Pharmaceuticals Inc   ACAD   ENDRA Life Sciences Inc   NDRA   AudioCodes Ltd   AUDC   Zix Corporation  ZIXI   Amarin Corporation plc  NASDAQ AMRN   FTI Consulting  Inc   NYSE FCN   Twitter  Inc   TWTR   Fate Therapeutics  Inc   NASDAQ FATE   Turkcell Iletisim Hizmetleri A S   NYSE TKC   TAL Education Group  TAL   and trivago N V   NASDAQ TRVG  
Watch video here ",2018-10-26,Harry Boxer,https://www.investing.com/analysis/acad-ndra-twtr-tal-200351024,200351024
129457,350972,ACAD,I m Watching These 4 Stocks,opinion,"ACADIA Pharmaceuticals  NASDAQ ACAD  popped 2 88  or 15   to 22 36  on 3 6 million shares on Thursday  Looking at the overall structure  this stock exploded  pulled back  and I gave you a swing on it  Then it went from 19 to 23  and change  but it pulled back when the market did  You can see that right now it looks like this remains the platform and you ve got to keep a stop under 19  I m looking for this stock to make it out over 23 1 2 and run to the 26 28 zone  The secondary target is 33  or thereabout 
Amarin Corporation  NASDAQ AMRN  has a great chart  and what a great company  Just a fantastic chart  folks  When you have a big gap and it won t back down  it just keeps going up in a rising flag or pattern  Look at Thursday  At 22 64  this stock never closed this high before  jumping 1 81  or 9   on 13 million shares  I think it s going higher  The next target is 22 1 2 
American Superconductor Corporation  NASDAQ AMSC   which I gave you a swing on Thursday  popped 1 56  or 26   to 7 55  on 675 200 shares traded  I just like the overall structure of this stock  The base  the breakout  it crawled up the 60 day moving average  and then got slammed back to support  In this zone  it bounced back up  and on Thursday  may have broken out  Thursday was a big key  and the volume was the best since January when it exploded  I m looking for this stock to get to 9 1 2  but on a longer term basis  this stock could be headed to 12 1 2  if not more 
ProQR Therapeutics  NASDAQ PRQR  shot up 3 97  or 22   to 22 17  on 542 700 shares traded on Thursday  It has got to take out the double top at 22 85  however  it did get closer to that number at 22 67  If it can get though here  I will be looking or 27 3 4 for the next target ",2018-11-02,Harry Boxer,https://www.investing.com/analysis/im-watching-these-4-stocks-200354151,200354151
129461,350976,ACAD,4 Stocks To Watch Today  ACAD  AMSC  RUN  SEDG ,opinion,"ACADIA Pharmaceuticals Inc  NASDAQ ACAD  had quite a day on Wednesday after getting crushed on a secondary all the way down under 17  It then gapped up and opened 19 10 red to 20 67  and closed up 3 53  or 21   to 20 53  on 10 million shares  That was an impressive day for this stock  closing not only above resistance and lateral price resistance  but 50 day moving average as well  This may very well run to 23  If it gets through the 23 1 2 area  26 7 is the next target 
American Superconductor Corporation  NASDAQ AMSC   one of our swing trades  after the falling wedge held the moving averages and recent prior highs with a snapback  It gained another 40 cents  or 4 45   to 9 39  on 321 938 shares traded on Wednesday  Watch for a move to take out 9 90  and then it has to move up to 11  and 12 1 4 
Sunrun Inc  NASDAQ RUN   another solar  broke out  followed through  then it had an up day on Wednesday  advancing another 42 cents  or 3   to 14 53  on 2 9 million shares  It ran up to resistance and may try to run up to the 15 1 2 16 1 2 zone  Once it gets through that  it will be on its way to a much bigger move  If it gets through 17  you may see 20 24 on this one 
SolarEdge Technologies Inc  NASDAQ SEDG  looks to me like the declining topsline may have been taken out  On Wednesday  it popped 3 02  or 7 63   to 42 61  on 900 325 shares traded  That s decent volume for this stock  It s right up against resistance at 40 3 4  Any movement across here and it could run to 49 51  and possibly  at some point  the 57 range again  For now  though  targets are 49 50  and then the high 50 s 
Stocks on the long side included ACADIA Pharmaceuticals Inc   ACAD   Alaska Air Group  Inc   ALK   American Superconductor Corporation  AMSC   Sphere 3D Corp   ANY   Bilibili Inc   BILI   BioScrip  Inc   BIOS   Codexis  Inc   CDXS   salesforce com  inc   CRM   Crocs  Inc   CROX   eHealth  Inc   EHTH   JinkoSolar Holding Co   Ltd   JKS   New Age Beverages Corporation  NBEV   NIO Inc   NIO   Sunrun Inc   RUN   SolarEdge Technologies  Inc   SEDG   Guggenheim Solar ETF  TAN   VelocityShares 3x Long Natural Gas ETN  UGAZ   United States Natural Gas  UNG   Vericel Corporation  VCEL   Vocera Communications  Inc   VCRA   Wayfair Inc   W   and YETI Holdings  Inc   YETI  
Watch video here ",2018-11-28,Harry Boxer,https://www.investing.com/analysis/acad-amsc-run-sedg-200363322,200363322
129464,350979,ACAD,Amgen s Postmenopausal Osteoporosis Drug Gets FDA Panel Nod,opinion,Amgen  Inc    NASDAQ AMGN   and its partner UCB announced that an FDA advisory committee has given a positive recommendation to approve their pipeline candidate  Evenity  romosozumab  for the treatment of postmenopausal women with osteoporosis at high risk of fracture Of the 19 members of FDA s Bone  Reproductive and Urologic Drugs Advisory Committee  BRUDAC   18 voted in favor of approval after reviewing safety and efficacy data from some pivotal phase III studies  The FDA is not mandated to follow the recommendation of an advisory committee but generally it does We remind investors that in the United States  Amgen re submitted the biologics license application   BLA   in July last year  The first BLA seeking approval of Evenity for the same indication in the United States was issued a complete response letter   CRL   by the FDA in July 2017  The CRL was issued due to a cardiovascular side effect observed in the ARCH study  The first BLA included data only from FRAME study  The FDA had requested a resubmission of the application with additional data from the ARCH and the BRIDGE studies  The second BLA included data from the ARCH and BRIDGE studies In the past year  Amgen s stock has risen 9 7  against 21 2  decrease of its    Earlier this month  Evenity was approved by regulatory authorities in Japan  its first approval anywhere in the world  Evenity is also under review in Europe In the United States  one in two women over the age of 50 usually suffers osteoporotic fracture  After such osteoporotic fracture  the risk of another fracture increases fivefold within the first year and rises further over time if untreated  If Evenity gets approval  these women who are at high risk of fracture could benefit from an additional treatment option that has the potential to increase bone formation while slowing down existing bone loss  This can bring in more sales and profits for Amgen Amgen currently carries a Zacks Rank  2  Buy   You can see  Better ranked stocks in the biotech sector are ACADIA Pharmaceuticals Inc    NASDAQ ACAD    Vanda Pharmaceuticals Inc    NASDAQ VNDA   and Exelixis  Inc    NASDAQ EXEL    all sporting a Zacks Rank  1 Vanda s earnings estimates have moved 11 1  north for 2019 over the past 90 days  The stock has surged 45 8  in the past six months Exelixis  earnings estimates have risen 14 7  in the past 90 days  The stock has risen 7 5  in the past six months ACADIA s stock has soared 23 8  in the past six months Today s Stocks from Zacks  Hottest StrategiesIt s hard to believe  even for us at Zacks  But while the market gained  21 9  in 2017  our top stock picking screens have returned  115 0    109 3    104 9    98 6   and  67 1  And this outperformance has not just been a recent phenomenon  Over the years it has been remarkably consistent  From 2000   2017  the composite yearly average gain for these strategies has beaten the market more than 19X over  Maybe even more remarkable is the fact that we re willing to share their latest stocks with you without cost or obligation ,2019-01-16,Zacks Investment Research,https://www.investing.com/analysis/amgens-postmenopausal-osteoporosis-drug-gets-fda-panel-nod-200376742,200376742
129471,350986,ACAD,4 Biotech Stocks Ready To Crush The Market In 2018,opinion,"The year 2017 has been quite a impressive one for the biotech sector as evident from the 19 4  gain registered so far by the NASDAQ Biotechnology Index     LON NBI    This is surely welcome news for investors since the industry suffered a decline of 19 2  last year While drug pricing issue  competition and a slowdown in growth of key drugs dented the sector s 2016 performance  new drug approvals and encouraging outlook by the companies boosted investor sentiment in 2017 Immuno oncology continued to remain in spotlight in 2017  The FDA s approval of CAR T  chimeric antigen T cell receptor  therapies like Kymriah and Gilead Sciences    NASDAQ GILD   Yescarta for leukemia and lymphoma shifted investors  attention toward small biotechs companies developing these therapies  Investors also kept tab of key candidates  data The slowdown in mature products forced bigwigs like Gilead to undertake acquisitions to bolster pipelines  Gilead acquired erstwhile Kite Pharma to add Yescarta to its kitty  The company also inked an agreement to acquire Cell Design Labs  Celgene Corporation   NASDAQ CELG   too might be on the look out for acquisitions to bolster its portfolio Approval of new drugs like Dupixient  Kevzara  Idhifa  Tremfya among others along with label expansion of existing drugs like Cabometyx boosted the respective companies  portfolios  We note that 2017 saw a larger number of drug approvals from the FDA than 2016 Although the threat of biosimilars loom large on the sector  we expect a further boost in performance from the sector in 2018   Notably  the Medical   Biomed Genetics sub industry carries a Zacks Industry Rank of 114  which places it at the top 45  of the 250 plus Zacks industries While the smaller biotechs have performed impressively in 2017  the bigwigs weren t far behind and we expect the momentum to continue in 2018 as well  Here we list a few biotech companies which should outperform the market in 2018 ACADIA Pharmaceuticals Inc    NASDAQ ACAD   s lead drug Nuplazid is approved for the treatment of hallucinations and delusions associated with Parkinson s disease psychosis  The drug was approved in 2016 by the FDA  Notably  it is the only drug approved in the United States for this condition  The drug generated sales of  81 3 million in the first nine months of 2017 and the company is looking to expand the drug s label further  2017 was a roller coaster ride for Acadia  Shares of the company have moved up 5 6  year to date compared with the   gain of 4 8   We believe this Zacks Rank  2  Buy  company should perform well in 2018 boosted by Nulpazid   You can see    Looking for the Best Stocks for 2018  Be among the first to see our   Sangamo Therapeutics  Inc    NASDAQ SGMO   focuses on translating ground breaking science into genomic therapies that transform patients  lives using the company s industry leading platform technologies in genome editing  gene therapy  gene regulation and cell therapy  Sangamo is conducting phase I II clinical trials in Hemophilia A and B  and lysosomal storage disorders MPS I and MPS II  The company has collaborated with leading global companies for various pipeline candidates   This Zacks Rank  2 company had a phenomenal run in 2017 with the stock soaring 455 7  year to date compared with the industry s gain of 5 2   AnaptysBio   NASDAQ ANAB   is  a clinical stage biotechnology company  Its anti inflammatory pipeline includes anti IL 33 antibody  ANB020  for the treatment of moderate to severe adult atopic dermatitis  severe adult peanut allergy and severe adult eosinophilic asthma  its anti IL 36R antibody  ANB019  for the treatment of rare inflammatory diseases  including generalized pustular psoriasis and palmo plantar pustular psoriasis  The company also has a portfolio of checkpoint receptor agonist antibodies for the treatment of certain autoimmune diseases where immune checkpoint receptors are insufficiently activated  which have demonstrated efficacy in an animal model of graft versus host disease  The company is expected to report top line data from its on going phase IIa studies on ANB020 in severe adult peanut allergy and severe adult eosinophilic asthma during the first and second quarters of 2018  respectively  This Zacks Rank  2 company had a phenomenal run in 2017 with the stock soaring 488 4  compared with the industry s gain of 5 2   Sino Biopharmaceutical Limited  researches  develops  manufactures and markets a wide array of Chinese medicines and chemical medicines for two major therapeutic categories   hepatitis and cardio cerebral diseases  The company also actively develops medicines for treating tumors  analgesia  orthopedic diseases  anti infection  parenteral nutrition  respiratory system diseases  anorectal diseases  diabetes and other diseases to meet the increasing demand of the market  medical practitioners and patients   The lead products include  Tianqingganmei injections  Runzhong dispersible tablets  Mingzheng capsules  Tianqingganping enteric capsules along with cardio cerebral medicines such as Yilunping and Tuotuo tablets   The company currently carries a Zacks Rank  2 We expect investors to remain focussed on this dynamic sector eying new drug approvals and important data read outs 
Wall Street s Next Amazon  NASDAQ AMZN Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time  It s a once in a generation opportunity to invest in pure genius ",2017-12-26,Zacks Investment Research,https://www.investing.com/analysis/4-biotech-stocks-ready-to-crush-the-market-in-2018-200276125,200276125
129472,350987,ACAD,The Zacks Analyst Blog Highlights  ACADIA Pharmaceuticals  Sangamo Therapeutics  AnaptysBio And Sino Biopharmaceutical,opinion,For Immediate ReleaseChicago  IL   Dec 28  2017   Zacks com announces the list of stocks featured in the Analyst Blog  Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets  Stocks recently featured in the blog include ACADIA Pharmaceuticals Inc    NASDAQ ACAD    Sangamo Therapeutics  Inc    NASDAQ SGMO    AnaptysBio   NASDAQ ANAB   and Sino Biopharmaceutical Limited  Today  Zacks is promoting its   Buy   stock recommendations   Here are highlights from Wednesday s Analyst Blog  4 Biotech Stocks Ready to Crush the Market in 2018The year 2017 has been quite a impressive one for the biotech sector as evident from the 19 4  gain registered so far by the NASDAQ Biotechnology Index  This is surely welcome news for investors since the industry suffered a decline of 19 2  last year While drug pricing issue  competition and a slowdown in growth of key drugs dented the sector s 2016 performance  new drug approvals and encouraging outlook by the companies boosted investor sentiment in 2017 Immuno oncology continued to remain in spotlight in 2017  The FDA s approval of CAR T  chimeric antigen T cell receptor  therapies like Kymriah and Gilead Sciences  Yescarta for leukemia and lymphoma shifted investors  attention toward small biotechs companies developing these therapies  Investors also kept tab of key candidates  data The slowdown in mature products forced bigwigs like Gilead to undertake acquisitions to bolster pipelines  Gilead acquired erstwhile Kite Pharma to add Yescarta to its kitty  The company also inked an agreement to acquire Cell Design Labs  Celgene Corporation  NASDAQ CELG  too might be on the look out for acquisitions to bolster its portfolio Approval of new drugs like Dupixient  Kevzara  Idhifa  Tremfya among others along with label expansion of existing drugs like Cabometyx boosted the respective companies  portfolios  We note that 2017 saw a larger number of drug approvals from the FDA than 2016 Although the threat of biosimilars loom large on the sector  we expect a further boost in performance from the sector in 2018   Notably  the Medical   Biomed Genetics sub industry carries a Zacks Industry Rank of 114  which places it at the top 45  of the 250 plus Zacks industries While the smaller biotechs have performed impressively in 2017  the bigwigs weren t far behind and we expect the momentum to continue in 2018 as well  Here we list a few biotech companies which should outperform the market in 2018 ACADIA Pharmaceuticals Inc s lead drug Nuplazid is approved for the treatment of hallucinations and delusions associated with Parkinson s disease psychosis  The drug was approved in 2016 by the FDA  Notably  it is the only drug approved in the United States for this condition  The drug generated sales of  81 3 million in the first nine months of 2017 and the company is looking to expand the drug s label further  2017 was a roller coaster ride for Acadia  Shares of the company have moved up 5 6  year to date compared with the   gain of 4 8   We believe this Zacks Rank  2  Buy  company should perform well in 2018 boosted by Nulpazid   You can see   Looking for the Best Stocks for 2018  Be among the first to see our   Sangamo Therapeutics  Inc  focuses on translating ground breaking science into genomic therapies that transform patients  lives using the company s industry leading platform technologies in genome editing  gene therapy  gene regulation and cell therapy  Sangamo is conducting phase I II clinical trials in Hemophilia A and B  and lysosomal storage disorders MPS I and MPS II  The company has collaborated with leading global companies for various pipeline candidates   This Zacks Rank  2 company had a phenomenal run in 2017 with the stock soaring 455 7  year to date compared with the industry s gain of 5 2  AnaptysBio is a clinical stage biotechnology company  Its anti inflammatory pipeline includes anti IL 33 antibody  ANB020  for the treatment of moderate to severe adult atopic dermatitis  severe adult peanut allergy and severe adult eosinophilic asthma  its anti IL 36R antibody  ANB019  for the treatment of rare inflammatory diseases  including generalized pustular psoriasis and palmo plantar pustular psoriasis  The company also has a portfolio of checkpoint receptor agonist antibodies for the treatment of certain autoimmune diseases where immune checkpoint receptors are insufficiently activated  which have demonstrated efficacy in an animal model of graft versus host disease  The company is expected to report top line data from its on going phase IIa studies on ANB020 in severe adult peanut allergy and severe adult eosinophilic asthma during the first and second quarters of 2018  respectively  This Zacks Rank  2 company had a phenomenal run in 2017 with the stock soaring 488 4  compared with the industry s gain of 5 2  Sino Biopharmaceutical Limited researches  develops  manufactures and markets a wide array of Chinese medicines and chemical medicines for two major therapeutic categories   hepatitis and cardio cerebral diseases  The company also actively develops medicines for treating tumors  analgesia  orthopedic diseases  anti infection  parenteral nutrition  respiratory system diseases  anorectal diseases  diabetes and other diseases to meet the increasing demand of the market  medical practitioners and patients   The lead products include  Tianqingganmei injections  Runzhong dispersible tablets  Mingzheng capsules  Tianqingganping enteric capsules along with cardio cerebral medicines such as Yilunping and Tuotuo tablets   The company currently carries a Zacks Rank  2 We expect investors to remain focussed on this dynamic sector eying new drug approvals and important data read outs Wall Street s Next Amazon  NASDAQ AMZN Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time  It s a once in a generation opportunity to invest in pure genius Today  Zacks is promoting its   Buy   stock recommendations   About Zacks Equity ResearchZacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long term Continuous coverage is provided for a universe of 1 150 publicly traded stocks  Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance  Recommendations and target prices are six month time horizons Strong Stocks that Should Be in the NewsMany are little publicized and fly under the Wall Street radar  They re virtually unknown to the general public  Yet today s 220 Zacks Rank  1  Strong Buys  were generated by the stock picking system that has nearly tripled the market from 1988 through 2015  Its average gain has been a stellar  26  per year Follow us on Twitter  Join us on Facebook  NASDAQ FB   Zacks Investment Research is under common control with affiliated entities  including a broker dealer and an investment adviser   which may engage in transactions involving the foregoing securities for the clients of such affiliates Media ContactZacks Investment Research800 767 3771 ext  9339Past performance is no guarantee of future results  Inherent in any investment is the potential for loss  This material is being provided for informational purposes only and nothing herein constitutes investment  legal  accounting or tax advice  or a recommendation to buy  sell or hold a security  No recommendation or advice is being given as to whether any investment is suitable for a particular investor  It should not be assumed that any investments in securities  companies  sectors or markets identified and described were or will be profitable  All information is current as of the date of herein and is subject to change without notice  Any views or opinions expressed may not reflect those of the firm as a whole  Zacks Investment Research does not engage in investment banking  market making or asset management activities of any securities  These returns are from hypothetical portfolios consisting of stocks with Zacks Rank   1 that were rebalanced monthly with zero transaction costs  These are not the returns of actual portfolios of stocks  The S P 500 is an unmanaged index  Visit  for information about the performance numbers displayed in this press release ,2017-12-27,Zacks Investment Research,https://www.investing.com/analysis/the-zacks-analyst-blog-highlights-acadia-pharmaceuticals-sangamo-therapeutics-anaptysbio-and-sino-biopharmaceutical-200276348,200276348
129477,350992,ACAD,Shorting Acadia s Triangle,opinion,"Today s big hit for me is ACADIA Pharmaceuticals  NASDAQ ACAD   I ve been tracking this one forever  since it s got a gorgeous symmetric triangle pattern  I shorted it yesterday as it approached its midline and today  blammo  it s down 16  

A closer view shows the clean pattern and how it has broken below the triangle now  I ve tightened my stop to just above the day s high and intend to hang on to this one ",2018-02-28,Tim Knight,https://www.investing.com/analysis/shorting-acadias-triangle-200295147,200295147
129480,350995,ACAD,Another SlopeCharts Victory,opinion,"Back on February 28th  I did this post about the triangle setup for ACADIA Pharmaceuticals  NASDAQ ACAD   Here s what the chart looked like 

And here s an update ",2018-04-09,Tim Knight,https://www.investing.com/analysis/another-slopecharts-victory-200304086,200304086
129483,350998,ACAD,Will ACADIA  ACAD  Disappoint Investors This Earnings Season ,opinion,ACADIA Pharmaceuticals Inc    NASDAQ ACAD   is expected to release first quarter 2018 results on May 8  In the last reported quarter  ACADIA delivered a positive earnings surprise of 5 17   The company delivered an average positive earnings surprise of 11 24  in the last four quarters ACADIA s shares have tumbled 47 5  year to date compared with the  s decline of 10 7    Let s see how things are shaping up for this announcement Factors at PlayACADIA is focused on developing products for treating unmet medical needs in central nervous system   CNS    The performance of its first approved drug  Nuplazid  pimavanserin   for treating hallucinations and delusions associated with Parkinson s disease   PD   psychosis  has been impressive since its launch in April 2016 The company is also on track with its multi year plans of developing Nuplazid in indications beyond PD psychosis  The company is studying the drug in five clinical programs for Nuplazid   Alzheimer s disease agitation  Alzheimer s disease psychosis  Schizophrenia inadequate response  Schizophrenia negative symptoms and major depressive disorders In October 2017  the company initiated a phase III HARMONY study in dementia related psychosis or DRP  The company also received Breakthrough Therapy Designation from the FDA for Nuplazid for the treatment of DRP  Following an End of Phase II meeting with the FDA  robust positive results from one phase III study  together with supported data from prior studies with Nuplazid could serve as the basis of a supplementary new drug application We expect the company to provide further update on the progress of this study during first quarter earnings call The company expects that full year Nuplazid net product sales for 2018 will be between  255 million and  270 million  with net sales for the first quarter of 2018 between  45 million and  48 million  The company expects strong volume growth for Nuplazid What Our Model IndicatesOur proven model does not show an earnings beat for ACADIA this quarter  This is because a stock needs to have both   a positive  and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold    for this to happen  However  that is not the case here as you will see below Zacks ESP  ACADIA has an Earnings ESP of  0 36   This is because the Most Accurate estimate and the Zacks Consensus Estimate are pegged at a loss of 56 cents  You can uncover the best stocks to buy or sell before they re reported with our  Zacks Rank  ACADIA currently has a Zacks Rank  2 which increases the predictive power of ESP  However  we need to have a positive ESP to be confident about an earnings beat Note that we caution against stocks with a Zacks Rank  4 or 5  Sell rated  going into an earnings announcement especially when the company is seeing negative estimate revisions  ACADIA Pharmaceuticals Inc  Price and EPS Surprise     Stocks That Warrant a LookHere are some biotech stocks that you may want to consider  as our model shows that these  have the right combination of elements to post an earnings beat this quarter Celgene Corporation   NASDAQ CELG   is scheduled to release its first quarter 2018  results on May 4  The company has an Earnings ESP of  0 63  and a Zacks Rank  3  You can see  Adverum Biotechnologies  Inc    NASDAQ ADVM   has an Earnings ESP of  6 9  and currently carries a Zacks Rank  3  The company is expected to release first quarter results on May 8 Emergent Biosolutions Inc    NYSE EBS   has an Earnings ESP of  61 8  and a Zacks Rank  3   The company is scheduled to release first quarter results on May 3 Wall Street s Next Amazon  NASDAQ AMZN  Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time  It s a once in a generation opportunity to invest in pure genius ,2018-04-30,Zacks Investment Research,https://www.investing.com/analysis/will-acadia-acad-disappoint-investors-this-earnings-season-200311323,200311323
129484,350999,ACAD,ACADIA Posts Narrower Than Expected Loss In Q1  Sales Beat,opinion,ACADIA Pharmaceuticals  Inc    NASDAQ ACAD   focuses on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system  CNS  disorders  The company has a portfolio of product opportunities led by its key drug  Nuplazid  pimavanserin   which was approved by the FDA in April  2016 for the treatment of hallucinations and delusions associated with Parkinson s disease psychosis   PD  Psychosis  and is the only drug approved in the United States for this condition  The company has worldwide commercialization rights to Nuplazid  The company plans to continue to study the use of Nuplazid in multiple disease states The company s track record has been impressive  Over the last four quarters  the company has beaten estimates on all four occasions  Overall  ACADIA has posted an average positive earnings surprise of 11 24  for the trailing four quarters Currently  ACADIA has a Zacks Rank  2  Buy   but that could definitely change following the company s earnings report which was just released  We have highlighted some of the key stats from this just revealed announcement below Earnings  ACADIA posted narrower than expected loss in the first quarter of 2018  Our consensus called for loss per share of 56 cents  and the company reported loss of 44 cents Revenue  Revenues  also  beat expectations  ACADIA posted revenues of  48 9 million  compared to our consensus estimate of  47 million Key Stats Nuplazid delivered strong performance in the first quarter of 2018 and reported sales of  48 9 million in the quarter  an increase of 220  year over year 2018 Guidance  The company reiterates its guidance for full year Nuplazid net product sales for 2018 and expects it to be in the range of  255 million and  270 million  For the second quarter of 2018  ACADIA expects Nuplazid net sales to be between  57 million and  61 million  The company expects strong volume growth for Nuplazid Share Price Impact Share went up 7 5  in pre market trading  ACADIA Pharmaceuticals Inc  Price and Consensus    Today s Stocks from Zacks  Hottest Strategies It s hard to believe  even for us at Zacks  But while the market gained  21 9  in 2017  our top stock picking screens have returned  115 0    109 3    104 9    98 6   and  67 1  And this outperformance has not just been a recent phenomenon  Over the years it has been remarkably consistent  From 2000   2017  the composite yearly average gain for these strategies has beaten the market more than 19X over  Maybe even more remarkable is the fact that we re willing to share their latest stocks with you without cost or obligation ,2018-05-03,Zacks Investment Research,https://www.investing.com/analysis/acadia-posts-narrower-than-expected-loss-in-q1-sales-beat-200312989,200312989
129487,351002,ACAD,What A Cad,opinion,Slope favorite ACADIA Pharmaceuticals  NASDAQ ACAD  continues to break down nicely  having completed a massive  multi year top ,2018-06-15,Tim Knight,https://www.investing.com/analysis/what-a-cad-200325315,200325315
129512,351027,ACAD,What s In The Cards For Adverum  ADVM  This Earnings Season ,opinion,"Adverum Biotechnologies  Inc    NASDAQ ADVM   is expected to report third quarter 2017 results on Nov 14 
The company has a dismal track record as it missed estimates in three of the last four quarters  resulting in an average negative earnings surprise of 11 95   In the last reported quarter  Adverum beat estimates  delivering a positive surprise of 27 03  
Also  Adverum s share price movement year to date indicates that the stock has outperformed the   The company s shares have gained 12 1  compared with the industry s gain of 2 3  

Factors to Consider
Adverum is a development stage biotech company with no approved product in its portfolio 
Adverum s pipeline consists of gene therapy programs for rare diseases  alpha 1 antitrypsin  A1AT  deficiency  wet AMD and hereditary angioedema   HAE    However  all the candidates are in pre clinical studies 
The company added multiple early stage candidates including ANN 043  ADVM 001   ANN 053  ANN 002  and ANN 003 among others with the acquisition of Annapurna Therapeutics in May 2016 
Based on pre clinical development results  the company is planning to advance its anti VEGF gene therapy candidate  ADVM 022  The candidate is being developed for treating wet age related macular degeneration   AMD    Adverum is in the process of filing a pre investigational new drug  IND   following its meeting with the FDA in the first quarter of 2017  The company is also developing another anti VEGF gene therapy  ADVM 032 
Adverum expects to initiate a phase I II study on ADVM 043 for the treatment of A1AT deficiency by the end of this year  The company filed an IND with the FDA and also met the agency in July for a review of the development plan 
Moreover  it is evaluating ADVM 053 to treat HAE and discussed a development plan with the FDA in the first quarter  It is preparing to file an IND 
Adverum extended its collaboration agreement with Regeneron Pharmaceuticals  Inc    NASDAQ REGN   by three years till May 1  2020  The companies will developeight distinct ocular therapeutic targets  including AVA 311  which is being developed for treating juvenile X Linked Retinoschisis 
The company has also collaborated with Editas Medicine  Inc    NASDAQ EDIT   for developing treatment for inherited retinal diseases using the latter s CRISPR based genome editing technologies 
We expect investor focus to remain on pipeline updates on the third quarter earnings call 
Earnings Whispers
Our proven model does not conclusively show that Adverum is likely to beat estimates this quarter  This is because a stock needs to have both a positive  and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  to be able to beat estimates  But that is not the case here  as you will see below 
Zacks ESP  Earnings ESP  which represents the difference between the Most Accurate estimate and the Zacks Consensus Estimate  is  3 33   This is because the Most Accurate estimate is at a loss of 31 cents while the Zacks Consensus Estimate stands at a loss of 30 cents  You can uncover the best stocks to buy or sell before they re reported with our  
Zacks Rank   Adverum s Zacks Rank  3 increases the predictive power of ESP  However  we need to have a positive ESP to be confident about an earnings surprise 
Note that we caution against stocks with a Zacks Rank  4 or 5  Sell rated  going into an earnings announcement  especially when the company is seeing negative estimate revisions Adverum Biotechnologies  Inc  Price and EPS Surprise
 

   Stocks That Warrant a Look
Here are a couple of health care stocks that you may want to consider  as our model shows that these have the right combination of elements to post an earnings beat this quarter 
ACADIA Pharmaceuticals Inc    NASDAQ ACAD   is scheduled to release results on Nov 7  The company has an Earnings ESP of  3 2  and a Zacks Rank  3  You can see  
Looking for Stocks with Skyrocketing Upside 
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana 
Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ",2017-11-03,Zacks Investment Research,https://www.investing.com/analysis/whats-in-the-cards-for-adverum-advm-this-earnings-season-200258208,200258208
129513,351028,ACAD,Spectrum Doubles In 3 Months  What s Driving The Rally ,opinion,"Shares of Spectrum Pharmaceuticals  Inc    NASDAQ SPPI   have been rising over the past year  This biotech company has more than doubled in the past three months surging 110   significantly outperforming the 5 3  rise of the  in this period Spectrum is focused on acquiring  developing and commercializing products  primarily in the fields of hematology and oncology  The company markets six products  which are utilized to treat several cancer indications including lymphoma  leukemia and myeloma  However  its primary focus focus is on the development of pipeline which includes poziotinib  Qapzola and Rolontis Pipeline in FocusIn the last three months  poziotinib has been the driving factor behind the stock s rally  In October  Spectrum announced encouraging preliminary data from a phase II study on poziotinib in non small cell lung cancer   NSCLC   patients with exon 20 insertion mutations in EGFR  The candidate achieved an objective response rate in 73  of patients  The stock witnessed a rise following the news  Spectrum also initiated a multicenter phase II study to evaluate poziotinib in NSCLC patients with exon 20 insertion mutations in EGFR or HER2 Meanwhile  Spectrum s most advanced candidate  Rolontis  is currently being evaluated in two separate phase III studies   ADVANCE and RECOVER   for treating chemotherapy induced neutropenia  Top line data from the ADVANCE study is expected in first quarter 2018  This will be followed by a biologics license application  BLA   likely to be filed by the end of 2018  A phase III study is evaluating Qapzola  another pipeline candidate  in patients with non muscle invasive bladder cancer 
The lackluster product sales have kept investors focused on pipeline development  Also  Spectrum s cash and cash equivalents rose about  109 million to  247 million in the third quarter of 2017 which should help the company fund the development of candidates  A potential success inthe Rolontis study expected in early 2018 can be the next catalyst for the stock s further rise 
Spectrum Pharmaceuticals  Inc  Price   Zacks Rank   Stocks to ConsiderSpectrum carries a Zacks Rank  3  Hold  Some better ranked stocks in the pharma sector include Ligand Pharmaceuticals Incorporated   NASDAQ LGND    ACADIA Pharmaceuticals Inc    NASDAQ ACAD   and ANI Pharmaceuticals  Inc    NASDAQ ANIP    All the three stocks carry a Zacks Rank  2  Buy   You can see  Ligand s earnings estimates were flat at  2 96 for 2017 and increased from  3 68 to  3 70 over the last 60 days  The company delivered a positive earnings surprise in two of the trailing four quarters with an average beat of 8 22   The company s shares have returned 31 6  year to date ACADIA s loss estimates narrowed from  2 53 to  2 42 for 2017 and from  1 82 to  1 62 over the last 30 days  The company came up with a positive earnings surprise in three of the trailing four quarters with an average beat of 9 95  ANI Pharma s earnings per share estimates increased from  3 87 to  3 93 for 2017 and from  4 56 to  4 67 over the last 30 days  The company delivered positive surprises in two of the trailing four quarters with an average beat of 0 13   The stock has returned 23  year to date Will You Make a Fortune on the Shift to Electric Cars Here s another stock idea to consider  Much like petroleum 150 years ago  lithium power may soon shake the world  creating millionaires and reshaping geo politics  Soon electric vehicles  EVs  may be cheaper than gas guzzlers  Some are already reaching 265 miles on a single charge With battery prices plummeting and charging stations set to multiply  one company stands out as the  1 stock to buy according to Zacks research It s not the one you think ",2017-11-26,Zacks Investment Research,https://www.investing.com/analysis/spectrum-doubles-in-3-months-whats-driving-the-rally-200268447,200268447
129514,351029,ACAD,Medicines Company To Sell Infectious Disease Unit To Melinta,opinion,"The Medicines Company   NASDAQ MDCO   announced that it has entered into a definitive agreement with antibiotics company  Melinta Therapeutics  Inc    NASDAQ MLNT    for selling its infectious disease business unit for an upfront payment of  270 million  The agreement will grant Melinta worldwide rights of Orbactiv  Minocin and recently launched Vabomere 
The Medicines Company plans to focus on developing its pivotal pipeline candidate   inclisiran   for treating hypercholesterolemia 
The Medicines Company s shares have fallen 11 1  so far this year  underperforming the  s rise of 1 3  in that period 

Per the cash and stock deal  Melinta will pay  215 million in cash  including  165 million at the time of the closing of the deal  and  55 million in common stock 
The Medicine Company will receive royalties in the range of 5  25  on Vabomere U S  sales  5  15  on U S  sales of Minocin   Orbactiv  and 15  on international sales of all the drugs 
The Medicine Company plans to focus on the development of inclisiran  which is currently being evaluated in a phase III study for the treatment of hypercholesterolemia  The company has burnt significant cash this year  This deal will help the company to recoup a major portion of it  Moreover  the cash will help to continue the inclisiran study till its anticipated completion in 2019 
The deal is expected to close in the first quarter of 2018 
Meanwhile  the company  as part of its earlier announced restructuring program  will cut its headcount by 60  This will also reduce its annual operating expenses The Medicines Company Price
 

   Zacks Rank   Stocks to Consider
The Medicines Company carries a Zacks Rank  3  Hold  
A couple of better ranked stocks in the pharma sector include Ligand Pharmaceuticals Inc    NASDAQ LGND   and ACADIA Pharmaceuticals Inc    NASDAQ ACAD    Both stocks carry a Zacks Rank  2  Buy   You can see  
Ligand s earnings estimates were increased from  2 96 to  2 97 for 2017 and increased from  3 68 to  3 70 over the last 60 days  The company delivered a positive earnings surprise in two of the trailing four quarters with an average beat of 8 22   The company s shares have returned 28 8  so far this year 
ACADIA s loss estimates narrowed from  2 53 to  2 42 for 2017 and from  1 82 to  1 62 over the last 30 days  The company came up with a positive earnings surprise in three of the trailing four quarters with an average beat of 9 95  
The Hottest Tech Mega Trend of All
Last year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ",2017-11-30,Zacks Investment Research,https://www.investing.com/analysis/medicines-company-to-sell-infectious-disease-unit-to-melinta-200269586,200269586
129515,351030,ACAD,TherapeuticsMD Falls Despite Acceptance Of NDA  Here s Why,opinion,"TherapeuticsMD  Inc    NASDAQ TXMD   announced that the FDA has accepted the resubmission of the New Drug Application   NDA   for its dyspareunia candidate  TX 004HR  The FDA also set a PDUFA date of May 29  2018 Shares of the company however fell 6 8  in after hours trading on Dec 19  presumably due to classification of resubmission as a Class 2 response by the FDA  Classification as a Class 1 response would have shortened the timeframe for a potential approval from six months to two months  We remind investors that the company had received a complete response letter   CRL   from the FDA in May for the same However  TherapeuticsMD s share price has increased 6 4  in the past six months  outperforming the  s decline 0 4  TX 400HR is an applicator free vaginal estradiol softgel drug for the treatment of moderate to  severe vaginal pain during sexual intercourse  dyspareunia  due to vulvar and vaginal atrophy  VVA  in post menopausal women The resubmission was supported by data from phase III Rejoice study  which demonstrated statistically significant and clinically meaningful improvements in dyspareunia and vaginal dryness from baseline compared to a placebo We note that the resubmission includes data only for two dosages   4 mcg and 10 mcg   of the candidate The CRL was a major setback for the company  Any issue with the resubmission may further delay the candidate s approval and result in a decline in shares According to the press release  an estimated 32 million women are currently suffering from symptoms of VVA in the United States We note that in April 2017  AMAG Pharmaceuticals  Inc    NASDAQ AMAG   had acquired commercial rights to Intrarosa  the only FDA approved non estrogen product for the treatment of moderate to severe dyspareunia from privately held Endoceutics  Inc TherapeuticsMD  Inc  Price
    Zacks Rank   Stocks to ConsiderTherapeuticsMD carries a Zacks Rank  3  Hold  A couple of better ranked stocks in the pharma sector include Celldex Therapeutics  Inc    NASDAQ CLDX   and ACADIA Pharmaceuticals Inc    NASDAQ ACAD    Both the stocks carry a Zacks Rank  2  Buy   You can see  Celldex s loss estimates narrowed from  1 03 to 93 cents for 2017 and from 96 cents to 90 cents over the last 60 days  The company delivered a positive earnings surprise in three of the trailing four quarters with an average beat of 15 36  ACADIA s loss estimates narrowed from  2 42 to  2 41 for 2017 and from  1 62 to  1 59 over the last 30 days  The company came up with a positive earnings surprise in three of the trailing four quarters with an average beat of 9 95  5 Medical Stocks to Buy NowZacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia  AIDS  muscular dystrophy  hemophilia  and other conditions New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline  Early investors could realize exceptional profits ",2017-12-19,Zacks Investment Research,https://www.investing.com/analysis/therapeuticsmd-falls-despite-acceptance-of-nda-heres-why-200274789,200274789
129518,351033,ACAD,Minerva Initiates Phase III Study On Schizophrenia Candidate,opinion,Minerva Neurosciences  Inc   NASDAQ NERV   announced that it has initiated a phase III study  MIN 101C07  to evaluate its lead pipeline candidate as monotherapy for the treatment of negative symptoms in patients diagnosed with schizophrenia Minerva s share price has declined 51 9  so far this year  while the  witnessed a gain of 7 5  The phase III study design is a 12 week  placebo controlled  monotherapy study testing two doses of MIN 101   32 mg and 64 mg   in schizophrenia patients with negative symptoms  The patients are required to have moderate to severe negative and stable positive symptoms over six months prior to enrollment The patients are also required to have a specified minimum threshold baseline score   20  on the Positive and Negative Syndrome Scale   PANSS   negative sub scale in order to be eligible for the study The primary endpoint of the study is to achieve an improvement in PANSS score  Top line data from the study is expected in the first half of 2019 The 12 week study will be followed by an open label extension study for period of 40 weeks The design of the phase III study is similar to the successfully completed phase IIb study  The phase IIb study showed improvement in schizophrenic patients with negative symptoms treated with MIN 101 compared to placebo With no approved products in its portfolio  Minerva is dependent on the progress of its pipeline  Moreover  with no major collaboration agreements the company doesn t have a source of funds while it continues to burn cash for the research and development process  The company expects to incur operating losses going forward  The cash available is expected to fund operations for the next 12 months only Any setback in the development of MIN 101 will adversely impact Minerva s shares Meanwhile  Minerva has a license agreement with Janssen Pharmaceuticals  a subsidiary of Johnson   Johnson   NYSE JNJ    for co development of orexin 2 receptor antagonist  MIN 202  for treating schizophrenia Minerva Neurosciences  Inc Price   Zacks Rank   Stocks to ConsiderMinerva Neurosciences carries a Zacks Rank  3  Hold  A couple of better ranked stocks in the pharma sector include Celldex Therapeutics  Inc    NASDAQ CLDX   and ACADIA Pharmaceuticals Inc    NASDAQ ACAD    Both the stocks carry a Zacks Rank  2  Buy   You can see  Celldex s loss estimates narrowed from  1 03 to 93 cents for 2017 and from 96 cents to 90 cents over the last 60 days  The company delivered a positive earnings surprise in three of the trailing four quarters with an average beat of 15 36  ACADIA s loss estimates narrowed from  2 42 to  2 41 for 2017 and from  1 62 to  1 59 over the last 30 days  The company came up with a positive earnings surprise in three of the trailing four quarters with an average beat of 9 95  5 Medical Stocks to Buy NowZacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia  AIDS  muscular dystrophy  hemophilia  and other conditions New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline  Early investors could realize exceptional profits ,2017-12-19,Zacks Investment Research,https://www.investing.com/analysis/minerva-initiates-phase-iii-study-on-schizophrenia-candidate-200274888,200274888
129521,351036,ACAD,Why The Earnings Streak Will Continue For ACADIA Pharmaceuticals  ACAD  ,opinion,Looking for a stock that might be in a good position to beat earnings at its next report  Consider ACADIA Pharmaceuticals Inc    NASDAQ ACAD    a firm in the Medical   Biomedical and Genetics industry  which could be a great candidate for another beat This company has seen a nice streak of beating earnings estimates  especially when looking at the previous two reports  In fact  in these reports  ACAD has beaten estimates by at least 15  in both cases  suggesting it has a nice short term history of crushing expectations Earnings in FocusTwo quarters ago  ACAD was expected to post a loss of 71 cents per share  while it actually produced a loss of 55 cents per share  a beat of 22 5   Meanwhile  for the most recent quarter  the company looked to deliver a loss of 63 cents per share  when it actually saw a loss of 53 cents per share instead  representing a 15 9  positive surprise ACADIA Pharmaceuticals Inc  Price and EPS Surprise   Thanks in part to this history  recent estimates have been moving higher for ACADIA Pharmaceuticals  In fact  the  for ACAD is positive  which is a great sign of a coming beat After all  the Zacks Earnings ESP compares the most accurate estimate to the broad consensus  looking to find stocks that have seen big revisions as of late  suggesting that analysts have recently become more bullish on the company s earnings prospects  This is the case for ACAD  as the firm currently has a Zacks Earnings ESP of 4 03   so another beat could be around the corner This is particularly true when you consider that ACAD has a great Zacks Rank  2  Buy   which can be a harbinger of outperformance and a signal for a strong earnings profile  You can see  When you add this solid Zacks Rank to a positive Earnings ESP   of the time  so it seems pretty likely that ACAD could see another beat at its next report  especially if recent trends are any guide Zacks Editor in Chief Goes  All In  on This Stock Full disclosure  Kevin Matras now has more of his own money in one particular stock than in any other  He believes in its short term profit potential and also in its prospects to more than double by 2019  Today he reveals and explains his surprising move in a new Special Report ,2017-12-25,Zacks Investment Research,https://www.investing.com/analysis/why-the-earnings-streak-will-continue-for-acadia-pharmaceuticals-acad-200275804,200275804
129541,351056,ACAD,Is A Beat In Store For Zoetis  ZTS  This Earnings Season ,opinion,"Zoetis Inc    NYSE ZTS   is scheduled to report third quarter 2017 results on Nov 2 before the market opens Zoetis  performance over the last four quarters has been mixed  with the company surpassing expectations thrice and meeting the same once  The average positive earnings surprise over the last four quarters is 6 98   Let s see how things are shaping up for this announcement Zoetis  share price movement year to date shows that the stock has outperformed the   The stock has moved up 19 7  compared with the industry s decline of 2 2  during this period Why a Likely Positive Surprise Our proven model shows that Zoetis is likely to beat estimates this quarter because it has the right combination of two key ingredients Zacks ESP    which represents the difference between the Most Accurate estimate and the Zacks Consensus Estimate  is  0 33   A favorable Zacks ESP serves as a meaningful and leading indicator of a likely positive earnings surprise  You can uncover the best stocks to buy or sell before they re reported with our  Zacks Rank  Zoetis currently carries a Zacks Rank  2  Buy   Note that stocks with a Zacks Rank  1  Strong Buy   2 or 3  Hold  have a significantly higher chance of beating earnings estimates The combination of Zoetis  Zacks Rank  2 and a positive ESP makes us confident of an earnings beat in the upcoming release Conversely  Sell rated stocks   4 or 5  should never be considered going into an earnings announcement  especially when the company is seeing negative estimate revisions Factors to ConsiderZoetis derives the majority of its revenues from a diversified product portfolio of medicines and vaccines used to treat and protect livestock and companion animals  The company continues to strengthen its diverse products portfolio through lifecycle innovations  strong customer relationships and access to new markets and technologies Concurrent with the second earnings call  Zoetis increased its 2017 outlook  The company expects earnings in the range of  2 30  2 37 per share and revenues of  5 15 billion  5 25 billion  The improved outlook also suggest a better results in the third quarter  The company s companion animal business has been boosted by further penetration of new products in key countries outside the United States  Apoquel and Cytopoint and new oral parasiticide Simparica are driving growth The company received approval for Clavamox Chewable in the United States in May 2017 and for Cytopoint in the European Union in April 2017 and in Canada in March 2017  The approvals strengthened its canine dermatology portfolio  thus providing a boost to its top line Zoetis completed the acquisition of Nexvet Biopharma  an innovator in monoclonal antibody therapies for companion animals  in July  The acquisition is expected to strengthen Zoetis  pipeline of solutions for chronic pain management in dogs and cats  which represents an area of high need in companion animal health We expect management to throw more light on its acquisition strategy Zoetis Inc  Price and EPS Surprise
    Other Stocks That Warrant a LookHere are some health care stocks that you may also want to consider  as our model shows that they too have the right combination of elements to post an earnings beat this quarter Clovis Oncology  Inc    NASDAQ CLVS   has an Earnings ESP of  2 01  and a Zacks Rank  2   The company is scheduled to release results on Nov 1  You can see  Agenus Inc    NASDAQ AGEN   has an Earnings ESP of  8 11  and a Zacks Rank  2  The company is scheduled to release third quarter results on Nov 7 ACADIA Pharmaceuticals Inc    NASDAQ ACAD   has an Earnings ESP of  3 2  and currently carries a Zacks Rank  3  The company is expected to release third quarter results on Nov 6 Zacks  Best Private Investment IdeasWhile we are happy to share many articles like this on the website  our best recommendations and most in depth research are not available to the public Starting today  for the next month  you can follow all Zacks  private buys and sells in real time  Our experts cover all kinds of trades  from value to momentum       from stocks under  10 to ETF and option moves       from stocks that corporate insiders are buying up to companies that are about to report positive earnings surprises  You can even look inside exclusive portfolios that are normally closed to new investors ",2017-10-29,Zacks Investment Research,https://www.investing.com/analysis/is-a-beat-in-store-for-zoetis-zts-this-earnings-season-200257091,200257091
129542,351057,ACAD,What s In The Cards For Prothena  PRTA  In Q3 Earnings ,opinion,"Prothena Corporation plc   NASDAQ PRTA   is expected to report third quarter 2017 results on Nov 7 Last quarter  the company reported a narrower than expected loss resulting in a positive earnings surprise of 48 31    Notably  Prothena s track record has been decent so far  The company reported a narrower than expected loss in two of the trailing four quarters  with an average positive surprise of 14 3  Prothena s share price has increased 17 1  in the year so far  better than the  s gain of 5 4  Let s see how things are shaping up for this announcement Pipeline Progress in FocusProthena s top line primarily comprises collaboration revenues earned through its license  development and commercialization agreements  In fact  the company earns collaboration revenues mainly under its license agreement with Roche Holding  SIX ROG  AG   OTC RHHBY   for PRX002 We expect  investors focus to remain on pipeline updates as it has no approved product in its portfolio The company is evaluating its lead candidate NEOD001 in the phase III VITAL Amyloidosis study in newly diagnosed treatment na ve patients with AL amyloidosis and cardiac dysfunction   Prothena is also evaluating the candidate in a phase IIb study  PRONTO  in previously treated patients with AL amyloidosis and persistent cardiac dysfunction  The company completed enrolment in this study and top line results from the study are expected following the 12 month study period in second quarter 2018 Moreover  Prothena is evaluating PRX002  in collaboration with Roche  for the treatment of Parkinson s disease and other related synucleinopathies  The company initiated a phase II study  PASADENA  in patients suffering from Parkinson s disease in second quarter 2017 The initiation triggered a  30 million milestone from Roche to Prothena Earlier in the month  Prothena announced disappointing results from a phase Ib multiple ascending dose  MAD  study of pipeline candidate  PRX003 in psoriasis patients  The primary objectives of the study were achieved  However  advancing PRX003 into mid stage clinical development required a well defined relationship between biological activity and meaningful clinical effects and these prerequisites were not met Prothena is also working to advance PRX004 in a phase I study in patients with ATTR amyloidosis  The candidate is expected to enter clinic in 2018 Moving ahead  like any other development stage biotechnology company  Prothena is likely to see an increase in research and development expenses due to higher spending on pipeline Prothena Corporation PLC Price and EPS Surprise
    Earnings WhispersOur proven model doesn t conclusively show that Prothena is likely to beat estimates this quarter  This is because a stock needs to have both a positive  and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  to be able to beat earnings  That is not the case here as you will see below Zacks ESP  The Earnings ESP  which represents the difference between the Most Accurate estimate and the Zacks Consensus Estimate  is 0 00   This is because both the Most Accurate estimate and the Zacks Consensus Estimate is pegged at a loss of  1 40  You can uncover the best stocks to buy or sell before they re reported with our  Zacks Rank  Prothena currently carries a Zacks Rank  3  Although the rank is favourable  the company s 0 00  ESP makes surprise prediction difficult Conversely  Sell rated stocks   4 or 5  should never be considered going into an earnings announcement especially when the company is seeing negative estimate revisions Stocks to ConsiderHere are some health care stocks that you may want to consider  as our model shows that they have the right combination of elements to post an earnings beat this quarter 
Agenus Inc    NASDAQ AGEN   has an Earnings ESP of  8 11  and a Zacks Rank  2  The company is scheduled to release third quarter results on Nov 7  You can see  ACADIA Pharmaceuticals Inc    NASDAQ ACAD   has an Earnings ESP of  3 2  and currently carries a Zacks Rank  3  The company is expected to release third quarter results on Nov 6 
Wall Street s Next Amazon  NASDAQ AMZN Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time  It s a once in a generation opportunity to invest in pure genius ",2017-10-30,Zacks Investment Research,https://www.investing.com/analysis/whats-in-the-cards-for-prothena-prta-in-q3-earnings-200257259,200257259
129543,351058,ACAD,Is A Beat In The Cards For Mylan  MYL  This Earnings Season ,opinion,"Mylan N V    NASDAQ MYL   is scheduled to report third quarter 2017 results on Nov 6  before the market opens The company s performance has been mixed so far  having topped earnings estimates in two of the trailing four quarters and in missing in other two  The company delivered an average negative earnings surprise of 0 59  in the trailing four quarters Last quarter  the company missed earnings estimates by 6 78   Let s see how things are shaping up for this announcement Mylan s stock has increased 0 3  year to date compared with the  decline of 27 8   The stock got a boost with the approval of generic Copaxone 40mg Why a Likely Positive Surprise Our proven model shows that Mylan is likely to beat estimates this quarter because it has the right combination of two key ingredients Zacks ESP  The   which represents the difference between the Most Accurate estimate and the Zacks Consensus Estimate  is  3 92   This is because the Most Accurate estimate is pegged at  1 25 while the Zacks Consensus Estimate is pegged at  1 21  A positive ESP serves as a meaningful and leading indicator of a likely positive earnings surprise  You can uncover the best stocks to buy or sell before they re reported with our  Zacks Rank  Mylan currently carries a Zacks Rank  2  Buy   Note that stocks with a Zacks Rank  1  Strong Buy   2 or 3  Hold  have a significantly higher chance of beating earnings estimates  The combination of Zacks Rank  3 and a positive ESP makes us confident of an earnings beat Conversely  Sell rated stocks   4 or 5  should never be considered going into an earnings announcement especially when the company is seeing negative estimate revisions Factors to Consider This QuarterConcurrent with the second quarter results  Mylan lowered its revenue guidance  The company now expects revenues of  11 5  12 5 billion in 2017  down from the earlier projection of  12 25  13 75 billion  The company now projects earnings in the range of  4 30  4 70  down from the previous projected range of  5 15  5 55  The guidance was lowered as a result of expected delays in the timing of certain new key product launches  Ongoing challenges in the United States and uncertain regulatory environment has led the company to defer all major launches in the United States from 2017 to 2018 including generic Advair and generic Copaxone  Pricing in generics is expected to decline in mid single digits globally  with high single digit erosion expected in North America Nevertheless  newly launched products are likely to perform well and aid the top line  while the acquisitions of Meda and the Renaissance Topicals Business should continue to boost the top line in the generics segment In a major boost  Mylan received FDA approval for a generic version of multiple sclerosis  MS  drug Copaxone 40mg   This is the first generic of Copaxone that has been approved  The company being one of the first filers  will also enjoy 180 days of exclusivity   According to QuintilesIMS  sales of Copaxone 20mg mL dose was approximately  700 million and for the 40 mg mL dose was  3 64 billion for the 12 months period ending July 31  2017 However  Mylan s Specialty segment  of which EpiPen is the most significant product  continues to be weak  Sales of EpiPen Auto Injector are anticipated to continue to decline in the current quarter as a result of increased competition and the impact of the authorized generic launch  Meanwhile  the company s efforts to get Advair s generic approved suffered a blow when the FDA issued a complete response letter to its ANDA for generic Advair Diskus  The FDA Oncologic Drugs Advisory Committee recently unanimously recommended approval of its biosimilar version of Roche Holdings   OTC RHHBY   Herceptin  However  the anticipated FDA goal date set under the Biosimilar User Fee Act  has been deferred to December from September 2017 During the earnings call  we expect investors to focus on the performance of EpiPen  newly launched drugs and progress with the biosimilars pipeline Mylan N V  Price and EPS Surprise
    Stocks to ConsiderHere are some health care stocks that you may want to consider  as our model shows that they have the right combination of elements to post an earnings beat this quarter 
Agenus Inc    NASDAQ AGEN   has an Earnings ESP of  8 11  and a Zacks Rank  2  The company is scheduled to release third quarter results on Nov 7  You can see  ACADIA Pharmaceuticals Inc    NASDAQ ACAD   has an Earnings ESP of  3 2  and currently carries a Zacks Rank  3  The company is expected to release third quarter results on Nov 6 Wall Street s Next Amazon  NASDAQ AMZN Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time  It s a once in a generation opportunity to invest in pure genius ",2017-10-30,Zacks Investment Research,https://www.investing.com/analysis/is-a-beat-in-the-cards-for-mylan-myl-this-earnings-season-200257313,200257313
129544,351059,ACAD,Jazz Pharmaceuticals  JAZZ  Q3 Earnings  A Beat In Store ,opinion,We expect Jazz Pharmaceuticals plc   NASDAQ JAZZ   to beat expectations when it reports third quarter 2017 results on Nov 7  after the market closes Jazz s shares have outperformed the  so far this year  The stock has rallied 25 1  compared with the industry s 1 3  decrease during the period Jazz s earnings history has been disappointing  The company missed estimates in three of the last four quarters and surpassed in one with an average negative earnings surprise of 1 53   Last quarter  the company lagged expectations with a negative earnings surprise of 5 54  Jazz Pharmaceuticals PLC Price and EPS Surprise   Let s see  how things have shaped up for this quarter Factors at PlayAt the third quarter conference call  investors  focus will be on the performance of Jazz s lead product  Xyrem  for cataplexy and excessive daytime sleepiness   EDS    Investors will also be looking out for the company s pipeline progress  Its business development plans are also expected to draw attention Xyrem should deliver a strong performance in the third quarter  given a continuous increase in active Xyrem patients  The company is striving to expand Xyrem s label and currently conducting a phase II III EXPRESS study on children and adolescents  suffering from cataplexy with narcolepsy  It is planning to submit an sNDA for Xyrem to include the pediatric phase III study results  later in 2017  The Zacks Consensus Estimate for Xyrem is  313 million for the third quarter The company s another drug Defitelio  veno occlusive disease  was launched in the United States in early April 2016  Though the drug witnessed a sequential decline in sales in second quarter 2017  the company s commercialization efforts are expected to boost its sales in the to be reported quarter  The Zacks Consensus Estimate for Defitelio is  38 3 million for the third quarter Presently  the company is enrolling patients for a phase III clinical trial on Defitelio for the potential prevention of veno occlusive disease   VOD   on high risk adults and pediatric patients  Also  the company is working to initiate a phase II proof of concept study for the prevention of acute graft versus host disease  later this year However  Jazz has been facing challenges in building sufficient inventory levels for another product  Erwinaze  due to constrained manufacturing capacity  The company may further continue to experience supply disruptions in certain markets this quarter  including the United States and beyond          Notably  the company drug Vyxeos received an FDA approval earlier in August for treatment of adults with acute myeloid leukemia   AML   and was launched in the market soon after the approval  The company is expected to recognize revenues for the first time from Vyxeos in the to be reported quarter  We expect management to update on commercialization launch plans of Vyxeos at the third quarter conference call  The company is also planning to submit regulatory applications in the EU later this year Earnings WhispersOur proven model shows that Jazz is likely to beat on earnings this quarter because it has the right combination of the two key ingredients   a positive  and a bullish Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  for this to happen Zacks ESP  Jazz has an Earnings ESP of  0 73   representing the difference between the Most Accurate estimate   2 91 per share  and the Zacks Consensus Estimate   2 89 per share   A positive ESP indicates a likely positive earnings surprise  You can uncover the best stocks to buy or sell before they re reported with our  Zacks Rank  Jazz has a Zacks Rank  3  which increases the predictive power of ESP We caution against all Sell rated stocks   4 or 5  going into the earnings announcement  especially when the company is seeing negative estimate revisions Other Stocks That Warrant a LookHere are some other health care stocks worth considering as per our model  these have the right combination of elements to beat estimates this quarter Clovis Oncology  Inc    NASDAQ CLVS   is scheduled to release results on Nov 1  The company has an Earnings ESP of  2 01  and a Zacks Rank  2  You can see  Agenus Inc    NASDAQ AGEN   is scheduled to release results on Nov 7  The company has an Earnings ESP of  8 11  and carries a Zacks Rank of 2 as well ACADIA Pharmaceuticals Inc    NASDAQ ACAD   is expected to release results on Nov 6  The company has an Earnings ESP of  3 20  and also carries a Zacks Rank of 3 Wall Street s Next Amazon  NASDAQ AMZN Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time  It s a once in a generation opportunity to invest in pure genius ,2017-10-30,Zacks Investment Research,https://www.investing.com/analysis/jazz-pharmaceuticals-jazz-q3-earnings-a-beat-in-store-200257295,200257295
129545,351060,ACAD,Will Endocyte  ECYT  Disappoint This Earnings Season  ,opinion,Endocyte  Inc    NASDAQ ECYT   is expected to report third quarter 2017 results on Nov 6 after the market closes Endocyte recorded a negative surpirise of 12 00  in the last quarter  The company has a mixed track record as it surpassed the Zacks Consensus Estimate in two of the trailing four quarters and missed the same in two quarters   Overall  the company delivered an average positive surprise of 2 45  Notably  Endocyte s share price has increased 78 5  year to date  as against the  s decline of 1 3  Let s see how things are shaping up for this quarter Factors at PlayEndocyte is a development stage biopharmaceutical company  focused on bringing targeted therapies for the treatment of cancer and inflammatory diseases to market In Jun 2017  Endocyte announced plans to reduce its workforce by about 40  in order to better focus its resources on the more valuable opportunities  The company also looks forward to shift its focus on its most promising programs  which include its CAR T cell small molecule drug conjugates  SMDCs   adaptor platform  the dual targeted DNA crosslinker drug EC2629 and the cohort of taxane exposed patients receiving EC1169 The restructuring will help the company to have increased cash balance at the end of 2017Although several companies are aggressively working on bringing new cancer treatments to market  demand for improved and targeted therapies makes this a space with high commercial potential  In fact  Endocyte uses its proprietary technology platform to develop various new SMDCs for a range of diseases Currently  EC1456 is being evaluated in a small number of patients in an ovarian cancer surgical study Endocyte also filed an Investigational New Drug  IND  application with the FDA for EC2629 and is planning to initiate a phase I study in patients selected as positive for the folate receptor in cancers where tumor associated macrophages  TAMs  are known to be prevalent in the tumor micro environment The company is also enrolling patients in the second part of the study of EC1169  which will evaluate radiographic progression free survival in mCRPC patients with PSMA positive  The enrollment is expected to be completed in the to be reported quarter However  with no approved product in its portfolio at the moment  Endocyte has to depend heavily on its partners for top line growth The investors can expect some news about the pipeline candidates EC1456 and EC2629 in the third quarter Earnings WhispersOur proven model does not conclusively show earnings beat for Endocyte this quarter  This is because a stock needs to have both   a positive and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold    to be able to beat estimates  But that is not the case here  as you will see below Zacks ESP  Endocyte s has an Earnings ESP of   45 71  as the Most Accurate estimate is 51 cents while Zacks Consensus Estimate is pegged at a loss of 35 cents  You can uncover the best stocks to buy or sell before they re reported with our  Zacks Rank  Endocyte s carries a Zacks Rank  4  Sell  As it is we caution against stocks with Zacks Ranks  4 or 5  Strong Sell  going into an earnings announcement  especially when the company is seeing a negative estimate revision  Endocyte  Inc  Price and EPS Surprise    Stocks to ConsiderHere are some health care stocks that you may want to consider  as our model shows that it has the right combination of elements to post an earnings beat this quarter Clovis Oncology  Inc    NASDAQ CLVS   is scheduled to release results on Nov 1  after market close  The company has an Earnings ESP of  2 01  and a Zacks Rank  2  You can see  Agenus Inc    NASDAQ AGEN   has an Earnings ESP of  8 11  and a Zacks Rank  2  The company is scheduled to release results on Nov 7 ACADIA Pharmaceuticals Inc    NASDAQ ACAD  has an Earnings ESP of  3 20  and a Zacks Rank  3  The company is scheduled to release results on Nov 6 Wall Street s Next Amazon  NASDAQ AMZN  Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time  It s a once in a generation opportunity to invest in pure genius ,2017-10-30,Zacks Investment Research,https://www.investing.com/analysis/will-endocyte-ecyt-disappoint-this-earnings-season-200257409,200257409
129547,351062,ACAD,Is ACADIA  ACAD  Likely To Beat Earnings Estimates In Q3 ,opinion,"We expect ACADIA Pharmaceuticals Inc    NASDAQ ACAD   to beat expectations when it reports its third quarter 2017 results expectedly on Nov 6  In the last reported quarter  ACADIA delivered a positive surprise of 22 54   It has an average positive earnings surprise of 7 97  in the last four quarters ACADIA s share price has increased 21 9  year to date compared with the  s gain of 3 9  Let s see how things are shaping up for this announcement Factors at PlayACADIA is focused on developing products for treating unmet medical needs in central nervous system  CNS  disorders  The growth of its first approved drug  Nuplazid  for treating hallucinations and delusions associated with Parkinson s disease   PD   psychosis  has been impressive since its launch in April 2016 Sales of the drug almost doubled sequentially in the second quarter  It generated revenues of  45 8 million in the first half of 2017 and  17 3 million in 2016  The company expects the trend to continue this time around as well and in the remainder of 2017  Moreover  reimbursement and access trends for Nuplazid remained strong during the last quarter  The company had increased price at the start of the second quarter  Also  the drug witnessed strong demand from new as well as old patients in the second quarter  Continued positive demand trends despite the price increase should further boost sales The company is also on track with its multiyear plans of developing Nuplazid in indications beyond PD psychosis  The company is studying the drug in five clinical programs for Nuplazid   Alzheimer s disease agitation  Alzheimer s disease  AD  psychosis  Schizophrenia inadequate response  Schizophrenia negative symptoms and major depressive disorders This month  the company initiated a phase III study to evaluate Nuplazid in treating hallucinations and delusions associated with dementia related psychosis  The company also said that the FDA has granted Breakthrough Therapy Designation to the drug for this indication  which should speed up the development process We expect the company to provide further update on the progress of this study in its third quarter earnings call The company expects research and operating expenses to increase in the third quarter due to higher clinical costs related to studies and to support its commercial activities for Nuplazid Why a Likely Positive Surprise Our proven model shows that ACADIA is likely to beat estimates this quarter  This is because a stock needs to have both a positive  and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  to be able to beat estimates Zacks ESP  Earnings ESP  which represents the difference between the Most Accurate estimate  loss of 61 cents  and the Zacks Consensus Estimate  loss of 63 cents   stands at  3 2   This is a leading indicator of a likely positive earnings surprise  You can uncover the best stocks to buy or sell before they re reported with our  Zacks Rank  Acadia currently has a Zacks Rank  3  The combination of a positive Earnings ESP and a favorable Zacks Rank makes us reasonably confident of an earnings beat Note that we caution against stocks with a Zacks Rank  4 or 5  Sell rated  going into an earnings announcement  especially when the company is seeing negative estimate revisions ACADIA Pharmaceuticals Inc  Price and EPS Surprise
    Other Stocks That Warrant a LookHere are some health care stocks that you may also want to consider  as our model shows that these have the right combination of elements to post an earnings beat this quarter Clovis Oncology  Inc    NASDAQ CLVS   is scheduled to release results on Nov 1 after market close  The company has an Earnings ESP of  2 01  and a Zacks Rank  2  You can see  Myriad Genetics  Inc    NASDAQ MYGN   has an Earnings ESP of  1 04  and a Zacks Rank  2  The company is scheduled to release results on Nov 7 Syndax Pharmaceuticals  Inc    NASDAQ SNDX   has an Earnings ESP of  2 9  and a Zacks Rank  3  The company is expected to release results on Nov 9 Wall Street s Next Amazon  NASDAQ AMZN Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time  It s a once in a generation opportunity to invest in pure genius ",2017-10-31,Zacks Investment Research,https://www.investing.com/analysis/is-acadia-acad-likely-to-beat-earnings-estimates-in-q3-200257395,200257395
129552,351067,ACAD,Horizon Pharma  HZNP  Q3 Earnings  A Disappointment In Store   revised ,opinion,"Horizon Pharma plc   NASDAQ HZNP   is scheduled to report third quarter 2017 results before the opening bell on Nov 6 
Last quarter  the company missed expectations by 16   Let s see how things are shaping up for this quarter  
 
Horizon Pharma s shares have declined 12  in the year so far  underperforming the  s gain of 0 9  
Factors Likely to Impact This Quarter
Concurrent with the second quarter earnings  the company raised its outlook for 2017 and now expects sales in the range of  1 010  1 045 billion  compared to the earlier estimate of  985  1 020 billion 
Horizon Pharma is significantly increasing investments in one of its key growth drivers  Krystexxa  and projects peak sales of around  400 million in 2017 driven by higher demand  The guidance includes assumption of lower net average net realized price from the U S  Government s Health Resource and Services Administration s Final Rule on 340B drug ceiling price implementation scheduled for Oct 1  
The company expects continued double digit net sales growth for Ravicti in 2017  with room for additional uptake due to the recent label expansion  The drug is also expected to be launched in Europe in the second half  However  sales of Procysbi will decline due to the divestiture of European rights  Sales of Actimmune are projected to grow in low single digits driven by a year over year growth in the second half 
Meanwhile  Horizon Pharma s primary care business is under pressure due to the implementation of a new commercial model  where the company is teaming up with pharmacy benefit managers and payers to help patients obtain access to its medicines 
During the third quarter earnings call  focus will be on the performance of the business units  along with that of products like Actimmune and Krystexxa 
Earnings Whispers
Our proven model does not conclusively show that Horizon Pharma is likely to beat estimates this quarter  That is because a stock needs to have both a positive  and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  for this to happen  But that is not the case here  as you will see below 
Zacks ESP  The Earnings ESP  which represents the difference between the Most Accurate estimate and the Zacks Consensus Estimate  is  8 48   This is because both the Most Accurate estimate is 21 cents while the Zacks Consensus Estimate is currently pegged at 22 cents  You can uncover the best stocks to buy or sell before they re reported with our   
Zacks Rank  Horizon Pharma currently carries a Zacks Rank  4  Sell   As it is  Sell rated stocks  Zacks Rank  4 or 5  should never be considered going into an earnings announcement  especially when the company is seeing negative estimate revisions Horizon Pharma PLC Price and EPS Surprise
    Stocks to Consider
Here are some health care stocks that you may want to consider  as our model shows that they have the right combination of elements to post an earnings beat this quarter 
Agenus Inc    NASDAQ AGEN   has an Earnings ESP of  8 11  and a Zacks Rank  2  The company is scheduled to release third quarter results on Nov 7  You can see  
ACADIA Pharmaceuticals Inc    NASDAQ ACAD   has an Earnings ESP of  3 2  and currently carries a Zacks Rank  3  The company is expected to release third quarter results on Nov 7 
Mylan N V    NASDAQ MYL   has an Earnings ESP of  3 9  and currently carries a Zacks Rank  2  The company is expected to release third quarter results on Nov 6 
 NOTE  We are republishing this article to correct a mistake  The original version  published earlier today  Thursday  November 2  2017  should no longer be relied upon  
Zacks  Best Private Investment Ideas
While we are happy to share many articles like this on the website  our best recommendations and most in depth research are not available to the public 
Starting today  for the next month  you can follow all Zacks  private buys and sells in real time  Our experts cover all kinds of trades  from value to momentum       from stocks under  10 to ETF and option moves       from stocks that corporate insiders are buying up to companies that are about to report positive earnings surprises  You can even look inside exclusive portfolios that are normally closed to new investors ",2017-11-02,Zacks Investment Research,https://www.investing.com/analysis/horizon-pharma-hznp-q3-earnings-a-disappointment-in-store-revised-200257980,200257980
129553,351068,ACAD,Is A Beat In The Cards For Perrigo  PRGO  In Q3 Earnings ,opinion,We expect Perrigo Company plc   NYSE PRGO   to beat expectations when it reports third quarter 2017 results before the opening bell on Nov 9 Perrigo has an average positive surprise of 13 13   Last quarter  the company delivered a positive surprise of 28 42  Perrigo s shares have lost 2 1  so far this year against the  s rally of 19 8  Let s see  how things are shaping up at the company this quarter Factors Influencing This QuarterPerrigo s product acquisitions and new product launches in the Prescription Pharmaceuticals  Rx  segment are expected to boost sales in the coming quarters  In September  Perrigo announced that it has initiated shipments of the first to market over the counter store brand equivalent of Nexium capsules to retail customers which is indicated to treat frequent heartburn  During the same month  the company also announced FDA approvals for generic version of Exalgo for management of moderate to severe pain in opioid tolerant patients and the generic version of Acanya for topical treatment of acne vulgaris  These launches and approvals are expected to contribute to the top line in the coming quarters Also  the ongoing restructuring initiatives and operating expense discipline are expected to support the bottom line However  price erosion and changing market dynamics amid a tough drug pricing environment across Perrigo s Rx segment is likely to continue hurting the segment s performance  It anticipates price erosion of approximately 9 11  at the Rx segment in the coming quarters The Branded Consumer Healthcare   BCH   business  part of Consumer Health Care International   CHCI   segment  is still being impacted by unfavorable market dynamics in countries like Belgium  France  Germany and Italy  This BCH segment is projected to underperform in the yet to be reported quarter due to lower than expected revenues from certain high margin products Earnings WhispersOur proven model shows that Perrigo is likely to beat on earnings because it has the right combination of the two key ingredients   a positive  and a favorable Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  for this to happen Zacks ESP  Perrigo has an Earnings ESP of  2 53   indicating a likely positive earnings surprise  The figure also represents the difference between the Most Accurate estimate of  1 15 per share and the Zacks Consensus Estimate of  1 12  You can uncover the best stocks to buy or sell before they re reported with our  Zacks Rank  Perrigo has a Zacks Rank  3  which increases the predictive power of ESP We caution against all Sell rated stocks   4 or 5  going into an earnings announcement  especially when the company is seeing negative estimate revisions Other Stocks That Warrant a LookSome other health care stocks worth considering with the right combination of elements to surpass estimates this quarter are Agenus Inc    NASDAQ AGEN   is scheduled to release results on Nov 7  The company has an Earnings ESP of  8 11  and carries a Zacks Rank  2  You can see  Syndax Pharmaceuticals  Inc    NASDAQ SNDX   is scheduled to release results on Nov 7  The company has an Earnings ESP of  2 90  and a Zacks Rank of 3 ACADIA Pharmaceuticals Inc    NASDAQ ACAD   is scheduled to release results on Nov 7  The Zacks  3 Ranked company has an Earnings ESP of  3 20  Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana      Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ,2017-11-03,Zacks Investment Research,https://www.investing.com/analysis/is-a-beat-in-the-cards-for-perrigo-prgo-in-q3-earnings-200258189,200258189
129570,351085,ACAD,AstraZeneca s Tagrisso Gets Breakthrough Therapy Designation ,opinion,AstraZeneca   NYSE AZN   announced that the FDA has granted Breakthrough Therapy Designation  BTD  for Tagrisso  osimertinib  for the first line treatment of patients with metastatic epidermal growth factor receptor  EGFR  mutation positive non small cell lung cancer  NSCLC  Tagrisso is currently approved in the United States  European Union  Japan and China  as second line treatment for patients with advanced NSCLC who progress following treatment with an EGFR TKI due to the EGFR T790M resistance mutation AstraZeneca s shares have outperformed the industry year to date  The stock has surged 25 4  compared with the   s gain of 18  The BTD is based on the phase III FLAURA study evaluating Tagrisso versus standard of care EGFR tyrosine kinase inhibitor  TKI  therapy in the first line lung cancer setting  The data showed that treatment with Tagrisso reduced the risk of progression or death by more than half compared with other commonly used EGFR inhibitors for the first line treatment of patients with EGFR mutation positive NSCLC  The median progression free survival  PFS  was 18 9 months for patients on Tagrisso as compared with 10 2 months in the comparator arm  Tagrisso was well tolerated with a safety profile consistent with previous experience BTD from the FDA will expedite the development and review of drugs that are intended to treat serious diseases and should provide access of the drug to patients as soon as possible In a separate release the company also announced that European Medicines Agency  EMA  has accepted a Marketing Authorisation Application  MAA  for Imfinzi  durvalumab  for the treatment of patients with locally advanced  Stage III   unresectable NSCLC whose disease has not progressed following platinum based chemoradiation therapy  The MAA submission was based on encouraging data from phase III PACIFIC study  Imfinzi has already received accelerated approval in the United States for the treatment of patients with locally advanced or metastatic urothelial carcinoma  who have disease progression during or following platinum containing chemotherapy  or whose disease has progressed within 12 months of receiving platinum containing chemotherapy before  neoadjuvant  or after  adjuvant  surgery A potential label expansion of the drugs will boost the sales of the company In June 2017  another pharmaceutical giant  Roche Holdings   OTC RHHBY   announced that the global  randomized phase III study  ALEX  on lung cancer drug Alecensa met its primary endpoint as an initial  first line  treatment  Alecensa significantly reduced the risk of disease worsening or death  progression free survival  PFS  compared with Pfizer s   NYSE PFE   Xalkori in patients suffering from anaplastic lymphoma kinase  ALK  positive advanced non small cell lung cancer  NSCLC   Astrazeneca  LON AZN  PLC Price    Zacks Rank   Stocks to ConsiderAstraZeneca carries a Zacks Rank  3  Hold   Another better ranked stocks in health care sector includes ACADIA Pharmaceuticals Inc    NASDAQ ACAD    carrying a Zacks Rank  2  Buy   You can see  ACADIA s loss per share estimates have narrowed from  2 63 to  2 52 for 2017 and from  1 92 to  1 85 for 2018 in the last 60 days  The company delivered positive earnings surprises in two of the trailing four quarters with an average beat of 7 97   Share price of the company has climbed 33 6  year to date Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ,2017-10-08,Zacks Investment Research,https://www.investing.com/analysis/astrazenecas-tagrisso-gets-breakthrough-therapy-designation-200217806,200217806
129572,351087,ACAD,Roche  RHHBY  Receives FDA Approval For Cobas Zika Test ,opinion,"Roche Holdings AG   OTC RHHBY   announced that it has obtained the FDA s approval for the cobas Zika test for use on the cobas 6800 8800 Systems The approval makes it the first commercially available test for the detection of the Zika virus RNA in human plasma intended for use in screening blood donations This test can be now used alongside other routine tests for the screening of blood and plasma donations in the United States We expect a strong uptake in the use of Zika test given the need to prevent the spread of the virus The cobas Zika also expands Roche s industry leading donor screening portfolio for blood borne diseasesWe note that the cobas Zika test has been used under the Investigational New Drug Application protocol to screen more than 4 million blood donations from the United States and Puerto Rico Roche s stock has rallied 14 2  year to date compared with  s gain of 21 1  Apart from providing therapeutic products and services for diverse medical needs  Roche also focuses on innovative diagnostic solutions for the early detection and treatment of diseases  Immunodiagnostics is the key focus area for this segment  In 2016  Roche added nine instruments and tests to its comprehensive portfolio  further improving decision making in healthcare  and supporting laboratories  efforts to increase efficiency  The launches including cobas e 801 immunoassay module  the CoaguChek INRange system to monitor vitamin K antagonist therapy  and the Accu Chek Guide  a next generation blood glucose monitoring system Meanwhile  Roche has a strong presence in the oncology market  The company dominates the breast cancer space with strong demand for its HER2 franchise drugs like Herceptin  Perjeta and Kadcyla  Apart from its strong breast cancer franchise  Roche s oncology portfolio also boasts drugs like Avastin and Tarceva for lung cancer However  sales of Avastin and Tarceva continue to decline  Generic competition for Xeloda continues to hurt sales  Competition from biosimilars looms large on Roche s key drugs like Herceptin  Avastin and Rituxan  The FDA accepted Novartis AG s   NYSE NVS   Biologics License Application for a proposed biosimilar version of Rituxan  Hence  approval of new drugs and label expansion of existing drugs will bode well for Roche   
Zacks Rank   Key Picks
Roche currently carries a Zacks Rank  3  Hold  
Some better ranked stocks in the health care sector are include ACADIA Pharmaceuticals Inc    NASDAQ ACAD   and Aduro Biotech  Inc    NASDAQ ADRO    Both carry a Zacks Rank  2  Buy   You can see  
ACADIA s loss per share estimates have narrowed from  2 82 to  2 57 for 2017 and from  2 07 to  1 90 for 2018 over the last 60 days  The company delivered positive earnings surprises in two of the trailing four quarters with an average beat of 7 97  
Aduro Biotech s loss per share estimates narrowed from  1 36 to  1 29 for 2017 over the last 30 days  The company delivered positive earnings surprises in two of the four trailing quarters with an average of 2 53  
Looking for Stocks with Skyrocketing Upside 
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana 
Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ",2017-10-09,Zacks Investment Research,https://www.investing.com/analysis/roche-rhhby-receives-fda-approval-for-cobas-zika-test-200217734,200217734
129574,351089,ACAD,Why Should You Invest In Novo Nordisk  NVO  Stock Right Now ,opinion,Novo Nordisk  CO NOVOb    NYSE NVO   enjoys a robust presence in the Diabetes care market  with a global value market share of 27   The company has a leading presence in the total insulin market  and modern and new generation insulin market  with a global value market share of 46  and 45   respectively The current quarter has seen some events happening for the company that bode well for its growth  One of such events include the FDA s approval for a new indication for Victoza  liraglutide  to reduce the risk of major adverse cardiovascular  CV  events in adults with type II diabetes and established CV disease in August 2017  The FDA s decision was based on the results from the landmark LEADER trial  which demonstrated that Victoza statistically significantly reduced the risk of cardiovascular death  non fatal heart attack or non fatal stroke by 13  versus placebo  when added to standard of care  with an absolute risk reduction of 1 9  Also  in September  the Committee for Medicinal Products for Human Use  CHMP   under the European Medicines Agency  EMA   endorsed an update of the European Union  EU  label for Tresiba  insulin degludec  to include results from the DEVOTE trial on severe hypoglycaemia   In addition  the European Commission in July approved an update to the Victoza  liraglutide  EU label that expands the indication to reflect both improving blood sugar and cardiovascular  CV  events as integral parts of type II diabetes treatment The label expansions for Victoza and Tresiba are anticipated to boost the company s sales in the near future Novo Nordisk s shares have outperformed the industry year to date  The stock has surged 37 3  compared with the  s gain of 18  Novo Nordisk also received the FDA approval for its fast acting mealtime insulin aspart   Fiasp   for the treatment of adults with diabetes in September 2017  This approval was based on results from a phase III study  showing that Fiasp improved overall blood sugar  HbA1c  and post meal sugar  postprandial glucose or PPG  control over 52 weeks compared with conventional insulin aspart  NovoRapid  Novo Nordisk has a sturdy pipeline  primarily focusing on therapeutic proteins within insulin  GLP 1  blood clotting factors and human growth hormone  We are encouraged by the company s efforts to develop new treatments for diabetes  which is its core area of expertise  Key pipeline candidates include semaglutide and nonacog beta pegol  Novo Nordisk A S Price and Consensus    Zacks Rank   Other Stocks to ConsiderCurrently  Novo Nordisk carries a Zacks Rank  2  Buy   Other similarly ranked stocks in the health care sector include Bayer Aktiengesellschaft   OTC BAYRY    ACADIA Pharmaceuticals Inc    NASDAQ ACAD   and Aduro BioTech  Inc    NASDAQ ADRO    You can see Bayer s earnings per share estimates have moved up from  2 17 to  2 24 for 2017 and from  2 37 to  2 39 for 2018  in the last 60 days  The company pulled off positive earnings surprises in three of the trailing four quarters  the average beat being 10 10   The share price of the company has increased 31 9  year to date Over the last 60 days  ACADIA s loss per share estimates narrowed from  2 63 to  2 52 for 2017 and from  1 92 to  1 85 for 2018  The company delivered positive earnings surprises in two of the trailing four quarters  with an average beat of 7 97   Year to date  share price of the company has climbed 30 3  Aduro s loss estimates per share have moved down from  1 36 to  1 29 for 2017  in 60 days  time  The company recorded positive earnings surprises in two of the trailing four quarters  generating an average beat of 2 53  Today s Stocks from Zacks  Hottest StrategiesIt s hard to believe  even for us at Zacks  But while the market gained  18 8  from 2016   Q1 2017  our top stock picking screens have returned  157 0    128 0    97 8    94 7   and  90 2  respectively And this outperformance has not just been a recent phenomenon  Over the years it has been remarkably consistent  From 2000   Q1 2017  the composite yearly average gain for these strategies has beaten the market more than 11X over  Maybe even more remarkable is the fact that we re willing to share their latest stocks with you without cost or obligation ,2017-10-09,Zacks Investment Research,https://www.investing.com/analysis/why-should-you-invest-in-novo-nordisk-nvo-stock-right-now-200217978,200217978
129578,351093,ACAD,Mallinckrodt To Begin Sarcoidosis Study On Acthar Gel,opinion,"Mallinckrodt plc   NYSE MNK   announced that it will initiate a new phase IV study on H P  Acthar Gel 
This multi center  randomized  double blind  placebo controlled study will further assess the efficacy of Acthar as a therapy option in patients with symptomatic sarcoidosis  The study will evaluate Acthar as a later line treatment option for sarcoidosis patients with persistent disease 
The drug is already approved in the United States for this indication   The company is conducting the study to determine which class of patients will benefit the most from an alternative treatment like Acthar 
Acthar became part of the company s portfolio following the Questcor acquisition and is currently approved for 19 indications  Mallinckrodt is working on boosting Acthar sales in the approved indications including rheumatology and pulmonology as well as underserved patient populations  The company intends to invest in research and development activities for developing Acthar for indications like lupus  proteinuria in nephrotic syndrome  amyotrophic lateral sclerosis and diabetic nephropathy 
Performance of the drug has been impressive so far  propelled by solid demand for rheumatology  pulmonology  ophthalmology and nephrology  and expanded access in more recently promoted indications such as lupus and sarcoidosis  as well as mature indications such as infantile spasms and nephrotic syndrome 

Mallinckrodt s stock price has declined 28 0  year to date  compared with the  s  fall of 20 7  
We note that Mallinckrodt is currently focused on reshaping its product portfolio through strategic acquisitions and non core asset divestitures to transform the portfolio and become a high performing specialty pharmaceutical company  The company recently acquired privately held InfaCare Pharmaceutical Corp  This specialty pharmaceutical company focuses on the development and commercialization of proprietary pharmaceuticals for neo natal and pediatric patients 
The company s generic segment continues to face weakness as various product categories are witnessing stiff competition  which is hurting both volumes and prices  The company expects double digit declines in revenues from this segment  In addition  continued expected weakness in this segment will adversely impact gross profit margins also 
The company sold its Nuclear Imaging business due to persistent challenges  The company also sold its Intrathecal Therapy business to focus on key areas  While Acthar Gel sales continue to be strong on the back of increased formulary positions and access for appropriate patients in both the commercial and public environments  sales of Therakos are expected to decline 
Zacks Rank   Stocks to Consider
Mallinckrodt currently carries a Zacks Rank  3  Hold   
Some better ranked stocks in the health care sector are ACADIA Pharmaceuticals Inc    NASDAQ ACAD    Celgene Corp    NASDAQ CELG   and Aduro Biotech  Inc    NASDAQ ADRO    All three stocks carry a Zacks Rank  2  Buy   You can see  
ACADIA s loss per share estimates have narrowed from  2 82 to  2 57 for 2017 and from  2 07 to  1 90 for 2018 over the last 60 days  The company delivered positive earnings surprises in two of the trailing four quarters with an average beat of 7 97  
Celgene s earnings estimates for both 2017 and 2018 have inched up by 0 7  over the past 90 days  The stock has rallied 20 7  year to date  outperforming the industry 
Aduro Biotech s loss per share estimates narrowed from  1 36 to  1 29 for 2017 over the last 30 days  The company delivered positive earnings surprises in two of the four trailing quarters with an average of 2 53  
Today s Stocks from Zacks  Hottest StrategiesIt s hard to believe  even for us at Zacks  But while the market gained  18 8  from 2016   Q1 2017  our top stock picking screens have returned  157 0    128 0    97 8    94 7   and  90 2  respectively And this outperformance has not just been a recent phenomenon  Over the years it has been remarkably consistent  From 2000   Q1 2017  the composite yearly average gain for these strategies has beaten the market more than 11X over  Maybe even more remarkable is the fact that we re willing to share their latest stocks with you without cost or obligation ",2017-10-10,Zacks Investment Research,https://www.investing.com/analysis/mallinckrodt-to-begin-sarcoidosis-study-on-acthar-gel-200218071,200218071
129579,351094,ACAD,Here s Why Intercept  ICPT  Stock Lost 37  So Far In 2017,opinion,"Shares of Intercept Pharmaceuticals  Inc    NASDAQ ICPT   declined 37 4  year to date against the  s gain of 15 4    In particular  shares have plunged 40 4  over a month due to safety issues regarding approved drug Ocaliva 

Per a recent news article  prescriptions of the drug have fallen by 25   The FDA issued a guideline regarding incorrect dosing of Ocaliva   The FDA reported 19 deaths due to Ocaliva  approved for primary biliary cholangitis  PBC  and stated that the drug may also affect the liver 
However  Intercept conducted an analysis and concluded that that these patients were prescribed once daily doses of Ocaliva  which is seven times higher than the recommended weekly dose  The analysis was conducted in consultation with the FDA  The company concluded that deaths occurred due to overdosing 
Consequently  Intercept issued the Dear Healthcare Provider letter  Thereafter  the FDA issued their own safety communication to reinforce recommended label dosing  Intercept is also working in tandem with the FDA to develop Ocaliva s label for safety purposes 
We note that Ocaliva was approved in the United States in May 2016  and subsequently in the European Union and Canada  for the treatment of PBC with an inadequate response to or intolerant to the standard of care  UDCA 
The dose recommended for earlier stage PBC patients with no or mild hepatic impairment was 5 mg once daily  which was increased after three months to 10 mg once daily based on tolerability and treatment response  On the other hand  in late stage patients with moderate or severe hepatic impairment  Child Pugh B or C cirrhosis   recommended dosing starts at 5 mg once weekly  with the possibility to gradually increase to a maximum of 10 mg twice weekly 
The warning comes a major setback for Intercept and we expect the company s sales to be hurt in the third quarter due to the same  The company expected the drug s sales to improve in 2017 as international demand was projected to pick up in the second half  Ocaliva is the company s only approved drug and such side effects will limit the sales potential 
Zacks Rank   Key Picks
Intercept currently carries a Zacks Rank  3  Hold    
Some better ranked stocks in the health care sector are ACADIA Pharmaceuticals Inc    NASDAQ ACAD    Celgene Corporation   NASDAQ CELG   and Aduro Biotech  Inc    NASDAQ ADRO    All three stocks carry a Zacks Rank  2  Buy   You can see  
ACADIA s loss per share estimates have narrowed from  2 82 to  2 57 for 2017 and from  2 07 to  1 90 for 2018 over the last 60 days  The company delivered positive earnings surprises in two of the trailing four quarters with an average beat of 7 97  
Celgene s earnings estimates for both 2017 and 2018 have inched up 0 7  in the past 90 days  The stock has rallied 20  this year  outperforming the industry 
Aduro Biotech s loss per share estimates narrowed from  1 36 to  1 29 for 2017 over the last 30 days  The company delivered positive earnings surprises in two of the four trailing quarters with an average of 2 53  
Wall Street s Next Amazon  NASDAQ AMZN Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time  It s a once in a generation opportunity to invest in pure genius ",2017-10-12,Zacks Investment Research,https://www.investing.com/analysis/heres-why-intercept-icpt-stock-lost-37-so-far-in-2017-200218541,200218541
129609,351124,ACAD,Glaxo Innoviva s Triple Combo Therapy Gets FDA Nod For COPD,opinion,"GlaxoSmithKline plc   NYSE GSK   and partner Innoviva  Inc    NASDAQ INVA   announced that the FDA has approved a once daily  single inhaler triple combination therapy   FF UMEC VI  fluticasone furoate umeclidinium vilanterol    as maintenance treatment for patients with chronic obstructive pulmonary disease  COPD   The drug is approved under the brand name  Trelegy Ellipta  The company said that the medicine will be available in the United States shortly 
While fluticasone furoate is an inhaled corticosteroid  ICS   umeclidinium is a long acting muscarinic antagonist  LAMA  and vilanterol is a long acting beta2 adrenergic agonist  LABA   This combination medicine will be delivered once daily in the Ellipta dry powder inhaler  Typically  the ICS LAMA LABA amalgamation for advanced COPD is delivered via two or more inhalers with potentially differing dose regime  However  GlaxoSmithKline s triple therapy combination offers a daily treatment in a single Ellipta inhaler 
Notably  closed triple combination therapy is not licensed as a single inhaler triple therapy anywhere outside the United States 
GlaxoSmithKline s shares are up 4  so far this year  comparing unfavorably with the 16 4  rally of the  during the period 

 
We remind investors that in November last year  GlaxoSmithKline and Innoviva announced filing of a regulatory submission for the triple combination therapy in the United States for the given indication  Good news is that the regulatory application was submitted around 18 months earlier than expectations 
Additionally  last December  GlaxoSmithKline and Innoviva had filed regulatory applications for the combination therapy in the EU 
The filing was based on data from the closed triple combination therapy development program as well as results of the phase III FULFIL study on FF  UMEC and VI  either alone or in combination  The study revealed superiority of the closed triple combination over Symbicort Turbohaler in improving lung function and health related quality of life in COPD patients 
Good news is that this month  European Medicines Agency s  EMA  Committee for Medicinal Products for Human Use  CHMP  has adopted a positive opinion for the combination treatment 
Notably  the combination therapy is also under assessment across a number of other countries  including Australia and Canada 
Per the company s press release  COPD is a progressive serious lung disease  commonly found to affect approximately 384 million people worldwide  representing a significant need for such therapies GlaxoSmithKline PLC Price

   Zacks Rank   Stocks to Consider
GlaxoSmithKline currently carries a Zacks Rank  3  Hold   Some better ranked stocks in the pharma sector are Aduro Biotech  Inc    NASDAQ ADRO   and ACADIA Pharmaceuticals Inc    NASDAQ ACAD    both carrying a Zacks Rank  2  Buy   You can see  
Aduro Biotech s loss per share estimates reduced from  1 46 to  1 32 for 2017 and from  1 41 to  1 24 for 2018 over the last 60 days  The company delivered positive surprises in two of the trailing four quarters with an average beat of 2 53  
ACADIA s loss per share estimates narrowed from  2 82 to  2 57 for 2017 and from  2 07 to  1 90 for 2018 over the last 60 days  The company came up with positive earnings surprises in two of the last four quarters with an average beat of 7 97  
4 Promising Stock Picks to Keep an Eye On 
With news stories about computer hacking and identity theft becoming increasingly commonplace  the cybersecurity industry looks like a promising investment opportunity  But which stocks should you buy  Zacks just released Cybersecurity  An Investor s Guide to Locking Down Profits to help answer this question 
This new Special Report gives you the information you need to make well informed investment choices in this space  More importantly  it also highlights 4 cybersecurity picks with strong profit potential ",2017-09-19,Zacks Investment Research,https://www.investing.com/analysis/glaxoinnovivas-triple-combo-therapy-gets-fda-nod-for-copd-200214224,200214224
129610,351125,ACAD,Supernus Drops SPN 810 s Lower Dose Test In Phase III Trials,opinion,"Supernus Pharmaceuticals  Inc  s   NASDAQ SUPN   shares have dropped almost 10  after the company announced decision to stop evaluating the lower dose option  18 mg  of its pipeline candidate  SPN 810  in two phase III clinical trials  However  the company will carry on with its 36 mg dose of SPN 810 or placebo of similar proportion in both the studies 
Significantly  SPN 810 is being developed as a novel treatment option for impulsive aggression  IA  in patients aged 6 12 years with attention deficit hyperactivity disorder  ADHD  
Supernus  shares have significantly soared 79 8  so far this year in contrast to the 18 2  decrease of the  during the period 

The two phase III studies were designed under a Special Protocol Assessment  SPA  by the FDA  The decision taken by the company to terminate the lower dose regime is an outcome of the planned interim analysis from the first phase III clinical trial on SPN 810  The interim analysis was planned when 50  of the patients  n 146  reached randomization in the first trial 
The program was conducted by an independent third party statistician to evaluate both the doses and provide optimization of the study design  The company believes that chances of achieving a statistically substantial result with the 36 mg dose will be high  Implementation of the suggested changes will be executed immediately 
Notably  enrollment in the first and second trial has already completed 64  and 56   respectively  The company expects enrollment to continue through mid 2018 
We remind investors that SPN 810 is a key candidate in Supernus  pipeline  already granted with a fast track designation from the FDA 
Additionally  Supernus is developing SPN 812 for ADHD treatment 
However  the ADHD market is currently dominated by companies like Shire plc   NASDAQ SHPG    Some drugs approved for this indication are Vyvanse  Adderall XR  Intuniv and Equasym XL Supernus Pharmaceuticals  Inc  Price

   Zacks Rank   Stocks to Consider
Supernuscurrently carries a Zacks Rank  3  Hold   Some better ranked stocks in the pharma sector are Aduro Biotech  Inc    NASDAQ ADRO   and ACADIA Pharmaceuticals Inc    NASDAQ ACAD    both carrying a Zacks Rank  2  Buy   You can see  
Aduro Biotech s loss per share estimates reduced from  1 46 to  1 32 for 2017 and from  1 41 to  1 24 for 2018 over the last 60 days  The company delivered positive surprises in two of the trailing four quarters with an average beat of 2 53  
ACADIA s loss per share estimates narrowed from  2 82 to  2 57 for 2017 and from  2 07 to  1 90 for 2018 over the last 60 days  The company came up with positive earnings surprises in two of the last four quarters with an average beat of 7 97  
4 Promising Stock Picks to Keep an Eye On 
With news stories about computer hacking and identity theft becoming increasingly commonplace  the cybersecurity industry looks like a promising investment opportunity  But which stocks should you buy  Zacks just released Cybersecurity  An Investor s Guide to Locking Down Profits to help answer this question 
This new Special Report gives you the information you need to make well informed investment choices in this space  More importantly  it also highlights 4 cybersecurity picks with strong profit potential ",2017-09-19,Zacks Investment Research,https://www.investing.com/analysis/supernus-drops-spn810s-lower-dose-test-in-phase-iii-trials-200214221,200214221
129611,351126,ACAD,Glaxo Innoviva s Triple Combo Inhaler Positive In Phase III,opinion,GlaxoSmithKline plc   NYSE GSK   and partner Innoviva  Inc    NASDAQ INVA   announced that its once daily single inhaler triple therapy   Trelegy Ellipta  FF UMEC VI  fluticasone furoate umeclidinium vilanterol    met primary endpoint in a phase III IMPACT study  showing reduction in exacerbations in patients with chronic obstructive pulmonary disease  COPD  While fluticasone furoate is an inhaled corticosteroid  ICS   umeclidinium is a long acting muscarinic antagonist  LAMA  and vilanterol is a long acting beta2 adrenergic agonist  LABA   This combination medicine will be delivered once daily in the Ellipta dry powder inhaler  Typically  the ICS LAMA LABA amalgamation for advanced COPD is delivered via two or more inhalers with a potentially differing dose regime  However  GlaxoSmithKline s triple therapy combination offers a daily treatment in a single Ellipta inhaler Notably  this week  the triple combination therapy was approved in the United States under the brand name  Trelegy Ellipta  as maintenance therapy for treatment of patients with COPD  Last week  the European Medicines Agency s  EMA  Committee for Medicinal Products for Human Use  CHMP  granted a positive opinion  recommending approval of this combination therapy in the EU Notably  the closed triple combination therapy is not licensed as a single inhaler triple therapy anywhere outside the United States GlaxoSmithKline s shares are up 4 3  so far this year  comparing unfavorably with the 16 8  rally of the  during the period  The IMPACT study was a randomised  double blind  3 arm parallel group  multicentre program  conducted on a total of 10 355 patients  The trial evaluated Trelegy Ellipta in comparison to the dual therapies of Anoro Ellipta  UMEC VI  and Relvar Breo Ellipta  FF VI  Data from the study demonstrated statistically significant reductions in the annual rate of on treatment moderate severe exacerbations in patients with COPD  which determines the primary endpoint of the study  The study met its secondary endpoints too  Based on the positive data from the IMPACT analysis  the company expects to commence global regulatory filing in the second quarter of 2018 for the given indication It is important to note that the combination therapy is also under assessment across countries including Australia and Canada Per the company s press release  COPD is a progressive serious lung disease  commonly found to affect approximately 384 million people worldwide  thus representing a significant need for such therapies GlaxoSmithKline PLC Price    Zacks Rank   Stocks to ConsiderGlaxoSmithKline currently carries a Zacks Rank  3  Hold   Some better ranked stocks in the pharma sector are Aduro Biotech  Inc    NASDAQ ADRO   and ACADIA Pharmaceuticals Inc    NASDAQ ACAD    both carrying a Zacks Rank  2  Buy   You can see  Aduro Biotech s loss per share estimates reduced from  1 46 to  1 32 for 2017 and from  1 41 to  1 24 for 2018 over the last 60 days  The company delivered positive surprises in two of the trailing four quarters with an average beat of 2 53  ACADIA s loss per share estimates narrowed from  2 82 to  2 57 for 2017 and from  2 07 to  1 90 for 2018 over the last 60 days  The company came up with positive earnings surprises in two of the last four quarters with an average beat of 7 97  Will You Make a Fortune on the Shift to Electric Cars Here s another stock idea to consider  Much like petroleum 150 years ago  lithium power may soon shake the world  creating millionaires and reshaping geo politics  Soon electric vehicles  EVs  may be cheaper than gas guzzlers  Some are already reaching 265 miles on a single charge With battery prices plummeting and charging stations set to multiply  one company stands out as the  1 stock to buy according to Zacks research It s not the one you think ,2017-09-20,Zacks Investment Research,https://www.investing.com/analysis/glaxoinnovivas-triple-combo-inhaler-positive-in-phase-iii-200214628,200214628
129612,351127,ACAD,9 To Watch Today  ADAD  Alerian  AXS  SAN  BWLD  CNK  CTRP  CXO  CZZ,opinion,"Tonight I think I ll share some of my favorite shorts     I only got through the first three letters of the alphabet before I had enough symbols  such we ll just do A through C  These are all  live  positions  and they re all short  naturally  
First up is ACADIA Pharmaceuticals Inc  NASDAQ ACAD   which has a well defined diamond topping pattern  as always  click on the SlopeCharts image for a bigger version  

Alerian Master Limited Partnership is coming up against an important gap 

Axis Capital Holdings Limited  NYSE AXS  has busted a long term trendline and has a very well formed topping pattern 

Banco Santander  MC SAN  had a gap down which seems to have permanently fractured the stock  so there s a very clean division between support and resistance 

Buffalo Wild Wings Inc  NASDAQ BWLD   purveyor of fine cuisine to middle America  had a sensational top 

Cinemark Holdings Inc  NYSE CNK   purveyor of fine cinematic arts to middle America  also has a terrific top  as well as a busted long term trendline 

Ctripcom International Ltd  NASDAQ CTRP   which I suppose had nothing to do with middle America at all  also has a busted trendline 

Concho Resources Inc  NYSE CXO  has been violently lurching up and down for months now  and we seem to be approaching another intermediate term reversal point 

Lastly  Cosan Ltd  NYSE CZZ  has a massive topping pattern  above the blue line   and we ve been carving out a series of lower highs recently beneath the aforementioned pattern ",2017-09-27,Tim Knight,https://www.investing.com/analysis/nine-from-abc-200215553,200215553
129636,351151,ACAD,The Medicines Company s Infection Drug Vabomere Gets FDA Nod,opinion,The Medicines Company   NASDAQ MDCO   announced that the FDA has granted accelerated approval to its experimental antibiotic  Vabomere  a combination of meropenem and vaborbactam  for treating complicated urinary tract infections  cUTI   including the pyelonephritis The company expects to make Vabomere available in the market in fourth quarter 2017  It filed a new drug application  NDA  for the antibiotic in February  currently under review in the EU Shares of The Medicines Company have outperformed the year to date  The stock has rallied 14 2  compared with the industry s 9 7  gain during the period The NDA was supported by positive data from a phase III  TANGO 1  multi center  randomized  double blind  double dummy study  The study  n 550  was designed to evaluate the efficacy  safety and tolerability of Vabomere in patients with cUTIs or acute pyelonephritis compared with Pfizer Inc  s   NYSE PFE   Zosyn  piperacillin tazobactam  Data from this trial showed that Vabomere achieved statistical superiority over Zosyn with successful results obtained from 98 4  of patients treated with Vabomere compared with 94 3  administered with Zosyn We remind investors that in July  an independent data safety and monitoring board stopped the phase III TANGO 2 study on Vabomere based on an interim analysis  Interim results from the study showed that Vabomere improved clinical cure rates across all infection types and reduced rate of renal adverse events in comparison to the best available therapy Vabomere has been designated as a Qualified Infectious Disease Product by the FDA  Antibiotic resistance  especially to carbapenems  is a rapidly growing problem in the medicine sector  In fact  carbapenem resistant enterobacteriaceae  CRE  infections are one of the deadliest diseases  given its 40  mortality rate  As a result  there is an urgent need for antimicrobials like Vabomere to effectively treat CRE and other resistant organisms Successful commercialization of Vabomere is expected to boost the company s top line  considering the lucrative market that it targets The Medicines Company Price   Zacks Rank   Stocks to ConsiderThe Medicines Company currently carries a Zacks Rank  3  Hold   Some better ranked stocks in the pharma sector are Aduro Biotech  Inc    NASDAQ ADRO   and ACADIA Pharmaceuticals Inc    NASDAQ ACAD    both carrying a Zacks Rank  2  Buy   You can see  Aduro Biotech s loss per share estimates reduced from  1 46 to  1 32 for 2017 and from  1 41 to  1 24 over the last 30 days  The company delivered positive surprises in two of the trailing four quarters with an average beat of 2 53  ACADIA s loss per share estimates narrowed from  2 82 to  2 59 for 2017 and from  2 07 to  1 92 for 2018 over the last 30 days  The company came up with positive earnings surprises in two of the last four quarters with an average beat of 7 97  One Simple Trading IdeaSince 1988  the Zacks system has more than doubled the S P 500 with an average gain of  25  per year  With compounding  rebalancing  and exclusive of fees  it can turn thousands into millions of dollars This proven stock picking system is grounded on a single big idea that can be fortune shaping and life changing  You can apply it to your portfolio starting today ,2017-08-30,Zacks Investment Research,https://www.investing.com/analysis/the-medicines-companys-infection-drug-vabomere-gets-fda-nod-200210728,200210728
129639,351154,ACAD,6 Stocks To Watch Going Into Labor,opinion,"NYSE AAP stop 106 34  this one may need to recover some more for an attractive entry 

NYSE ABG stop 56 40  nice broken trendline on this one  but will wait for a good entry 

The stop on NASDAQ ACAD is tougher  I ll just say 38 00  but this is a large  well formed diamond pattern  and ultimately the stop may be tighter 

NYSE AMJ stop 28 83  very nice gap fill  Once again  may need to wait a little for better price entry 

Stop 991 75 on NASDAQ AMZN  this one is I think  good to go  

NYSE AXL stop 16 38  definitely want to wait on this one to burn off oversold condition ",2017-09-03,Tim Knight,https://www.investing.com/analysis/going-into-labor-part-1-of-6-200211184,200211184
129640,351155,ACAD,Merck  MRK  Opts For Buying German Immuno Oncology Biotech ,opinion,Merck   NYSE MRK   announced that it will acquire Germany based Rigontec  a privately held immuno oncology focused biotech for an upfront cash payment of almost  137 million  115 million euros  Rigontec is a leader in retinoic acid inducible gene I  RIG I   targeting therapeutics   It is a novel immuno oncology treatment approach The deal s completion date is not yet disclosed  subject to certain closing conditions Apart from the upfront payment  based upon achievement of certain milestones  Merck may also make additional contingent payments worth approximately 349 million euros Shares of Merck have underperformed the year to date  The stock has gained 8 7  compared with the industry s 12 6  rally during the period The acquisition complements Merck s current immuno oncology pipeline of Keytruda label expansion studies  With the winding up of this buyout  Merck will add Rigontec s lead candidate  RGT100  in its portfolio  Notably  RGT100 is currently under evaluation in a phase I study for treatment of patients with various tumors Significantly  Merck is actively pursuing deals in order to build a long term portfolio  The company entered into several licensing deals in the past few of years and targets to achieve more in the future We remind investors that in July  Merck announced an oncology collaboration with AstraZeneca   NYSE AZN   to jointly commercialize and develop the latter s PARP Inhibitor  Lynparza and MEK 1 2 inhibitor  selumetinib  another oncology candidate of AstraZeneca   both as monotherapy and in combination studies  for multiple cancer types Merck will make an upfront payment of  1 6 billion to AstraZeneca  Presently marketed for advanced ovarian cancer  Lynparza is in different studies for a range of tumor types including breast  prostate and pancreatic cancers Merck and AstraZeneca will independently develop combination medicines with Lynpraza or selumetinib with their respective PD L1 PD 1 inhibitors  Imfinzi and Keytruda Merck   Company  Inc  Price    Zacks Rank   Stocks to ConsiderMerck currently carries a Zacks Rank  3  Hold   Some better ranked stocks in the pharma sector are Aduro Biotech  Inc    NASDAQ ADRO   and ACADIA Pharmaceuticals Inc    NASDAQ ACAD    both carrying a Zacks Rank  2  Buy   You can see  Aduro Biotech s loss per share estimates reduced from  1 46 to  1 32 for 2017 and from  1 26 to  1 24 for 2018 over the last 30 days  The company delivered positive earnings surprises in two of the trailing four quarters with an average beat of 2 53  ACADIA s loss per share estimates narrowed from  2 80 to  2 57 for 2017 and from  2 06 to  1 90 for 2018 over the last 30 days  The company posted positive earnings surprises in two of the last four quarters with an average beat of 7 97  One Simple Trading IdeaSince 1988  the Zacks system has more than doubled the S P 500 with an average gain of  25  per year  With compounding  rebalancing  and exclusive of fees  it can turn thousands into millions of dollars This proven stock picking system is grounded on a single big idea that can be fortune shaping and life changing  You can apply it to your portfolio starting today ,2017-09-06,Zacks Investment Research,https://www.investing.com/analysis/merck-mrk-opts-for-buying-german-immunooncology-biotech-200211964,200211964
129641,351156,ACAD,Acadia s Diamond,opinion,I ve mentioned this in passing earlier  but I want to point out once again the well formed diamond topping pattern in ACADIA Pharmaceuticals  NASDAQ ACAD  ,2017-09-07,Tim Knight,https://www.investing.com/analysis/acadias-diamond-200211990,200211990
129642,351157,ACAD,Alexion  ALXN  Reports Interim Results For Soliris Study ,opinion,Alexion Pharmaceuticals  Inc    NASDAQ ALXN   announced results from an interim analysis of an ongoing phase III REGAIN study of lead drug Soliris for the treatment of patients with refractory generalized myasthenia gravis  gMG   who are anti acetylcholine receptor  AChR  antibody positive We note that  Soliris is approved for the treatment of two severe and ultra rare disorders resulting from chronic uncontrolled activation of the complement component of the immune system  paroxysmal nocturnal hemoglobinuria  PNH  and atypical hemolytic uremic syndrome  aHUS  Alexion s shares have outperformed the industry year to date  The stock has been up 19 6  compared with the  s gain of 16  in the same time frame Coming back to the release  the study showed sustained treatment benefits of Soliris treatment for patients with refractory generalized myasthenia gravis  Additionally  it revealed that safety profile of Soliris was consistent with that observed in the REGAIN study Furthermore  the evaluation showed that the benefits for patients treated with Soliris in REGAIN through 26 weeks were maintained in the extension study across all four assessment scales for an additional 52 weeks  78 weeks in total   In fact  the patients who received placebo in REGAIN and then were treated with Soliris in the extension study  demonstrated significant treatment benefits within 1 to 4 weeks and were sustained through 52 weeks across all four assessment scales Meanwhile  Alexion has filed regulatory applications with the FDA as well as the European Medicines Agency  EMA  for Soliris for the treatment of refractory gMG in patients who are anti acetylcholine receptor antibody positive  The FDA accepted the supplemental Biologics License Application  sBLA  and set a Prescription Drug User Fee Act date of Oct 23 The Committee for Medicinal Products for Human Use  CHMP  of the European Medicines Agency  EMA  has also adopted a positive opinion for the same and the final decision from the European Commission  EC  is anticipated in the third quarter of 2017 Additionally  a phase III study  PREVENT  on Soliris in patients with relapsing neuromyelitis optica spectrum disorder is ongoing with enrollment being expected to be completed in 2017 and data expected in 2018  Label expansion into additional indications would give Soliris access to a higher patient population and increase the commercial potential of the drug significantly Alexion Pharmaceuticals  Inc  Price   Zacks Rank   Key PicksAlexion currently sports a Zacks Rank  1  Strong Buy   Some other top ranked stocks in health care sector include Regeneron Pharmaceuticals  Inc    NASDAQ REGN    ACADIA Pharmaceuticals Inc    NASDAQ ACAD   and Aduro BioTech  Inc    NASDAQ ADRO    While Regeneron carries the same bullish rank as Alexion  ACADIA and Aduro hold a Zacks Rank  2  Buy   You can see  ACADIA Pharmaceuticals loss estimates per share have narrowed from  2 59 to  2 57 for 2017 and from  1 92 to  1 90 for 2018 over the last 30 days  The company pulled off positive earnings surprises in two of the trailing four quarters  with an average beat of 7 97   The share price of the company has increased 25 7  year to date Regeneron s earnings per share estimates have increased from  12 83 to  14 99 for 2017 and from  15 38 to  16 64 for 2018 over the last 30 days  The company delivered positive earnings surprises in two of the trailing four quarters  with an average beat of 10 11   The share price of the company has increased 17 6  year to date Aduro s loss estimates per share have narrowed from  1 46 to  1 32 for 2017 and from  1 55 to  1 24 for 2018 over last 30 days  The company came up with positive earnings surprises in two of the trailing four quarters  with an average beat of 2 53  5 Trades Could Profit  Big League  from Trump PoliciesIf the stocks above spark your interest  wait until you look into companies primed to make substantial gains from Washington s changing course Today Zacks reveals 5 tickers that could benefit from new trends like streamlined drug approvals  tariffs  lower taxes  higher interest rates  and spending surges in defense and infrastructure ,2017-09-13,Zacks Investment Research,https://www.investing.com/analysis/alexion-alxn-reports-interim-results-for-soliris-study-200213319,200213319
129643,351158,ACAD,GTx s  GTXI  Enobosarm Positive In Phase II  Shares Down,opinion,"GTx  Inc    NASDAQ GTXI   announced positive top line data from a phase II study  evaluating lead pipeline candidate  enobosarm 3 mg  GTx 024   for treating postmenopausal women with stress urinary incontinence  SUI   Data from the study was presented at International Continence Society  ICS  Annual Meeting 
Shares of GTx have decreased almost 9  despite the good news as the data announced was probably below market expectations  However  shares of the company have outperformed the  so far this year  The stock has surged 42 4  compared with the broader industry s increase of 16  

The open label  non placebo controlled  proof of concept phase II study was conducted on 17 postmenopausal women with SUI  The trial met primary endpoints and revealed that women treated with enobosarm experienced significant reduction  50  or greater  in incontinence episodes per day compared with baseline  which sustained for up to seven months following completion of treatment  Mean stress leaks declined by 83  from baseline over a period of 12 weeks  Adverse events reported in the study were minimal 
Based on results from the study  GTx started a randomized  placebo controlled phase II clinical trial to evaluate the safety and efficacy of enobosarm across two doses  1 mg and 3 mg  compared with placebo in postmenopausal women with SUI 
Investors are reminded that presently  the company is conducting another phase II study  evaluating enobosarm in patients whose advanced breast cancer is both estrogen receptor  ER  positive and androgen receptor  AR  positive  Top line data from the program is expected later in 2017 
Notably  enobosarm has already been assessed in 24 completed or ongoing clinical trials for SUI enrolling over 1 700 subjects  of which  approximately 1 200 were treated with enobosarm at doses  ranging from 0 1 100 mg GTx  Inc  Price

   Stocks to Consider
Some stocks worth considering in the pharma sector are Akebia Therapeutics  Inc    NASDAQ AKBA    Aduro Biotech  Inc    NASDAQ ADRO   and ACADIA Pharmaceuticals Inc    NASDAQ ACAD    all three carrying a Zacks Rank  2  Buy   You can see  
Akebia s loss per share estimates narrowed from  4 14 to  3 85 for 2017 and from  1 98 to  1 88 for 2018 over the last 60 days  Its share price soared 69  so far this year 
Aduro Biotech s loss per share estimates reduced from  1 46 to  1 32 for 2017 and from  1 55 to  1 24 for 2018 over the last 60 days  The company delivered positive surprises in two of the trailing four quarters with an average beat of 2 53  
ACADIA s loss per share estimates lessened from  2 82 to  2 57 for 2017 and from  2 07 to  1 90 for 2018 over the last 60 days  The company came up with positive earnings surprises in two of the last four quarters with an average beat of 7 97  
5 Trades Could Profit  Big League  from Trump Policies  
If the stocks above spark your interest  wait until you look into companies primed to make substantial gains from Washington s changing course 
Today Zacks reveals 5 tickers that could benefit from new trends like streamlined drug approvals  tariffs  lower taxes  higher interest rates  and spending surges in defense and infrastructure ",2017-09-14,Zacks Investment Research,https://www.investing.com/analysis/gtxs-gtxi-enobosarm-positive-in-phase-ii-shares-down-200213375,200213375
129668,351183,ACAD,Ultragenyx  RARE  Posts Disappointing Phase III Ace ER Data,opinion,"Ultragenyx Pharmaceutical Inc    NASDAQ RARE   announced discouraging top line data from a phase III study  evaluating its investigational Ace ER  aceneuramic acid extended release  on patients with GNE Myopathy  GNEM   a progressive muscle wasting disorder  As a result  the company plans to discontinue any further clinical development of the candidate 
Shares of Ultragenyx have underperformed the  year to date  The stock has been dismally down 16 3  as against the industry s 7 2  gain during the period 

The phase III study  conducted on 89 adults afflicted with GNEM  missed both the primary and secondary endpoints  Data from this trial did not demonstrate any statistically significant improvement in UEC  upper extremity muscle strength composite  score for patients treated with Ace ER in comparison to placebo which was its primary endpoint  Also  there were three pre specified key secondary endpoints none of which the study could meet 
We remind investors that in November 2016  Ultragenyx has also withdrawn its conditional filing application for Ace ER s regulatory approval in the EU for treatment of adult patients with GNEM  This conditional filing was withdrawn based on feedback from the Committee for Medicinal Products for Human Use  CHMP  indicating that the submitted phase II study results were not sufficient to support the approval 
However  the company clarified that the discontinuation of Ace ER will not impact its overall strategies as it s already on a progressing track with several developmental activities and regulatory filings lined up ahead 
Notably  in July 2016  Ultragenyx announced positive top line data from a pivotal phase III study on recombinant human beta glucuronidase  rhGUS  for treating mucopolysaccharidosis 7  MPS 7   The candidate is presently under review in both the U S  and EU with responses expected on Nov 16  2017 and in the first half of 2018  respectively 
We expect investors  focus to remain on further pipeline updates from the company Ultragenyx Pharmaceutical Inc  Price

   Zacks Rank   Stocks to Consider
Ultragenyx currently carries a Zacks Rank  3  Hold   Some better ranked stocks in the pharma sector are Aerie Pharmaceuticals  Inc    NASDAQ AERI    Aduro Biotech  Inc    NASDAQ ADRO   and ACADIA Pharmaceuticals Inc    NASDAQ ACAD    all three carrying a Zacks Rank  2  Buy   You can see  
Aerie s loss per share estimates narrowed from  2 62 to  2 53 for 2017 over the last 30 days  The company delivered a positive earnings surprise in three of the trailing four quarters with an average beat of 0 64   Its share price soared 39 5  so far this year 
Aduro Biotech s loss per share estimates reduced from  1 46 to  1 32 for 2017 and from  1 41 to  1 24 over the last 30 days  The company delivered positive surprises in two of the trailing four quarters with an average beat of 2 53  
ACADIA s loss per share estimates narrowed from  2 82 to  2 59 for 2017 and from  2 07 to  1 92 for 2018 over the last 30 days  The company came up with positive earnings surprises in two of the last four quarters with an average beat of 7 97  
4 Surprising Tech Stocks to Keep an Eye On 
Tech stocks have been a major force behind the market s record highs  but picking the best ones to buy can be tough  There s a simple way to invest in the success of the entire sector  Zacks has just released a Special Report revealing one thing tech companies literally cannot function without 
More importantly  it reveals 4 top stocks set to skyrocket on increasing demand for these devices  I encourage you to get the report now   before the next wave of innovations really take off ",2017-08-23,Zacks Investment Research,https://www.investing.com/analysis/ultragenyx-rare-posts-disappointing-phase-iii-aceer-data-200209096,200209096
129669,351184,ACAD,Kite Pharma At New 52 Week High  What s Driving The Stock ,opinion,"Kite Pharma  Inc  s   NASDAQ KITE   shares hit a new 52 week high of  143 00 on Thursday before eventually closing at  138 17 
Shares of the company have risen sharply so far this year as its CAR T therapy axicabtagene ciloleucel  previously KTE C19  is nearing an FDA approval  In fact  Kite Pharma s year to date share price movement shows that the stock has substantially outperformed the   having skyrocketed 209 7  during the period  while the industry has gained 6 9  

Kite Pharma has been riding on the back of an impressive progress made by axicabtagene ciloleucel  The candidate is currently under priority review in the United States for treating aggressive non Hodgkin lymphoma  NHL  with an FDA decision expected on Nov 29  The Biologics License Application  BLA  filing was based on data from a phase I II study  ZUMA 1 
We believe that the solid efficacy profile demonstrated by the pivotal ZUMA 1 trial should support the candidate s approval this year  At the second quarter conference call  the company announced that the FDA has informed that an Advisory Committee meeting will not be required to review the company s BLA for axicabtagene ciloleucel  The candidate is expected to be approved of and launched in the United States this year 
In July  a regulatory application was also filed in the EU for the given indication with sanction and unveiling also expected next year 
Immuno oncology is one of the most actively pursued areas of research today  There are several other companies working to bring about innovative immuno oncology treatments to the market 
Juno Therapeutics Inc    NASDAQ JUNO   and Novartis AG   NYSE NVS   are also developing JCAR017 and CTL019  respectively  utilizing the CAR T cell technology  Though the efficacy profile of all the three candidates is comparable  axicabtagene ciloleucel is likely set to hit the market first 
Other studies revolving around axicabtagene ciloleucel are also advancing fast 
Apart from axicabtagene ciloleucel  Kite Pharma is developing additional CAR based candidates including KITE 585 and KITE 718 
Phase I study on the first of the four TCR CAR T candidates   KITE 718 in solid tumors  including non small cell lung cancer  bladder cancer plus head and neck cancer   was initiated in the second quarter  KITE 718  a TCR cell therapy candidate  targets cancer antigens MAGE A3 and MAGE A6 in a solid tumor 
Kite Pharma has also recently filed an investigational new drug  IND  application for CAR T candidate  KITE 585  targeting BCMA antigen for multiple myeloma  Phase I studies are expected to be initiated in the second half of the year Kite Pharma  Inc  Price

   Zacks Rank   Stocks to Consider
Kite Pharma currently carries a Zacks Rank  3  Hold   A better ranked stock in the pharma sector is ACADIA Pharmaceuticals Inc    NASDAQ ACAD    carrying a Zacks Rank  2  Buy   You can see  
ACADIA s loss per share estimates narrowed from  2 82 to  2 59 for 2017 and from  2 07 to  1 92 for 2018 over the last 30 days  The company came up with positive earnings surprises in two of the last four quarters with an average beat of 7 97  
One Simple Trading Idea
Since 1988  the Zacks system has more than doubled the S P 500 with an average gain of  25  per year  With compounding  rebalancing and exclusive of fees  it can turn thousands into millions of dollars 
This proven stock picking system is grounded on a single big idea that can be fortune shaping and life changing  You can apply it to your portfolio starting today ",2017-08-24,Zacks Investment Research,https://www.investing.com/analysis/kite-pharma-at-new-52week-high-whats-driving-the-stock-200209359,200209359
129670,351185,ACAD,Ultragenyx Files BLA To FDA For Hypophosphatemia Candidate,opinion,Ultragenyx Pharmaceutical Inc    NASDAQ RARE   along with Japanese partner Kyowa Hakko Kirin Co   Ltd announced filing of a biologics license application  BLA  to the FDA for its pipeline candidate burosumab  KRN23  to treat patients with X linked hypophosphatemia  XLH   The FDA informed that a decision on acceptance of the same will be made within 60 days Notably  in January  European Medicines Agency  EMA  had accepted the company s marketing application for burosumab for review  The company now expects an opinion from the EMA s Committee for Medicinal Products for Human Use  CHMP  in the second half of this year Shares of the company have inched up almost 1  following the news release   However  Ultragenyx s share price movement shows that the stock has underperformed the  so far this year  Specifically  the stock plunged 26 8  as against the industry s 8  gain The BLA submission was supported by positive data from a phase III study on adults and a phase II trial on pediatric patients for the aforementioned indication  The data was announced in April  The 24 week phase III study met the primary endpoint as the patients treated with burosumab achieved a statistically significant improvement in serum phosphorus levels compared with placebo  Further  the secondary endpoint of the study was also met as patients administered with burosumab attained a substantial improvement in stiffness as well as witnessed a strong progress in physical function and pain On the other hand  the 64 week data from the pediatric phase II study showed better results in serum phosphorus levels  rickets  growth rates and other functional outcomes with use of burosumab  sustained through a prolonged period of treatment In fact  in June 2016  the FDA had granted a therapy designation to burosumab for treatment of XLH in pediatric patients aged one year and above Currently  burosumab is also being evaluated in a phase II study for treating tumor induced osteomalacia  TIO  Importantly  Ultragenyx is making a significant progress with other pipeline candidates as well  Another candidate rhGUS  UX003  is under review in both the U S  and the EU for treatment of mucopolysaccharidosis 7  MPS 7   The company expects a response from the FDA by this year end and the EU s feedback is awaited in the first half of 2018 In the near term  we expect investors  focus to remain on the opinion of Committee for Medicinal Products for Human Use  CHMP  on burosumab and for regulatory responses to rhGUS Ultragenyx Pharmaceutical Inc  Price   Zacks Rank   Stocks to ConsiderUltragenyx currently carries a Zacks Rank  3  Hold   Some better ranked stocks in the pharma sector are Aerie Pharmaceuticals  Inc    NASDAQ AERI    Aduro Biotech  Inc    NASDAQ ADRO   and ACADIA Pharmaceuticals Inc    NASDAQ ACAD    all three carrying a Zacks Rank  2  Buy   You can see  Aerie s loss per share estimates narrowed from  2 62 to  2 53 for 2017 over the last 30 days  The company delivered a positive earnings surprise in all three of the trailing four quarters with an average beat of 0 64   Its share price soared 39 7  so far this year Aduro Biotech s loss per share estimates reduced from  1 46 to  1 32 for 2017 and from  1 41 to  1 24 over the last 30 days  The company delivered positive surprises in two of the trailing four quarters with an average beat of 2 53  ACADIA s loss per share estimates narrowed from  2 82 to  2 59 for 2017 and from  2 07 to  1 92 for 2018 over the last 30 days  The company came up with positive earnings surprises in two of the last four quarters with an average beat of 7 97  4 Surprising Tech Stocks to Keep an Eye On Tech stocks have been a major force behind the market s record highs  but picking the best ones to buy can be tough  There s a simple way to invest in the success of the entire sector  Zacks has just released a Special Report revealing one thing tech companies literally cannot function without  More importantly  it reveals 4 top stocks set to skyrocket on increasing demand for these devices  I encourage you to get the report now   before the next wave of innovations really takes off ,2017-08-24,Zacks Investment Research,https://www.investing.com/analysis/ultragenyx-files-bla-to-fda-for-hypophosphatemia-candidate-200209618,200209618
129671,351186,ACAD,3 Stocks You Should Watch  ACAD  AMD  BWLD,opinion,"We gave our daughter an epic birthday party this weekend  dinner out with a bunch of friends  took the same bunch to the  musical in San Francisco  campout in a big tent in the back yard  s mores over the fire pit  swimming in the pool  and crepes by me   So I m crouched in a corner right now  suffering from blogger s guilt  putting together a little post for my readers  Even Sunday is not a day of rest  although God ordained  for Tim bot 
So here are three ideas I m short  out of my 48 positions  that I found of special interest  First up is ACADIA Pharmaceuticals Inc  NASDAQ ACAD   which is sporting a well formed diamond pattern  If broken  this becomes a powerful reversal pattern 

Next is Advanced Micro Devices  NASDAQ AMD   Semiconductors had an incredible run until a few months ago  and they re all starting to fizzle and pop  AMD seems especially prone to failure to my eyes 

Lastly is Buffalo Wild Wings Inc  NASDAQ BWLD   which has been  Old Faithful  lately  This is a massive topping pattern with plenty of downside potential left ",2017-08-28,Tim Knight,https://www.investing.com/analysis/sunday-trio-200209776,200209776
129672,351187,ACAD,Anthera s Blisibimod Positive In Phase II Extension Study,opinion,Anthera Pharmaceuticals  Inc    NASDAQ ANTH   announced positive top line data from the extension of a phase II BRIGHT SC study  evaluating key pipeline candidate  blisibimod for treatment of patients with IgA nephropathy  IgAN  Notably  the BRIGHT SC study is randomized  double blind and placebo controlled  initiated in June 2013  to evaluate the efficacy  safety  tolerability and immunogenicity of blisibimod in patients with IgAN Anthera s share price movement shows that the stock has significantly underperformed the  so far this year  The stock has plunged 73  versus the industry s 9 4  increase during the period The extension of phase II BRIGHT SC study demonstrated a tendency toward lower proteinuria in blisibimod when compared to placebo treated patients  The study also showed a trend toward preservation of renal function  eGFR  in patients treated with blisibimod  The candidate was well tolerated during the study compared with placebo The trial was conducted on total 58 patients  Patients enrolled in the study were treated for up to 2 years and had the opportunity to complete at least 60 weeks of treatment  Anthera is planning to share these results with the FDA and proceed with a phase III trial for patients with the same indication We remind investors that the company has a mid stage development candidate  Sollpura  acquired from Eli Lilly and Company   NYSE LLY   in July 2014  The candidate is being developed for treating patients with low digestive enzyme levels or exocrine pancreatic insufficiency  EPI  due to cystic fibrosis or other potential diseases The company initiated a phase III SOLUTION study on Sollpura in the third quarter of 2015  In December 2016  the company announced that the study had narrowly missed the primary endpoint of a change in the Coefficient of Fat Absorption  CFA  non inferiority margin  However  Sollpura achieved a statistical criterion for nitrogen absorption and later on  Anthera too reported positive data from the extension phase of the SOLUTION study earlier in March The company currently has no approved products  Hence  the successful development of these candidates is crucial for its portfolio boost Anthera Pharmaceuticals  Inc  Price   Zacks Rank   Stocks to ConsiderAntheracurrently carries a Zacks Rank  3  Hold   Some better ranked stocks in the pharma sector are Aduro Biotech  Inc    NASDAQ ADRO   and ACADIA Pharmaceuticals Inc    NASDAQ ACAD    both carrying a Zacks Rank  2  Buy   You can see  Aduro Biotech s loss per share estimates reduced from  1 46 to  1 32 for 2017 and from  1 41 to  1 24 over the last 30 days  The company delivered positive surprises in two of the trailing four quarters with an average beat of 2 53  ACADIA s loss per share estimates narrowed from  2 82 to  2 59 for 2017 and from  2 07 to  1 92 for 2018 over the last 30 days  The company came up with positive earnings surprises in two of the last four quarters with an average beat of 7 97  Zacks  10 Minute Stock Picking SecretSince 1988  the Zacks system has more than doubled the S P 500 with an average gain of  25  per year  With compounding  rebalancing  and exclusive of fees  it can turn thousands into millions of dollars But here s something even more remarkable  You can master this proven system without going to a single class or seminar  And then you can apply it to your portfolio in as little as 10 minutes a month ,2017-08-28,Zacks Investment Research,https://www.investing.com/analysis/antheras-blisibimod-positive-in-phase-ii-extension-study-200210212,200210212
129673,351188,ACAD,FDA s Refusal to File Letter For Inbrija Pushes Acorda Down,opinion,Shares of Acorda Therapeutics  Inc    NASDAQ ACOR   have plunged almost 25  after the company announced that it has received a refusal to file  RTF  letter from the FDA in connection with the new drug application  NDA  for pipeline candidate  Inbrija Notably  Acorda is seeking approval for Inbrija  CVT 301  levodopa inhalation powder  in the United States as a treatment option for symptoms of OFF periods in people with Parkinson s taking a carbidopa   levodopa regimen Shares of Acorda have underperformed the year to date  The stock has increased 3 7  as against the industry s 9 7  gain during the period We remind investors that Acorda had submitted the NDA as a 505 b  2  application in June and was expecting the FDA to inform whether the application was complete by the end of September However  the FDA has deemed the application incomplete after a preliminary review and as a result  the regulatory body now requires additional supporting information to review the application The FDA stated two main reasons for the RTF  date specification as to when the manufacturing site can be ready for inspection and questions related to drug master production record  Additionally  the FDA has also asked for some extra data  unrelated to the main issues of the RTF Notably  Acorda mentioned that it will request the FDA for a Type A meeting in a bid to resolve the issues The FDA s refusal for Inbrija s NDA is a major setback for the company as this would delay its commercial launch  previously expected in the first half of 2018  However  good news is that the FDA has not recommended any additional efficacy safety study to be conducted to resubmit the filing It is important to note that the NDA application was based on positive data from one phase III safety and efficacy study  SPAN PD  and from two ongoing long term safety studies  CVT 301 005 and CVT 301 004E  on people with Parkinson s Significantly  Acorda is planning to submit regulatory applications for Inbrija in the EU by the end of 2017 for the given indication Going forward  we expect investors to remain focused on further updates on this development around Inbrija Acorda Therapeutics  Inc  Price    Zacks Rank   Stocks to ConsiderAcorda currently carries a Zacks Rank  3  Hold   Some better ranked stocks in the pharma sector are Akebia Therapeutics  Inc    NASDAQ AKBA    Aduro Biotech  Inc    NASDAQ ADRO   and ACADIA Pharmaceuticals Inc    NASDAQ ACAD    all three carrying a Zacks Rank  2  Buy   You can see  Akebia s loss per share estimates narrowed from  4 14 to  3 85 for 2017 and from  1 98 to  1 88 for 2018 over the last 30 days  The company delivered a positive earnings surprise in three of the trailing four quarters with an average beat of 25 93   Its share price soared 60 5  so far this year Aduro Biotech s loss per share estimates reduced from  1 46 to  1 32 for 2017 and from  1 41 to  1 24 over the last 30 days  The company delivered positive surprises in two of the trailing four quarters with an average beat of 2 53  ACADIA s loss per share estimates narrowed from  2 82 to  2 59 for 2017 and from  2 07 to  1 92 for 2018 over the last 30 days  The company came up with positive earnings surprises in two of the last four quarters with an average beat of 7 97  4 Surprising Tech Stocks to Keep an Eye On Tech stocks have been a major force behind the market s record highs  but picking the best ones to buy can be tough  There s a simple way to invest in the success of the entire sector  Zacks has just released a Special Report revealing one thing tech companies literally cannot function without  More importantly  it reveals 4 top stocks set to skyrocket on increasing demand for these devices  I encourage you to get the report now   before the next wave of innovations really take off ,2017-08-29,Zacks Investment Research,https://www.investing.com/analysis/fdas-refusaltofile-letter-for-inbrija-pushes-acorda-down-200210517,200210517
129709,351224,ACAD,Economic Calendar And Watch List 12 20 2016,opinion,"Morning Notes
US Futures are pointing slightly higher this morning while European stocks are also trading higher after Japan boosted its 2017 GDP outlook  The price of crude is edging higher as well this morning by   5   giving energy producing stocks a lift  Asian stocks closed mostly mixed 
Technicals

The SPY  NYSE SPY  consolidated further on lighter volume and traded in a tight range throughout yesterday s session  Support will lie at the low of yesterday s range at  225 08  followed by  224 67   224 26  and  221 28  Resistance will lie at the high of yesterday s range at  226 02  followed closely by  226 08  then  227 81 and record highs at  228 34 
Small Cap Watch List
 Please refer to the momentum scanners displayed live in the chat room for potential plays at the market open  
  Others On Watch  
ACADIA Pharmaceuticals Inc  NASDAQ ACAD 
Economic Calendar
NONE
Notable Earnings Before Open
NONE
Notable Earnings After Close
NONE",2016-12-20,Warrior Trading,https://www.investing.com/analysis/economic-calendar---watch-list-12-20-2016-200170387,200170387
129710,351225,ACAD,ACADIA Pharmaceuticals Inc  Stock Positive Phase II Data Gives A Boost,opinion,"ACADIA Pharmaceuticals Inc  NASDAQ ACAD 
On Tuesday before the market opened  ACADIA Pharmaceuticals announced that they reached positive top line results in its Phase II study of pimavanserin in patients with Alzheimer s disease psychosis  The study met the primary endpoint with statistical significance and showed that patients tolerated the treatment within the safety parameters 
ACAD Technicals

Shares of ACAD spiked to highs of  40 in the pre market session after closing the previous day at  25 43 marking a 57  pop in price  Shares came off highs and opened the day at  29 26 and should see some resistance at the 200 day moving average currently sitting at  30 59  Look for support to come in at the 20 day moving average currently at  26 66 and  26 50 which has been an important pivot spot on the daily chart  Look for shares to get back above the 200 day moving average to show that bulls have taken over and until it does be careful of going long 
CEO Comments

 Alzheimer s disease patients suffer from a number of debilitating symptoms  of which psychosis carries a poor prognosis and is associated with earlier placement into nursing homes   said Steve Davis  ACADIA s President and Chief Executive Officer   Data from the  019 Study provide solid evidence that pimavanserin can improve psychosis in another major neurological disorder and provide strategic momentum for the further development of pimavanserin to address the needs of AD Psychosis patients     

Company Profile
ACADIA Pharmaceuticals Inc  is a biopharmaceutical company  The Company is focused on the development and commercialization of medicines for central nervous system disorders  The Company s lead drug candidate  NUPLAZID  pimavanserin   is under development for the treatment of Parkinson s disease psychosis  PDP   NUPLAZID is a selective serotonin inverse agonist  SSIA   targeting 5 HT2A receptors  The Company s Pimavanserin is a chemical entity  which has completed Phase III development  and is indicated for the treatment of Parkinson s disease psychosis  NUPLAZID  pimavanserin  is a selective serotonin inverse agonist preferentially targeting the 5 HT2A receptor  a key serotonin receptor that plays a role in psychosis  Through this mechanism  NUPLAZID has demonstrated efficacy in Parkinson s disease psychosis in its Phase III pivotal trial and avoids the side effects of existing antipsychotics ",2016-12-20,Ticker.tv News,https://www.investing.com/analysis/acadia-pharmaceuticals-inc.-$acad-stock-|-positive-phase-ii-data-gives-200170391,200170391
129711,351226,ACAD,Best Biotech Stock Buys In January,opinion,"With the biotech sector going on sale due to its massive underperformance in the S P 500 year to date  it is likely to generate bargains 
This bargain will definitely draw in traders and investors  but which biotech company stocks are the best to buy for the beginning of 2017  Here are   four biotech stock highlights that we think would be the best buys as we welcome the coming year 
ACADIA Pharmaceuticals Inc  NASDAQ ACAD 
Acadia Pharmaceuticals is making a buzz in the biotech sector as its drug Nuplazid is the first and only FDA approved  Food and Drug Administration  treatment for Parkinson s disease Psychosis  PDP   While launching a new medicine to the market is difficult  the challenge isn t quite hampering when there isn t any rival to worry about 
Nuplazid was previously introduced only a few months back  but the early results are positive  Third quarter total sales poured in at  5 3 million  an amount that exceeded than double of analysts  expectations  This is seen as a good beginning for the biotech even if the total sales are nowhere near to balance the company s massive spending 
While the said drug has just hardly begun to penetrate into the PDP market  the Acadia management is also proposing for expanding Nuplazid s labeling 
Overall  Acadia gives investors a lot of reasons to believe that it will display an incredibly fast growth for the coming years ahead a long term gain  It is a recommended bet to get shares for Acadia while they are currently trading at a discount 
The ACAD stock finished the prior trading session at  29 750  up by 7 52  or  2 08 
Geron Corporation  NASDAQ GERN 
Geron comes as one of the sector s most intriguing long term value plays after suffering a market beat down in the year  While this biotech firm doesn t possess a product to offer to the market yet  its lead candidate  imetelstat  has generated attractive trial results that indicate it could potentially take over a somewhat underserved niche 
Its partner Johnson   Johnson  NYSE JNJ  is anticipating additional data from continued studies with the said drug next year  Should trial results for myelofibrosis  a bone marrow disorder that unsettles the body s normal production of blood cells  remain consistent with prior observations  the healthcare giant will aid in funding larger trials in order to support New Drug Applications 
As it stands  there is only one treatment for myelofibrosis  and that is Jakafi  manufactured by Incyte  According to third quarter earnings report  Jafaki has generated sales and royalty revenue at a year run rate of  1 01 billion  The drug has also gained the FDA approval in 2011 due to its capability to lower spleen size  which is a symptom of the disease 
But Geron s imetelstat is the first to reveal clear signs of decreased disease activity and even push the rare blood cancer to total diminution 
Currently  Geron s enterprise value is a mere  340 million  But with a partner ready to usher the lead drug through the regulatory pathway and eventually into the commercial scene  there is a likely chance Geron could offer great returns to persevering investors next year 
At Monday s close  GERN shares earned 5 39  or  0 110 to trade at 2 150 
Ligand Pharmaceuticals  NASDAQ LGND 
Ligand Pharmaceuticals boasts of a market cap less than  3 billion with a deep pipeline  eight programs in late stage clinical studies and 18 more in mid stage levels  which is a considerable amount the competes better against other larger biotech firms 
The success behind this is Ligand s partnerships  the company has more than 90 partners and licenses for its drug development platforms  and many of which are the largest drug manufacturers in the market 
The appeal that comes with Ligand s products is that they aid biopharmaceutical firms develop new drugs more effectively  Captisol  its leading technology  possesses a chemical structure that enhances solubility  stability  bioavailability and dosing of active pharmaceutical components 
From January to September 2016  Ligand s revenue surged almost 40  in comparison to the same period last year  The biotech is seen to sustain this pace of growth for the next couple of years  supported by its solid pipeline and the soaring sales of Kyprolis and Promacta its current products 
LGND ended Monday s trading session with a gain of 3 12  or  3 14 to trade at 103 65 
Trevena Inc  NASDAQ TRVN 
The clinical stage biotech Trevena is scheduled to post top line results from two phase 3 studies  namely APOLLO 1 and APOLLO 2  for its lead drug in the first quarter of 2017  The said experimental drug  oliceridine  is an injected dose for the treatment of moderate to severe pain in post surgery 
Oliceridine should not be taken lightly because the acute pain market is enormous  and there s an urgent need for viable substitutes to addictive drugs like morphine  With these descriptions  this specific drug market has all the factors in place to possibly make a highly lucrative product such as oliceridine 
All the evidence so far indicates that this experimental drug is an effective pain reliever  which suggests that it may hit the mark in each trial regarding its primary point  the ability to beat placebo as a pain reliever  This is a feat achieved successfully in its mid stage trials that even led to a breakthrough therapy designation from the FDA previously in February 
However  oliceridine s value proposition depends on how well it stacks up against morphine in regards to safety and efficacy  the secondary standpoint in the trials  Should Trevena s drug generate a promising clinical profile relative to morphine  it may produce hundreds of millions in sales a great potential haul for a firm with a market cap of roughly  300 million 
Keep in mind that there is a gripping bear case surrounding the drug s ultimate commercial potential  Bears have shared that oliceridine s target market is just a minute fraction of the acute pain aspect  and the biotech company may not be able to persuade payers to cover for an obviously more costly drug than morphine 
In the previous Monday session  TRVN was last up by 3 11  or  0 18 to  5 97 ",2016-12-27,FSM News,https://www.investing.com/analysis/best-biotech-stock-buys-in-january-200170871,200170871
129712,351227,ACAD,Geron s  GERN  Imetelstat Progressing Well  Setbacks Concern,opinion,"We issued an updated research report on Menlo Park  CA based Geron Corporation   NASDAQ GERN   on Aug 11 Geron is developing anti cancer therapies based on telomerase inhibitors  The company currently has one candidate in its pipeline  imetelstat  It is being developed for the treatment of hematologic myeloid malignancies like myelofibrosis  MF  and myelodysplastic syndromes  MDS   Geron has a collaboration with Johnson   Johnson s  JNJ  subsidiary Janssen for imetelstat Geron has no approved product in its portfolio and its top line solely comprises license fees and royalties Imetelstat is being evaluated for myelofibrosis  MF  in a phase II IMbark study and for myelodysplastic syndromes  MDS  in a phase II III IMerge study Geron announced in Apr 2017 that Janssen has completed the second internal data review of the two studies  Janssen said that the benefit risk profile of imetelstat in the treated patients supports continued development in lower risk MDS indication  Owing to the favorable update  both trials are continuing unmodified If Janssen decides to proceed to Part 2 of IMerge  a larger  170 patient  phase III study   patient enrollment is expected to begin in the fourth quarter of this year  Moreover  Geron announced in July that Part 1 of IMerge will be expanded to enroll additional patients in a refined MDS population to confirm the clinical benefit and safety observed from the current result Meanwhile  the results from IMbark study suggested that the clinical benefit and a potential overall survival benefit observed supports continuation of the trial without modifications  Janssen is expected to evaluate maturing data from the IMbark study next year  including an assessment of overall survival Geron s shares have underperformed the  so far this year  Shares of Geron rose 0 5  during the period compared with the industry s gain of 6 2  However  we are concerned about Geron s dependence on a single pipeline candidate  Geron has faced setbacks as imetelstat was placed under clinical hold in 2014  It also faced unfavorable findings in internal reviews of initial data from IMbark and IMerge studies  Any further setback may have significant negative impact on the company s stock Geron Corporation Price and Consensus
    Zacks Rank   Stocks to ConsiderGeron carries a Zacks Rank  3  Hold  Some better ranked stocks in the pharma sector include ACADIA Pharmaceuticals Inc    NASDAQ ACAD    Aduro Biotech  Inc    NASDAQ ADRO   and Enzo Biochem  Inc    NYSE ENZ    All the three stocks carry a Zacks Rank  2  Buy   You can see  ACADIA Pharma s loss estimates narrowed from  2 82 to  2 69 for 2017 and  2 07 to  1 99 for 2018 over the last 30 days  The company came up with a positive earnings surprise in two of the four trailing quarters with an average beat of 3 25   The stock is up 8 2  so far this year Aduro Biotech s loss per share estimates narrowed from  1 46 to  1 36 for 2017 and  1 54 to  1 26 for 2018 over the last 30 days  The company delivered a positive surprise in two of the four trailing quarters with an average beat of 2 53  Enzo Biochem s loss estimates narrowed from 12 cents to 7 cents for 2017 and 11 cents to 3 cents for 2018 over the last 60 days  The company came up with a positive earnings surprise in the four trailing quarters with an average beat of 55 83   The stock is up 59 3  so far this year 5 Trades Could Profit  Big League  from Trump PoliciesIf the stocks above spark your interest  wait until you look into companies primed to make substantial gains from Washington s changing course Today Zacks reveals 5 tickers that could benefit from new trends like streamlined drug approvals  tariffs  lower taxes  higher interest rates  and spending surges in defense and infrastructure ",2017-08-13,Zacks Investment Research,https://www.investing.com/analysis/gerons-gern-imetelstat-progressing-well-setbacks-concern-200207094,200207094
129713,351228,ACAD,FDA Accepts Portola s  PTLA  BLA Resubmission For AndexXa,opinion,Portola Pharmaceuticals  Inc   NASDAQ PTLA   recently announced that the FDA has accepted its resubmitted biologics license application  BLA  for the reversal agent for Factor Xa inhibitors  AndexXa  Andexanet Alfa   A decision from the U S  regulatory body is expected on Feb 2  2018 AndexXa has been developed for patients treated with a direct or indirect Factor Xa inhibitor  when reversal of anticoagulation is needed due to life threatening or uncontrolled bleeding Notably  AndexXa is also under review in the EU with marketing application filed in the third quarter of 2016 Portola s shares have significantly outperformed the so far this year  The stock has soared 143 8  compared with the broader industry s decrease of 1 9  The resubmission includes additional information requested by the FDA in a complete response letter  CRL  issued to Portola in August last year  In the letter  the FDA had requested for information related to product manufacturing  It had also asked for more data to support the inclusion of direct Factor Xa inhibitor Lixiana  edoxaban  and indirect Factor Xa inhibitor Lovenox  enoxaparin  on the product label We remind investors that the BLA was based on positive data from two phase III ANNEXA studies that evaluated the safety and efficacy of AndexXa in reversing the anticoagulant activity of the Factor Xa inhibitors  Xarelto  rivaroxaban  of Johnson and Johnson  Inc    NYSE JNJ   and Eliquis  apixaban  of Bristol Myers Squibb Company   NYSE BMY    in older healthy volunteers  Significantly  AndexXa enjoys an Orphan Drug Status in the United States Per the company s press release  more than 90 000 U S  patients treated with oral Factor Xa inhibitors in 2016 were admitted to hospital due to excessive bleeding  It has also been estimated that more than 150 000 patients taking the injectable Factor Xa inhibitor Lovenox in the United States could benefit from an antidote each year With no currently approved antidote for Factor Xa inhibitors yet  there is a high unmet need for the same in the market Going ahead  we expect investors  focus to remain on further details of AndexXa s regulatory aspect Portola Pharmaceuticals  Inc  Price   Zacks Rank   Stocks to ConsiderPortola currently carries a Zacks Rank  3  Hold   A better ranked stock in the pharma sector is ACADIA Pharmaceuticals Inc    NASDAQ ACAD    carrying a Zacks Rank  2  Buy   You can see  ACADIA s loss estimates narrowed from  2 82 to  2 65 for 2017 and from  2 07 to  1 98 for 2018 over the last 30 days  The company came up with a positive earnings surprise in two of the trailing four quarters with an average beat of 3 52  One Simple Trading IdeaSince 1988  the Zacks system has more than doubled the S P 500 with an average gain of  25  per year  With compounding  rebalancing  and exclusive of fees  it can turn thousands into millions of dollars This proven stock picking system is grounded on a single big idea that can be fortune shaping and life changing  You can apply it to your portfolio starting today ,2017-08-16,Zacks Investment Research,https://www.investing.com/analysis/fda-accepts-portolas-ptla-bla-resubmission-for-andexxa-200207917,200207917
129714,351229,ACAD,Jazz Pharmaceuticals Arm Announces  500M Senior Notes Offer ,opinion,Jazz Pharmaceuticals Public Limited Company   NASDAQ JAZZ   announced that its wholly owned subsidiary  Jazz Investments I Limited  intends to offer exchangeable Senior Notes  due 2024  for an aggregate principal amount of  500 million in a private offering to qualified institutional buyers Notably  the notes will be exchangeable for cash  ordinary shares or a combination of both to certain circumstances Jazz s shares have significantly outperformed the  so far this year  The stock has surged 33 9  compared with the industry s 3  decrease during the same period The initial purchasers have a 13 day option to buy up to an additional  75 million aggregate principal amount of notes The net proceeds from the offering are expected to be used by Jazz to fully or partially repay a portion of its outstanding  500 million debt under its revolving credit facility  Also  the company plans to use the remaining net proceeds  if any  for general corporate purposes  including potential business development activities            The company already completed a private placement of another  575 0 million principal amount of exchangeable notes due 2021 in August 2014  bearing an annual interest of 1 87  Significantly  Jazz has been very active on the acquisition front  Deals include the company s buyout of biopharma company  Gentium  which added Defitelio  treatment of severe hepatic VOD  to its portfolio  With the Celator merger in May last year  Jazz has added Vyxeos to its pipeline The company completed the rolling NDA submission for Vyxeos to the FDA in March for treatment of acute myeloid leukemia  AML   Later in May  the FDA accepted Vyxeos NDA under priority review  Hence  Jazz expects this Celator takeover to be earnings accretive from 2018 Jazz Pharmaceuticals PLC Price   Zacks Rank   Stocks to ConsiderJazz currently carries a Zacks Rank  2  Buy   Some other stocks worth considering in the pharma sector are Summit Therapeutics PLC   NASDAQ SMMT    Aduro Biotech  Inc    NASDAQ ADRO   and ACADIA Pharmaceuticals Inc    NASDAQ ACAD    all three carrying a Zacks Rank  2 as well  You can see  Summit s loss estimates narrowed from  2 59 to 32 cents for 2018 over the last 60 days  The company delivered a positive earnings surprise in each of the trailing four quarters with an average beat of 25 55   Its share price soared 48 4  so far this year Aduro Biotech s loss per share estimates narrowed from  1 46 to  1 32 for 2017 and from  1 54 to  1 24 for 2018 over the last 30 days  The company delivered positive surprises in two of the trailing four quarters with an average beat of 2 53  ACADIA s loss estimates narrowed from  2 82 to  2 65 for 2017 and from  2 07 to  1 98 for 2018 over the last 30 days  The company came up with a positive earnings surprise in two of the trailing four quarters with an average beat of 3 52  4 Surprising Tech Stocks to Keep an Eye on Tech stocks have been a major force behind the market s record highs  but picking the best ones to buy can be tough  There s a simple way to invest in the success of the entire sector  Zacks has just released a Special Report revealing one thing tech companies literally cannot function without  More importantly  it reveals 4 top stocks set to skyrocket on increasing demand for these devices  I encourage you to get the report now   before the next wave of innovations really take off ,2017-08-17,Zacks Investment Research,https://www.investing.com/analysis/jazz-pharmaceuticals-arm-announces-500m-senior-notes-offer-200208131,200208131
129741,351256,ACAD,3 Stocks To Watch  GNCA  INGN  LABU,opinion,"The market had a decent day on Thursday  but there was a mixed session at the end  A lot of stocks we follow did very well and are trending  So let s see what s going on with them now and where they might be headed 
Genocea Biosciences  Inc   NASDAQ GNCA  was the star of the day on Thursday  up 3 77 to 7 74  or 95   on 24 million shares  It exploded from 5 37 to 8 07  and in afterhours it made it all the way back to 8 45 before dropping back to 6 50  However  it edged up another 1 50 to 7 65  That kind of breakout move  and volume of 24 million  is unheard of for this stock  The Oct high was 8 20  that s why the target on Thursday was 8 15  If it does punch through here  don t be surprised if it gets up to 10 or 11 
Inogen  Inc   NASDAQ INGN  had a great day  The swing trade that was put on it a week ago has finally come to fruition  with a pop on Thursday of 2 97 to 44 98  or 7   on 565 900  It broke out and got right up to the next resistance  I do think it s going to take a run at the 47 47 1 2 range short term  and then 55 intermediate term 
The Direxion Daily S P Biotech Bull 3X ETF  NYSE LABU  is still basing  but looking better  It was up 2 29 to 27 47  or 9 1   on 57 million shares traded  That s the biggest volume in its history on Thursday on an up day  That s a good sign  Watch the declining topsline  and later resistance at the 30 range  it could very well run up to 34 very quickly  and then it will really take off 
Stocks on the long side included ACADIA Pharmaceuticals Inc   NASDAQ ACAD   Celator Pharmaceuticals  Inc   NASDAQ CPXX   Dynagas LNG Partners LP  NYSE DLNG   Genocea Biosciences  Inc   GNCA   Inogen  Inc   INGN   Direxion Daily S P Biotech Bull 3X ETF  LABU   Medivation  Inc   NASDAQ MDVN   MaxLinear  Inc   NYSE MXL   NeoPhotonics Corporation  NYSE NPTN   Primo Water Corporation  NASDAQ PRMW   SciClone Pharmaceuticals  Inc   NASDAQ SCLN   Targa Resources Corp   NYSE TRGP   and Xerox Corporation  NYSE XRX  ",2016-04-01,Harry Boxer,"https://www.investing.com/analysis/gnca,-ingn,-labu-200123570",200123570
129742,351257,ACAD,3 Stocks To Watch Today  INO  PRMW  SSTK,opinion,"It was kind of a consolidation day on Wall Street on Monday  The market was down  but it looked like the indices didn t want to take them too far down  Certainly  a lot of our stocks are still acting well 
Inovio Pharmaceuticals Inc  NASDAQ INO  is acting great  but a little long in the tooth  It was up 41 cents to 9 66  or 4 4   on nearly 3 million shares on Monday  It got up to 9 90  which is the first target that was put on this stock  The second target is around 11 00 
Primo Water Corporation  NASDAQ PRMW  is acting well  After breaking out it s run up four days in a row  It s touching secondary resistance and my first target at 11 00  The second target is 13 1 2 14 
Shutterstock  NYSE SSTK   a swing trade of ours  finally got a breakout on Monday  up 77 cents to 38 24  or 2   on 356 300 shares traded  It popped as high as 40  but finished at 38 24  It made it over the hump and may very well consolidate for a day or two and continue  Targets are 44 and 50 52 going forward 
Stocks on the long side included ACADIA Pharmaceuticals Inc  NASDAQ ACAD   Boston Scientific Corporation  NYSE BSX   Celator Pharm  NASDAQ CPXX   3D Systems Corporation  NYSE DDD   Editas Medicine Inc  NASDAQ EDIT   Fireeye Inc  NASDAQ FEYE   Genocea Bioscnc  NASDAQ GNCA   Groupon Inc  NASDAQ GRPN   Hawaiian Holdings Inc  NASDAQ HA   Inovio Pharmaceuticals Inc  NASDAQ INO   Direxion Daily S P Biotech Bull 3X Shares  NYSE LABU   MediciNova Inc  NASDAQ MNOV   Ocular Therapeutix Inc  NASDAQ OCUL   Primo Water Corporation  NASDAQ PRMW   Sientra Inc  NASDAQ SIEN   Sky Solar Holdings Adr Rep 8  NASDAQ SKYS   Sorrento Therape  NASDAQ SRNE   Shutterstock  NYSE SSTK   Stratasys Ltd  NASDAQ SSYS   Supernus Pharmaceuticals Inc  NASDAQ SUPN   Transenterix Inc  NYSE TRXC   and TherapeuticsMD Inc  NYSE TXMD  ",2016-04-05,Harry Boxer,"https://www.investing.com/analysis/ino,-prmw,-sstk-200123924",200123924
129743,351258,ACAD,Here s Why ACADIA Pharmaceuticals Is Up,opinion,"ACADIA Pharmaceuticals Inc   NASDAQ ACAD  is having an incredible day in the market today  and for good reason  Late Friday  the company announced positive news it had received from the FDA  One of the treatments the company has been working on has been approved  Today  we ll talk about that treatment  how the market reacted to the news  and what we can expect to see from ACAD moving forward  So  let s get right to it 
ACAD Announces The Approval Of NUPLAZID
For some time now  ACADIA Pharmaceuticals has been working on a treatment for hallucinations and delusions that are associated with Parkinson s disease psychosis  That treatment is known as NUPLAZID or pimavanserin  On Friday  the company announced that the FDA has approved NUPLAZID as a Breakthrough Therapy to treat hallucinations and delusions associated with Parkinson s disease psychosis  NUPLAZID is the first treatment of its kind  and the only FDA approved treatment designed for this indication  In a statement  Steve Davis  the President and CEO at ACAD had the following to say with regard to the approval   

NUPLAZID represents a major medical advancement for patients with Parkinson s disease psychosis who suffer from hallucinations and delusions    We are grateful to the many patients and investigators who participated in NUPLAZID s clinical studies  NUPLAZID represents the culmination of many years of work across our entire organization to bring this novel medicine  discovered by our scientists to patients in need 

How The Market Reacted To The News
As investors  we know that the news moves the market  Any time positive news is released with regard to a publicly traded company  we can expect to see gains in the value of the company as a result  Adversely  when negative news is released  we can expect to see declines  Considering the fact that NUPLAZID has been approved  the news surrounding ACAD is overwhelmingly positive  As a result  we re seeing strong positive movement in the market surrounding the news  Currently  9 27   the stock is trading at  33 96 per share after a gain of  1 66 per share or 5 14  thus far today 
What We Can Expect To See Moving Forward
Moving forward  I have an overwhelmingly bullish opinion with regard to what we can expect to see from ACAD  The reality is that the FDA s decision to approve NUPLAZID is an overwhelmingly positive decision for ACADIA  Currently  there is a major medical need for the treatment the company is now approved to offer  According to the National Parkinson s Foundation  in the United States  there are about one million people that suffer from this condition and between four and six million around the world  It is estimated that about 40  of the patients that are dealing with Parkinson s disease also are forced to deal with Parkinson s disease psychosis  This means that ACAD has a relatively large audience for the treatment that it has created  Aside from NUPLAZID  ACAD has an incredibly strong company  They have a wide range of both approved treatments  and treatments that they are working on  With strong management  an incredible team  and great products  it only makes sense that this stock will soar from here 
What Do You Think 
Where do you think ACAD is headed and why  Let us know your opinion in the comments below ",2016-05-02,Joshua Rodriguez,https://www.investing.com/analysis/acadia-pharmaceuticals-(acad)-stock:-heres-why-its-up!-200127200,200127200
129744,351259,ACAD,Puma Biotechnology  PBYI  Q3 Earnings  What s In Store ,opinion,"Puma Biotechnology  Inc    NYSE PBYI   is expected to report third quarter 2016 results in November  The company s track record has been mostly disappointing  While it missed estimates in two of the trailing four quarters  it met the same in one and surpassed in the other  The company recorded an average negative surprise of 5 23  PUMA BIOTECHNLG Price and EPS Surprise

   Let s see how things are shaping up for this announcement 
Neratinib in Focus
Puma Biotech has made significant progress with its lead candidate  neratinib  The candidate is currently under review  in both the U S  and the EU for the extended adjuvant treatment of HER2 positive early stage breast cancer that has previously been treated with Herceptin based adjuvant therapy 
We note that several phase II combination studies on neratinib for the treatment of breast cancer are currently underway 
At the time of announcing second quarter 2016 results  the company projected that net loss may narrow in the subsequent quarters due to continued reduction in clinical trial expenses and expenses associated with the completion of regulatory filings for neratinib  The company also expects its research and development expenses to decrease in subsequent quarters for the same reasons 
Being a development stage company  Puma Biotech does not have any approved product in its portfolio  Thus  investor focus should remain on updates pertaining to the development of neratinib 
Earnings Whispers
Our proven model does not conclusively show that Puma Biotech is likely to beat estimates this quarter  That is because a stock needs to have both a positive Earnings ESP and a Zacks Rank  1  Strong Buy    2  Buy  or  3  Hold  for this to happen  That is not the case here  as you will see below 
Zacks ESP  The   which represents the difference between the Most Accurate Estimate and the Zacks Consensus Estimate  is pegged at 0 00   This is because both the Most Accurate Estimate and the Zacks Consensus Estimate stand at a loss of  2 00  Please check our  that enables you to find stocks that are expected to come out with earnings surprises 
Zacks Rank  Although Puma Biotech s carries a favorable Zacks Rank  2  its 0 00  ESP makes surprise prediction difficult 
Note that we caution against stocks with a Zacks Rank  4 or 5  Sell rated stocks  going into the earnings announcement  especially when the company is seeing negative estimate revisions 
Stocks That Warrant a Look
Here are some health care stocks that you may want to consider instead  as our model shows that they have the right combination of elements to post an earnings beat this quarter 
ARIAD Pharmaceuticals Inc    NASDAQ ARIA   is scheduled to report on Nov 7  It has an Earnings ESP of  5 26  and carries a Zacks Rank  2  You can see the  
Synergy Pharmaceuticals  Inc    NASDAQ SGYP   has an Earnings ESP of  18 18  and carries a Zacks Rank  3  It is expected to report on Nov 14 
ACADIA Pharmaceuticals Inc    NASDAQ ACAD   has an Earnings ESP of  5 46  and carries a Zacks Rank  3  It is scheduled to report on Nov 7 
Confidential from Zacks 
Beyond this Analyst Blog  would you like to see Zacks  best recommendations that are not available to the public  Our Executive VP  Steve Reitmeister  knows when key trades are about to be triggered and which of our experts has the hottest hand ",2016-11-03,Zacks Investment Research,https://www.investing.com/analysis/puma-biotechnology-(pbyi)-q3-earnings:-what's-in-store-200162696,200162696
129745,351260,ACAD,Will Kite Pharma  KITE  Stock Surprise Post Q3 Earnings ,opinion,"Kite Pharma  Inc    NASDAQ KITE   will be reporting third quarter 2016 earnings on Nov 9  before market open  Last quarter  the company delivered a negative earnings surprise of 2 34  
The company  which started trading from Jun 2014  has a mixed record of earnings surprises  It delivered positive earnings surprises in two of the past four quarter while missed in the other two  bring the average surprise to a positive 8 48  
Let s see how things are shaping up for this announcement KITE PHARMA INC Price and EPS Surprise

   Factors to Consider
Kite Pharma  a development stage biopharmaceutical company  is looking to transform the paradigm of treating cancer which involves using the body s immune system to recognize and destroy cancer cells 
Kite Pharma s revenues comprise the amortization of deferred collaboration revenues related to the  60 million upfront payment received under its collaboration agreement with Amgen  Inc    NASDAQ AMGN   in the first quarter of 2015 
With no approved products in its portfolio  investor focus will primarily be on the company s cash burn and pipeline updates 
At the time of releasing second quarter results  Kite had guided toward 2016 net cash burn of  235  250 million 
KTE C19  Kite s lead pipeline candidate  is currently in the pivotal phase of a phase I II study  ZUMA 1  in patients with refractory diffuse large B cell lymphoma  DLBCL  including primary mediastinal B cell lymphoma  PMBCL  and transformed follicular lymphoma  TFL   All these are types of aggressive non Hodgkin s lymphoma  NHL   In Sep 2016  the company announced encouraging top line results from the phase II part of ZUMA 1 study and expects to file a Biologic license application  BLA  based on this data  Moreover  the primary analysis of 101 patients with chemorefractory aggressive NHL  DLBCL  TFL and PMBCL   which will include about six months of follow up data  is anticipated in the first quarter of 2017  KTE C19 studies will be initiated in Europe later this year 
Kite is also evaluating KTE C19 in a phase II study  ZUMA 2  in patients with relapsed refractory mantle cell lymphoma  MCL  and in two additional pivotal studies  phase I II  for acute lymphoblastic leukemia  ALL    ZUMA 3 for adult ALL and ZUMA 4 for pediatric ALL  with results from all these studies due in 2017  Kite plans to move KTE C19 into a second series of studies for additional indications and earlier lines of therapy in DLBCL patients in 2017  A phase Ib II combination study evaluating KTE C19 plus Genentech s Tecentriq  atezolizumab  in patients with chemorefractory DLBCL is scheduled to commence soon 
Apart from updates on KTE C19  investor focus will remain on the company s progress with its collaboration with several companies including Amgen 
Earnings Whispers
Our proven model does not conclusively show that Kite Pharma is likely to beat on earnings this quarter  That is because a stock needs to have both a positive  and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  for this to happen  That is not the case here  as you will see below 
Zacks ESP  The Earnings ESP is 0 0  as both the Most Accurate estimate as well as the Zacks Consensus Estimate is pegged at a loss of  1 68  Please check our  that enables you find stocks that are expected to come out with earnings surprises 
Zacks Rank  Kite Pharma has a Zacks Rank  4  We caution against Sell rated stocks  Zacks Rank  4 or 5  going into the earnings announcement  especially when the company is seeing negative estimate revisions 
Stocks to Consider
Here are some companies to consider as our model shows that they have the right combination of elements to post an earnings beat this quarter 
ARIAD Pharmaceuticals Inc    NASDAQ ARIA   is expected to release results on Nov 7  The company has an Earnings ESP of 5 26  and a Zacks Rank  2  You can see  
ACADIA Pharmaceuticals Inc    NASDAQ ACAD   with an Earnings ESP of  5 46  and a Zacks Rank  3  The company is scheduled to release results on Nov 7 
Confidential from Zacks
Beyond this Analyst Blog  would you like to see Zacks  best recommendations that are not available to the public  Our Executive VP  Steve Reitmeister  knows when key trades are about to be triggered and which of our experts has the hottest hand ",2016-11-04,Zacks Investment Research,https://www.investing.com/analysis/will-kite-pharma-(kite)-stock-surprise-post-q3-earnings-200162906,200162906
129746,351261,ACAD,What To Expect From Repros  RPRX  This Earnings Season,opinion,Repros Therapeutics Inc    NASDAQ RPRX   is expected to report third quarter 2016 results on Nov 14  The company has reported an average positive surprise of 24 56  in the last two quarters  Let s see how things are shaping up for this quarter Factors at PlayRepros is a development stage biotech company focused on the development of treatments for hormonal and reproductive system disorders  With no approved products in its portfolio yet  investors are expected to keep an eye on pipeline related updates by the company  Repros  pipeline presently comprises enclomiphene and Proellex The most advanced candidate in Repros  pipeline is enclomiphene  which is currently under review in the EU  The company is looking to get the candidate approved for the treatment of secondary hypogonadism  A decision on the approval status of the candidate should be out in 2017 Meanwhile  Repros is conducting a placebo controlled  double blind  proof of concept phase II study  ZA 205  on enclomiphene in obese secondary hypogonadal men to assess its impact on metabolic parameters and quality of life with a routine diet and exercise  Six month interim data from the study were reported in Aug 2016 Also  Repros plans to hold a discussion with the FDA regarding the prospects of advancing Proellex into phase III studies for the treatment of women struggling with painful menstruation  In addition  Proellex is being evaluated for the treatment of uterine fibroids Repros currently carries a Zacks Rank  3  Hold  Stocks that Warrant a LookHere are some companies in the health care sector you may want to consider as our model shows that they have the right combination of elements   a positive  and a Zacks Rank  1  Strong Buy   2  Buy  or 3   to post an earnings beat this quarter ARIAD Pharmaceuticals Inc    NASDAQ ARIA   is expected to release results on Nov 7  The company has an Earnings ESP of 5 26  and a Zacks Rank  2  You can see  ACADIA Pharmaceuticals Inc    NASDAQ ACAD   is scheduled to release results on Nov 7  The company has an Earnings ESP of 5 46  and a Zacks Rank  1 Synergy Pharmaceuticals Inc   NASDAQ SGYP   is expected to release results on Nov 14  The company has Earnings ESP of 18 18  and a Zacks Rank  3 Please check our  that enables you to find stocks that are expected to come out with earnings surprises  REPROS THERAPEU Price and EPS Surprise   Confidential from ZacksBeyond this Analyst Blog  would you like to see Zacks  best recommendations that are not available to the public  Our Executive VP  Steve Reitmeister  knows when key trades are about to be triggered and which of our experts has the hottest hand ,2016-11-04,Zacks Investment Research,https://www.investing.com/analysis/what-to-expect-from-repros-(rprx)-this-earnings-season-200162805,200162805
129768,351283,ACAD,Stocks Little Changed In Quiet Trade,opinion,Monday was a slow day in the equity markets  with the major averages closing near the unchanged mark   There were no significant domestic economic reports and news flow was muted  Among the day s top stories  however  was the upgrade in the outlook for U S  debt from  negative  to  stable  at Standard   Poor s  removing the near term threat of another downgrade   Major Averages The Dow Jones Industrial Average fell around 10 points  or 0 06 percent  to 15 239   The S P 500 lost less than a point  or 0 03 percent  to close at 1 643   The Nasdaq added a little less than 5 points  or 0 13 percent  to 3 474   Commodities Crude oil futures traded down slightly on Monday  Near the close of equities  NYMEX crude futures were down 0 25 percent to  95 79 while Brent contracts had lost 0 70 percent to  103 83  At last check  natural gas was lower by 0 68 percent to  3 80   Precious metals were up marginally on the session  COMEX gold futures were last up 0 22 percent to  1 386 00  Silver contracts had risen 0 86 percent and were last trading at  21 93  Copper lost a little less than 1 percent on the day to  3 2405   In the grains complex  both corn and wheat fell to start the week  At last check  corn contracts were down 2 24 percent while wheat had lost a little less than 1 percent  Movers in soft commodities included coffee  which climbed 1 42 percent  and cotton  which was up better than 2 percent on the day   Bonds Near the close of equities  the iShares Barclays 20  Year Treasury Bond ETF  TLT  was trading down 0 50 percent to  112 59  Yields rose as prices fell on the day   The yield on the 2 Year Note was last at 0 31 percent  after rising eight basis points over the last month  The 5 Year Note yield was at 1 12 percent and the 10 Year yield was sitting at 2 21 percent  Over the last month  the 30 Year Bond yield has risen twenty seven basis points to 3 36 percent   Currencies The U S  Dollar was essentially unchanged on Monday  The PowerShares DB US Dollar Index Bullish ETF  UUP   which tracks the performance of the greenback versus a basket of foreign currencies  was last down 0 02 percent to  22 16   The closely watched EUR USD pair was last trading up 0 30 percent to  1 3258  The Japanese Yen fell sharply against the greenback to start the week  with the USD JPY last up 1 24 percent   Volatility and Volume The VIX rose on Monday despite little change in equity markets  At last check  the widely watched barometer of volatility expectations had climbed 2 percent to 15 44   Volume was lighter than usual on the session after elevated trading levels last week  Around 93 million SPDR S P 500 ETF  SPY  shares traded hands on the day compared to a 3 month daily average of 131 million   Stock Movers ACADIA Pharmaceuticals  ACAD  jumped around 15 percent on Monday after hedge fund Baker Brothers disclosed a 22 6 percent stake in the stock last week   Sodastream International  SODA  rose 5 percent on Monday on continued speculation about a possible acquisition   RF Micro Devices  RFMD  climbed around 4 percent on the session  The reason for the move in the stock was not immediately clear   Shares of Dynavax Technologies  DVAX  lost around 43 percent after the FDA said that the company doesn t have enough data to confirm the safety of its hepatitis B vaccine Heplisav   Titan International  TWI  fell almost 14 percent on Monday after the company said that it plans to lower its full year guidance   Consulting firm Booz Allen Hamilton  BAH  lost a little less than 3 percent after a former employee  Edward Snowden  revealed that he was the source of the leaks regarding NSA spying programs BY Scott Rubin,2013-06-11,Benzinga ,https://www.investing.com/analysis/stocks-little-changed-in-quiet-trade-170782,170782
129769,351284,ACAD,Analysts Remain Bullish on Acadia Pharma Despite Drug Approval Delay,opinion,ACADIA Pharmaceuticals Inc  NASDAQ ACAD  is making headlines with the sudden announcement of the CEO s retirement and an application delay for the company s leading drug  Acadia focuses on developing treatment for neurological and central nervous system disorders On March 11  CEO Uli Hacksell abruptly retired after 16 years with the company  He will also be retiring from his position on the board of directors  Acadia applauded Hacksell s tenure in a press release  noting that Acadia  has grown from a small startup to a fast growing biopharmaceutical company with innovative drug candidates  under his leadership  CFO Steve David will take over immediately as the interim CEO Also on March 11  Acadia announced a delay in submitting the New Drug Application for Nuplazid  The application was scheduled for submission in the first quarter of 2015 but is being pushed back to the second half of 2015  Nuplazid is intended to treat Parkinson s disease psychosis and is Acadia s primary pipeline drug  The drug already reported successful results in a Phase III clinical trial  Acadia noted that the prudent delay is necessary to complete the application and emphasized that the  change in submission timing is not a result of any change to NUPLAZID s clinical or safety profile  nor is it a result of any interaction with or request for information from the FDA  On March 12  analyst  of Needham   Company reiterated a Buy rating on Acadia Pharmaceuticals and lowered his price target from  40 to  38  Carr made the rating in light of Hacksell s retirement and Nuplazid s delay  In response to Nuplazid s delay  he noted    Management  admitted that preparations for FDA review were inadequate  Changes have been made to address the matter  including hiring additional staff and external consultants as well as shifts in senior management responsibilities   Carr emphasized that the delay  is not tied to any new communication from the FDA or any new safety data  Our enthusiasm for the drug and its commercial potential as an antipsychotic is unchanged  Alan Carr has rated Acadia Pharma 10 times since March 2012 with a 100  success rate recommending the pharmaceutical company and an impressive  91 5  average return per ACAD recommendation  Overall  Carr has a 76  success rate recommending stocks with a  44 3  average return per recommendation Separately on March 12  analyst  of H C  Wainright maintained a Buy rating on Acadia Pharmaceuticals with a price target of  50  Fein was not fazed by Nuplazid s delay because the drug still has  Breakthrough Therapy designation from the FDA   which will allows for  rolling NDA submission with communication feedback at every step   Furthermore  Fein noted that  since there are no changes to the formulation or safety and efficacy data of the drug  nothing has changed with the agency s regard for the drug  and in our view  its approvability   The analyst concluded   We look forward to further granularity on such potential developments  which would remind everyone that none of the fundamental components of the bull thesis have changed  Andrew Fein has rated Acadia once before and earned a  22 6  return  Overall  Fein has a 69  success rate recommending stocks with a  36 5  average return per recommendation On average  the top analyst consensus for Acadia Pharmaceuticals on is Strong Buy ,2015-03-12,Sarah Roden,https://www.investing.com/analysis/analysts-remain-bullish-on-acadia-pharma-despite-drug-approval-delay-244873,244873
129770,351285,ACAD,ACADIA Pharmaceuticals Stock  Here s Why We re Seeing Gains,opinion,"ACADIA Pharmaceuticals Inc  NASDAQ ACAD  is having an incredible time in the market at the moment  and for good reason  The company recently announced incredibly positive news with regard to a treatment for Parkinson s Disease Psychosis that it has been working on for some time now  Today  we ll talk about the news  how the market is reacting  and what we can expect to see from ACAD 
ACAD Submits A New Drug Application 
On Monday  it was announced that ACADIA Pharmaceuticals had submitted a New Drug Application or NDA to the United States Food and Drug Administration  The NDA surrounds a treatment the company has been working on for quite some time  known as NUPLAZID  The treatment was designed for Parkinson s Disease Psychosis  According to ACAD  the drug  provides clinically meaningful benefit  with robust improvements observed across multiple measures of psychosis that were achieved without causing adverse effects to motor function  
What We re Seeing In The Market 
As investors  we know that any time there is news released with regard to a publicly traded company  we can expect to see movement in the value of the stock associated with that company  Good news will lead to positive movement and bad news will cause declines  It s no secret that the news surrounding ACADIA is overwhelmingly positive news  As a result  we ve seen strong gains on the stock since Monday  Currently  9 31   ACAD is trading at  28 34 per share after a gain of  4 53 per share or 19 03  thus far today 
What We Can Expect To See Moving Forward
Moving forward  I m expecting to see overwhelmingly positive movement out of ACAD  The reality is that what they ve done with NUPLAZID is absolutely amazing  Parkinson s Disease Psychosis is an incredibly common problem and as of today  the treatments used for it don t have anywhere near the amounts of benefits that we see from NUPLAZID  I ve been following the studies on the treatment since they started  and based on what I ve seen  ACAD has come up with something that s absolutely incredible here 
Now  it s one thing to have a solid treatment  but it s also important to look at the target market associated with the treatment when gauging the profitability of the treatment  In this particular case  the target market is gigantic  According to the National Parkinson Foundation  it is estimated that one million people in the United States and between four and six million people around the world suffer from Parkinson s disease  It is also estimated that of the millions of people suffering from the ailment  about 40  of them have Parkinson s Disease Psychosis  These people suffer with hallucinations  delusions  and a diminished quality of life  With that said  the new treatment offered by ACADIA is much needed in the treatment of Parkinson s disease and will likely lead to incredible amounts of sales 
All in all  ACAD is an incredible company that has created a much needed product  With a strong management team and a proven ability in medical innovation  I m expecting to see strong long run gains out of ACAD ",2016-03-30,Joshua Rodriguez,https://www.investing.com/analysis/acadia-pharmaceuticals-(acad)-stock:-heres-why-were-seeing-gains-200123367,200123367
129792,351307,ACAD,Obagi Medical Products Acquired  These Biotechs May Be Next,opinion,Yesterday  Obagi Medical Products  OMPI  was acquired by Valeant Pharmaceuticals  VRX  for  19 75 a share in an all cash deal  Last summer I covered in depth  acquisition rumors regarding Obagi  At the time  good private sources of mine confirmed that companies were interested in Obagi  I was informed by these sources that a well known large cosmetic company was very interested in acquiring the company for up to  22 50 a share  Based on the available information I had to work with at the time  I predicted that Obagi would see an acquisition soon  However  as I found out after there was no acquisition  the Obagi Board of Directors  BOD  was continuing to entrench themselves  refusing to open up the books to the potential suitor  Needless to say at the time  I was very frustrated with the events that were taking place with Obagi  as I strongly felt the BOD was neglecting its fiduciary duties  I was not alone in my frustrations  Enter in activist shareholder David Callan  who up to yesterday was a large block private shareholder of Obagi  I had the pleasure of meeting David both via a mutual acquaintance and speaking with him on the phone about the situation at Obagi  David was very upset with the company s BOD  and was prepared to take whatever legal steps he deemed necessary to see Obagi sold  With yesterday s acquisition now firmly in place  the Obagi acquisition story is for all intensive purposes  over  Because of the delay in the Obagi Acquisition  I have been hesitant to write on other companies I have heard through various sources have acquisition interest  However  in this article I will mention companies I believe will be acquired this year  based on my own speculation and some of the same chatter from the same sources who originally brought Obagi to my attention  Antares Pharma  ATRS  focuses on developing self administered parenteral pharmaceutical products  injectors   The company currently has an NDA pending with the FDA for OTREXUP  which is a self injector product for the delivery of methotrexate using Medi Jet technology for the treatment of rheumatoid arthritis  poly articular course juvenile rheumatoid arthritis  and psoriasis  An approval decision from the FDA is expected in October of this year  Many who follow me both on Seeking Alpha and twitter know that I used to own a good size block of shares in Antares  which I originally purchased in the summer of 2011  In December of the same year  I began to hear chatter than Pfizer  PFE  was interested in acquiring Antares  I did not think much of it at the time  until I saw a short time later that the company made a deal with Pfizer to partner on an unknown over the counter drug  I inquired back with my source at the time to ask him how solid the rumor was  and he felt it was  very solid   A few months later  the company  Jack Howarth  a former King Pfizer executive  as Vice President of Corporate Affairs  Additionally  I had a few conversations with Jack  where he said he owned over 400k shares of Antares  but was not  an official insider   I then speculated that Jack was appointed by Antares at the request of Pfizer  to in essence   bird dog  the company  Oct 2007 Alphapharma hires Howarth VP of Investor RelationsNov 2008 King acquires AlphapharmaJune 2009 King hires Howarth VP of Investor RelationsOct 2010 Pfizer acquires KingFeb 2011 Antares appoints Howarth VP of Corportate Affairs  Investor RelationsBased on Jack s above history and timeframe  and with Antares virtually assured approval of its current NDA in submission to the FDA  notwithstanding what sources have informed me in the past  I speculate that Antares will be acquired sometime this summer early fall  The main reason I believe Pfizer will acquire Antares is for its patent profile it holds in regards to biosimilars  Biosimilars biobetters  or follow on biologics  are terms used to describe officially approved subsequent versions of innovator biopharmaceutical products made by a different sponsor following patent and exclusivity expiry on the innovator product  biosimilars being  similar   biobetters being  better    Follow on manufacturers do not have access to the originator s molecular clone and original cell bank  the exact fermentation and purification process  or to the active drug substance  In other words  companies do not need to wait for patent expiration of a biologic to get its hands on the exact formulation  In fact  because biosimilars biobetters do not use the exact composition of the biologic drug it is  following after   it is not considered a  copy   therefore  it is not a generic  but a new composition capable of its own unique patent protection  Many large pharmas are gearing up for what I believe to be the wave of the future in biopharmas  biosimilars and biobetters  For those of you wonder how Pfizer might have got wind of Antares  patent profile  I would point out that Pfizer had a lawsuit engaged against Teva over epipen which was settled late last year  While I will not go into the exact details of this lawsuit  it s entirely possible that during the discovery phase of the litigation  Pfizer s lawyers might have seen something in Teva Antares patent profile that may have sparked Pfizer to approach Antares with an  unknown product  which subsequently led to a partnership deal with Antares for the product  A little more than 2 months afterwards  Antares  appointed  the former Pfizer King Corporate Affairs VP Jack Howarth to be its VP of Corporate Affairs    strange coincidence  or something more  As stated  I believe Antares will be acquired by Pfizer by the end of Summer  early Fall  for a price range between  6 50 and  9  and I plan to buy back in at some point before Summer of this year  AcelRx  ACRX  AcelRx focuses on therapies for the treatment of acute and breakthrough pain  The company s principal product candidate is ARX 01  a Sufentanil NanoTab PCA system  which has  successful Phase III  a 3rd Phase III data release is set for release in June of this year  clinical trials for acute post operative pain in patients in the hospital setting  AcelRx has basically up to this point been under my radar  That was until a source informed me that he was hearing strong back chatter about the company shopping itself around  along with institutions showing interest to purchase shares in the company  I decided to take a look at AcelRx to see if the rumor might hold any water  The  rumor  focuses on Adrian Adams who is Chairman of The Board  COB   just appointed recently in February  Adams is also the current CEO and President of Auxilium Pharmaceuticals  AUXL   joining that company in December  2011  Mr  Adam s pattern of joining companies and engaging in selling them is clear from what we read from Auxilium s website   Prior to joining Auxilium  Mr  Adams served as Chairman and Chief Executive Officer of Neurologix  a Company focused on development of multiple innovative gene therapy development programs  Before Neurologix  Mr  Adams served as President and Chief Executive Officer of Inspire Pharmaceuticals  Inc   where he oversaw the commercialization and development of prescription pharmaceutical products and led the company through a strategic acquisition by global pharmaceutical leader Merck   Co  MRK    Inc  in May 2011  Prior to Inspire  Mr  Adams served as President and Chief Executive Officer of Sepracor Inc  from December 2006 until February 2010  Under his leadership  Sepracor conducted multiple strategic corporate development activities  including the in licensing of seven products and out licensing deals with two major pharmaceutical companies  prior to its acquisition by Dainippon Sumitomo Pharma Co  Before Sepracor  Mr  Adams was President and Chief Executive Officer of Kos Pharmaceuticals  Inc  from 2002 until the acquisition of the company by Abbott Laboratories  ABT  in December 2006  During his tenure he led the transformation of Kos into a fully integrated and profitable pharmaceutical company with annual revenues approaching  1 billion  Mr  Adams graduated from the Royal Institute of Chemistry at Salford University in the U K   My source informs me that the company is being shopped around  and that there might be an interested party at this time  Considering Mr  Adams executive history from above  I give the rumor relayed to me a lot of credit  As mentioned  AcelRx has had two recent successful Phase III data releases  with a 3rd upcoming Phase III data release in June  which is expected to produce positive results  Because of this  the company has become considerably de risked  The post operative pain market in the United States  Europe  and Japan has been growing steadily over the last few years and is expected to reach  6 5 billion by 2018  Acelrx s Nanotab tech could potentially grab a significant piece of this market  especially in the hands of a larger pharma that could leverage it with substantial capital to introduce the product correctly to the market  With Obama care basically subsidizing healthcare as we know it  there will be more incentive for companies to produce new and innovative drugs and treatments  with a design to offer care to most people at an affordable price  With insurance companies receiving more government money subsidy under Obama care  there should be more patient coverage which would support and pay for new products and treatments as well  Nanotab  if introduced correctly to market  should be a product that benefits from Obama care  AcelRx s market cap of  106 44M is a dirt cheap for a company that is significantly de risked  I would expect an acquisition price at a minimum premium of 70  of its current market cap  With the first two companies  I have the same source that introduced me to Obagi s potential buy out  The following two companies have no solid rumors that I am aware of connected to them  but do have some buy out buzz associated with them  and make for attractive acquisitions  Sarepta  SRPT  Sarepta focuses on the discovery and development of RNA based therapeutics for the treatment of rare and infectious diseases  Its lead product candidate is eteplirsen  designed to treat Duchene muscular dystrophy  DMD   The drug is currently under review by the FDA for accelerated approval  and a decision is expected by the middle of this year  Valuation is the name of the game in speculative Biotech  and finding companies that have high upside as well as mitigated risk is not only a challenge for investors  but big pharma as well  One such company is Sarepta  and many reading this article are undoubtedly familiar with its lead drug eteplirsen and its clinical success treating DMD  The drug alone makes Sarepta a very attractive candidate to be bought out  Recent struggles by Glaxo Smith Kline s  GSK  drug drisapersen highlight both the desire and difficulty that big pharma is having trying to enter this space  One additional caveat to consider is that most Americans have some knowledge of DMD as a disease  if treated  would garner a tremendous amount of positive Press coverage  Companies like Pfizer and Bristol Meyers Squib  BMY  could see eteplirsen as a way to bolster their reputations as well as their bottom line  Another reason that I think an acquisition bid could be in order for Sarepta is because when a company has tremendous stock appreciation in a short amount of time or a dramatically positive event  sometimes management does not have experience in executing the  next step   Sarepta s management was previously operating as a developmental company versus one ready to go to the next level  At minimum  bringing in some high profile resume s or the completion of a partnership would seem reasonable  if not a full buyout  Acadia Pharmaceuticals  ACAD  Acadia is a developmental biopharma that focuses on the development of drugs for central nervous system disorders  Acadia shares have been on the rise from the  1 50 range to a close of  6 65  on 3 20 13   Acadia has drug candidates for the treatment of Parkinson s disease  Alzheimers  schizophrenia  and glaucoma  These conditions are all connected with large market size and present significant opportunities for big pharma  Acadia has shown ability in the past to partner or collaborate with larger companies such as Biovail  Allergan  and Meija Seika Kaisha  LTD  It is not being overly presumptive to assume that big pharma would have interest in Acadia for its lead drug pimavanserin  which possess potential for massive revenue in multiple applications  On Tuesday of this week  Acadia received new coverage from Jefferies who initiated the company as a  Buy  with a  13 price target  The firm says notes that pimavanserin is a drug for which there is currently no FDA approved counterpart  Jefferies also commented on Acadia being a highly attractive licensing acquisition target for big pharma companies  I will be interested in seeing what happens this year regarding the companies listed  My source s  ultimately proved to be correct regarding Obagi  and I believe he they will be right about Antares and AcelRx  Certainly  the condition of The United States economy along with anticipated health care measures should have an effect on big pharma s appetite for acquisitions    something we all should watch closely  Disclosure  I am long ACRX ,2013-03-21,Scott Matusow,"https://www.investing.com/analysis/obagi-medical-products-acquired,-these-biotechs-may-be-next-159924",159924
129793,351308,ACAD,Stocks Give Back Wednesday s Gains,opinion,The U S  stock market gave back its gain from Wednesday as the ongoing bank crisis in Cyprus undermines investor confidence   The major averages in the United States tumbled and stocks were mostly lower across the world  Overall  however  the market remains on solid footing and economic reports continue to exceed economists  expectations   Major Averages The Dow Jones Industrial Average lost around 90 points  or 0 62 percent  to 14 421   The S P 500 fell around 13 points  or 0 83 percent  to close at 1 546   The Nasdaq Composite lost 32 points  or 0 97 percent  to 3 223   Jobless Claims Initial jobless claims rose slightly for the week ending March 9 to 336 000 from an upwardly revised 334 000  This was below the consensus which expected a rise to 345 000   Continuing jobless claims also rose slightly in the week ending March 9 to 3 053 million from 3 048 million  This was below consensus expectations which expected the continuing claims rate to rise to 3 065 million   Existing Home Sales Existing home sales rose 0 8 percent in February to 4 98 million from 4 94 million in the prior month  This barely missed consensus estimates which called for existing home sales to rise to 5 00 million   Philadelphia Fed Data from the Philadelphia Fed s Business Outlook index showed a strong uptick in March  The index rose from  12 5 in February to 2 0 in March  which was ahead of consensus expectations that expected a rise to  3 0   Leading Indicators The Conference Board s Index of Leading Indicators registered a gain of 0 5 percent for February after rising 0 5 percent in January  This was in line with consensus expectations   Commodities Crude oil fell along with the stock market on Thursday  Late in the day  NYMEX crude futures were down 1 21 percent to  92 37  Brent futures had lost 1 33 percent and were trading at  107 26  Natural gas had lost  0 03  or 0 83 percent  to  3 93 late in the day on Thursday   Precious metals rose on the session as stocks fell  COMEX gold futures were last up 0 41 percent to  1 614 10 and silver had climbed 1 28 percent to  29 19 near the close of equity trading  Copper futures fell 0 20 percent on the session   Grain prices were higher on the session with the exception of wheat and oats  both of which lost around 1 percent  Corn was last trading up 0 07 percent on the day  In soft commodities  orange juice futures added around 1 80 percent and cotton lost 1 percent   Bonds Near the close of equity trading  the iShares Barclays 20  Year Treasury Bond ETF  TLT  had jumped 0 84 percent to  117 07  The rise in bond prices pushed yields lower on Thursday   While the yield on the 2 Year Note was unchanged at 0 25 percent  the yield on the 5 Year Note fell one basis point to 0 80 percent  The 10 Year Note yield fell three basis points to 1 93 percent and the 30 Year Bond yield was down five basis points to 3 15 percent   Currencies The U S  dollar was largely unchanged on the session  Near the close of equity trading  the PowerShares DB US Dollar Index Bullish ETF  UUP   which tracks the performance of the greenback versus a basket of foreign currencies  was down 0 04 percent to  22 54   The closely watched EUR USD pair was last down around 0 16 percent to  1 2915  Other significant movers included the USD JPY  which fell 1 22 percent  and the AUD USD  which rose 0 74 percent   Volatility and Volume The VIX moved up on Thursday as the markets fell  The widely watched CBOE Volatility Index jumped a little less than 10 percent to 13 90   Volume was below average even as the major averages fell  Around 112 million SPDR S P 500 ETF  SPY  shares traded hands compared to a 3 month daily average of 130 million   Stock Movers Enterprise software giant Oracle  ORCL  fell almost 10 percent after the company missed Q3 earnings expectations   After days of sharp gains  shares of Fannie Mae  FNMA  and Freddie Mac  FMCC  pulled back significantly  Near the close  FNMA was down 24 percent while FMCC had lost almost 26 percent   Shares of ACADIA Pharmaceuticals  ACAD  were up around 24 percent heading into the close after the company reported data from its late stage Parkinson s disease psychosis study with Pimavanserin   Perry Ellis  PERY  climbed almost 7 percent after the company released bullish fourth quarter financial results   Shares of apparel retailer Guess   GES  lost around 7 percent after the company s fiscal fourth quarter earnings results   Affymax  AFFY  was trading up around 16 percent heading into the closing bell  The micro cap stock is down better than 92 percent over the last three months after its only marketed product was recalled   Jabil Circuit  JBL  lost more than 4 percent after releasing its second quarter earnings results and providing weak Q3 guidance BY Scott Rubin,2013-03-22,Benzinga ,https://www.investing.com/analysis/stocks-give-back-wednesday's-gains-160025,160025
129794,351309,ACAD,3 Small Cap Biopharmas Primed To Move Much Higher Now,opinion,With the current record market run  small cap biopharma stocks have kept pace and continue to trend higher  being one of the best sectors for both trading and investing over the past year  With   2012 showed the most new approvals since 1996  In this article  I list three companies I believe will exceed this current trend moving forward  Aveo Pharma  AVEO  A Food and Drug Administration  FDA  Advisory committee will convene on May 2nd to vote for or against recommending tivozanib for approval  Tivozanib is a low molecular weight inhibitor of the VEGF receptor designed for the treatment of metastatic renal cell carcinoma  RCC   which is more widely known as kidney cancer  In January of this year  the company reported positive  from a study of 517 patients with RCC  The study compared tivozanib to sorafenib  which is the current front line treatment for RCC  Sorafenib is marketed by Onyx Pharmaceuticals  ONXX  under the trade name of Nexavar    global Nexavar net sales  in 2011  Perhaps the most important positive quality of tivozanib is the fact that patients tolerated the drug very well  Dose reductions of the drugs compared were 11 6  with tivozanib versus 42 8  with sorafenib  PThis is a clear indicator that patients tolerated tivozanib much better than sorafenib  Patient tolerability is perhaps the most important deciding factor for physicians to prescribe a drug other than efficacy  If a patient discontinues use of a drug  any possible benefit from the drug is obviously lost  I am very confident that the adcomm will recommend Tivozanib for approval  but yet the stock has a healthy amount of short interest in it  Simply stated  the bears have it wrong here with tivozanib and are misunderstanding the lack of impact the overall survival  OS  numbers will have on the FDA s decision to approve the drug  First off  the OS for tivozanib was 77  versus 81  for sorfenib  which is statistically about the same  The Phase III head to head study was based on one way crossover to the experimental therapy after disease progression in the control arm  According to   Crossover studies are a type of clinical trial in which the study participants receive each treatment in a random order  With this type of study  every patient serves as his or her own control  Crossover studies are often used when researchers feel it would be difficult to recruit participants willing to risk going without a promising new treatment  A one way cross over study is a trial design that is used in cases where two treatments are administered successively in the same group of trial subjects  The company  tivozanib because more than 60  of the patients randomized to the Nexavar arm  crossed over  to receive tivozanib or some other therapy upon tumor progression  These Nexavar crossover patients might be surviving at a higher rate because they benefited from receiving treatments with two active kidney cancer drugs  Furthermore  many  test subjects  were from Central and Eastern Europe  and access to good treatment options for RCC are limited in this part of the world  In North America and Western Europe where better treatment options exist  longer OS was observed  It s worth noting that there are nine analysts covering Aveo who have an  of  11 30  If tivozanib is approved by the FDA  my one year price target opinion is  15  based on its current price of  7 55  representing a market cap of  328 68M  Potentially  tivozanib could rake in yearly average sales of near  1B when considering sorfenib generated over  1B in 2011  After reviewing the Aveo s website  the company seems to be highly confident that tivozanib will be approved by the FDA  and are taking the necessary prudent steps to ensure the product garners success  Under   clicking  view all open job positions  shows three pages of new positions  a majority of which are  Oncology Sales Specialist  positions and located all across the United States  Aveo is clearly confident tivozanib will be approved  as am I  In addition  the  notes a  4 6 million increase in salaries  benefits  and other hiring costs in 2012 due to an overall increase in personnel in preparation for the potential launch of tivozanib  This was while completing a restructuring in October which included laying off forty eight people  With the company claiming it still had an  overall increase in personnel   clearly a new type of employee had to be hired  A good portion of this includes the new sales force the company is still actively recruiting along with other people experienced in new product roll outs  Aveo also has more drugs in its clinical pipeline  and an approval of tivozanib would give this pipeline more validity  which should equate to higher investor speculation  Considering the near term large catalyst event of an Acomm combined with the factors I mention  Aveo has the potential to double from its current price in the next year or so  Acadia  ACAD  Acadia Pharmaceuticals has been surging higher lately on huge volume relative to what is typical for the company  I wrote about Acadia  talking about its takeover potential as well as its amazing run from  1 50 to  6 50 share  Incredibly  as of close of business just four business days later  3 26 13   the shares were trading at  8 23  Acadia is a developmental biopharma that focuses on the development of drugs for central nervous system disorders  The company has drug candidates for the treatment of Parkinson s disease  Alzheimer s  schizophrenia  and glaucoma  These conditions are all connected with large market size and present significant opportunities for big pharma  Acadia appears to be drawing interest from big pharma because of its lead drug pimavanserin  which possesses potential for massive revenue in multiple applications  The surge in the past week can be mainly attributed to the  positive Phase III 020 results for pimavanserin in patients with Parkinson s disease psychosis  This was announced at the Emerging Science session of the 65th American Academy of Neurology  AAN  Annual Meeting  The analysis of the full data set from the Phase III  020 Study showed Meeting  The analysis of the full data set from the Phase III  020 study showed robust and consistent efficacy of pimavanserin across a wide array of study measures and confirmed the positive top line results previously reported   The significant and consistent results observed across measures in the Phase III  020 study are impressive and potentially very encouraging for Parkinson s patients who suffer from the psychosis frequently associated with this disease   said the presenter Dr  Jeffrey Cummings  M D   Sc D   Director of Cleveland Clinic Lou Ruvo Center for Brain Health   Importantly  regardless of whether assessments were performed by independent blinded raters  site investigators  or caregivers  clear benefits were observed and clinical measures were well aligned  The results of this study suggest that a selective  non dopaminergic based therapy has the potential to transform the standard of care by providing an effective  safe and well tolerated treatment for patients suffering from this large unmet medical need  As I referred to in my prior article  Acadia recently received  from Jefferies who initiated the company as a  Buy  with a  13 price target  The firm notes that pimavanserin is a drug for which there is currently no FDA approved counterpart  Jefferies also commented on Acadia being a highly attractive licensing acquisition target for big pharma companies  As an added bonus for the company  it has  108 million in cash and short term investments plus no debt as of 12 31 2012  This gives the company extra leverage in any possible partnership or acquisition talks  Also with this cash position  the company is far more de risked than other developmental biopharmas  Acadia likely has a lot of gas left in the tank to drive the stock price higher in the short term  Sarepta  SRPT  The buzz on Sarepta continues as the stock seems to climb on a daily basis  Sarepta is working on what many consider to be a huge break through with its clinical drug eteplirsen  an antisense PMO based therapeutic for the treatment of individuals with Duchenne Muscular Dystrophy  DMD   A big reason the stock continues to climb is because epteplirsen is currently being evaluated for accelerated approval  If the FDA decides to grant accelerated approval  DMD patients will finally have a drug that can help them live better lives  and owners of the stock will certainly see better equity returns The worst part about DMD is that it only affects children  affecting roughly around 1 in 3 600 boys  Over the years  many of us have watched the Jerry Lewis telethons on television  To see children suffer from various forms of Muscular Dystophy is heart wrenching  Philanthropist investors are also watching and Sarepta is the kind of company that attracts them in droves  which subsequently drives the stock price higher  Some might argue that accelerated approval would only temporarily drive the stock price much higher  only to see the stock price retrace near to where it started  Regardless  I would like to see an acceptance of the drug now so that children who need eteplirsen can receive it  Because of the current political scope  good efficacy  and positive safety data  eteplirsen should see an accelerated approval  There is no question in my mind that once the drug gains early approval  the stock will gap up at least 50  from its current levels  and likely will not hold that gap in the short term  The question for those currently holding the stock is whether to wear a trader s hat and take the profit  or put on an investor s hat and simply hold the stock for the long term  If you are a philantrophist  you are likely well off investing in Sarepta to be part of something potentially life changing  However  if you are a trader  your main concern should be profits   period  Sarepta is a story stock  and story stocks can either make you a ton of money  or leave you holding a massive bag  Dendreon  DNDN  stock holders unfortunately became familiar with this  Dendreon saw an epic stock price run on speculation for its prostate cancer vaccine provenge  The stock ran from around  5 to  57 in a short period of time  only to come crashing back down when people realized that  the provenge story  did not measure up to the actual reality of the drug  Insurance companies were not informed of provenge s pricing  and subsequently  many of them did not support the drug  To this day  Dendreon s stock price is nowhere near the highs it saw 3 years ago  and company management is still trying to get its act together  Sarepta s story is different than Dendreon s  Eteplirsen is potentially one of the biggest breakthroughs in a generation  and again  DMD affects young children who have a whole life ahead of them  Let s hope for their sake that eteplirsen gains accelerated approval    it s good for everyone  2013 is sure to either meet or exceed 2012 s drug approval rate  and both traders and investors who pick the right companies should enjoy some serious monetary gains  Disclosure  I am long AVEO  Disclaimer  This article is intended for informational and entertainment use only  and should not be construed as professional investment advice  They are my opinions only  Trading stocks is risky    always be sure to know and understand your risk tolerance  You can incur substantial financial losses in any trade or investment  Always do your own due diligence before buying and selling any stock  and or consult with a licensed financial adviser ,2013-03-27,Scott Matusow,https://www.investing.com/analysis/3-small-cap-biopharmas-primed-to-move-much-higher-now-160612,160612
129795,351310,ACAD,Thursday s BioPharma Movers,opinion,Today  I have compiled a small list of biopharmas I feel offer strong upside potential in short and midterm  Some have event catalysts quickly approaching  while others are strong speculation investments  As we draw closer to  sell in May and go away   the market will become more stock picker orientated  Making the right trades and investments during this period will be crucial for portfolio appreciation Aveo Pharma  AVEO A Food and Drug Administration  FDA  Advisory committee will convene on May 2nd to vote for or against recommending tivozanib for approval  Tivozanib is a low molecular weight inhibitor of the VEGF receptor designed for the treatment of metastatic renal cell carcinoma     which is more widely known as kidney cancer In January of this year  the company reported positive  from a study of 517 patients with RCC  The study compared tivozanib to sorafenib  which is the current front line treatment for RCC  Sorafenib is marketed by Onyx Pharmaceuticals  ONXX  under the trade name of Nexavar    global Nexavar net sales topped over  1billion in 2011 Tivozanib should receive a positive recommendation from the FDA Adcomm  so I would expect to see a stock price of  8 50 or higher as we get closer to the Adcomm date in May  AVEO is also a strong acquisition target for a larger pharma as tivozanib might eventually be approved to treat such diseases as triple negative breast cancer and colorectal cancer Sarepta Therapeutics  SRPT On Monday April 15th  the FDA asked Sarepta to provide additional information on the drug  eteplirsen  to consider early approval  Eteplirsen is an antisense PMO based therapeutic for the treatment of individuals with Duchenne Muscular Dystrophy    After shares initially gaped up on the news  they slid back down to the mid  30 dollar range  Many investors took this news as a negative  I take the news as actually positive  If the FDA had no intention to grant an early approval for the drug  the organization would not be asking for more information from the company  To date  every study shows that the drug is successful  and being that DMD is so debilitating  and effects only children  it s a good bet the FDA will in fact grant early approval  By asking for more information from the company  the FDA wants to be sure they are doing the right thing in granting early approval  in my opinion There is no question in my mind that once the drug gains early approval  the stock will gap up at least 50  from its current levels  so Sarepta at its current price range offering a nice entry point for both investors and traders  This delay in early approval should allow for a longer period of slow price appreciation  which I believe offers a great midterm investment opportunity ACADIA Pharmaceuticals  ACAD On Thursday April 11th  ACADIA  that the FDA has agreed to allow the company to file a New Drug Application  NDA  for the treatment of Parkinson s disease psychosis     The FDA agreed that the data from the pivotal Phase III  020 study  together with supportive data from other studies with pimavanserin  were sufficient to support the NDA filing On the news  the stock gaped up from a prior session s close of  7 97 to close the next trading session at  13 10  Since then  the stock has pulled back a bit  currently trading around  12 a share PDP is a large unmet need market  and could bring the company billions in revenues  which would support a much higher valuation from the current levels  It is also possible the FDA will allow an expediated review based on the fact that there are currently no treatments on the market for PDP  A stock price north of  20 a share is possible this year if everything pans out for the company  and I think it will Antares Pharma  ATRS I continue to maintain that Pfizer  PFE  will acquire Antares sometime before the end of this year Pfizer and Antares already have a working relationship in the form of a  secret deal  that I speculate is an Advil gel based formulation  Company CEO Paul Wotton mentioned last year that Pfizer came to Antares to inquire about one of Antares products  but company Vice President Jack Howarth said that Antares sought out Pfizer for the same deal  Someone is obviously  mistaken  here  I first heard the buyout rumors surrounding Antares in December of 2011  well before the company  appointed  Jack Howarth as a Vice President  Jack is not an official  insider  at Antares  yet has informed some Antares investors that he holds over 400 000 shares of the company  So who does Jack work for  Jack s last official job was with King Pharma  a company Pfizer acquired a few years ago The main reason I believe Pfizer will acquire Antares is for its patent profile it holds in regards to biosimilars Biosimilars biobetters  or follow on biologics  are terms used to describe officially approved subsequent versions of innovator biopharmaceutical products made by a different sponsor following patent and exclusivity expiry on the innovator product  biosimilars being  similar   biobetters being  better   Follow on manufacturers do not have access to the originator s molecular clone and original cell bank  the exact fermentation and purification process  or to the active drug substance In other words  companies do not need to wait for patent expiration of a biologic to get its hands on the formulation  In fact  because biosimilars biobetters do not use the exact composition of the biologic drug it is  following after   it is not considered a  copy   therefore  it is not a generic  but a new composition capable of its own unique patent protection  Many large pharmas are gearing up for what I believe to be the wave of the future in biopharmas    biosimilars and biobetters Antares has been locking down patents for the past few years with biosimilars  and many speculate the company has a raftload of these patents secured  Since biosimilars are likely to be the future of biopharma  Antares has placed itself as a strong acquisition target  and as mentioned  I believe Pfizer will be the buyer Also  starting in June  there will be warrant expiration occuring  Last year I predicted that Antares would see a pop in its stock price to over  5 a share when the stock was selling for around  3  I based my prediction primarily on the fact of warrant expiration at the time I am predicting a similar occurrence this year  and expect a price approaching  5 by the middle of this summer  Afterwards  I believe the company will be acquired for a price between  7 to  9 a share  Therefore  I have taken a position in Antares for a midterm investment Disclosure  I am long ATRS  AVEO  Disclaimer  This article is intended for informational and entertainment use only  and should not be construed as professional investment advice  They are my opinions only  Trading stocks is risky    always be sure to know and understand your risk tolerance  You can incur substantial financial losses in any trade or investment  Always do your own due diligence before buying and selling any stock  and or consult with a licensed financial adviser ,2013-04-17,Scott Matusow,https://www.investing.com/analysis/thursday's-biopharma-movers-163385,163385
129820,351335,ACAD,Investors Note Acadia Pharmaceuticals  Late Stage Progress,opinion,Acadia Pharmaceuticals  NASDAQ  ACAD  has pulled back only slightly after pushing new highs on the prospects of its flagship Parkinson s Disease Psychosis treatment  Pimavanserin   which is now undergoing phase III trials  The development of pimvanserin also includes a program for schizophrenia and Alzheimer s disease  which have progressed into phase II trials Though our knowledge of structure and location of neurotransmitter receptors is incomplete  Acadia has developed a molecule that is able to block the activity of receptors that are suspected links to certain psychiatric disorders  The market potential for the treatment of these disorders  on paper  looks enormous  Take Abilify  Aripiprazole   which now generates around  5 5 billion in annual revenue for Bristol Myers Squibb  NYSE  BMY  as a treatment for schizophrenia  and as a secondary medication for more common disorders like manic depression  Pimavanserin is an inhibitor of a certain class of serotonin receptors  which means that it inhibits the normal biochemical activity of serotonin in certain areas   and may have diverse applications like many of the blockbuster drugs that are generating billions every year  Pimavanserin was specifically tailored to be a potent inhibitor of serotonin receptor 5 HT2A  which is a specific receptor in the brain that is thought to play a vital role in patients that experience psychosis  The 5 HT2A receptor was originally known for being the target receptor of hallucinogens like LSD  but contemporary studies have noticed biochemical downregulation of 5 HT2A under the effects of classical antipsychotic medications  In simpler terms  we saw traditional antipsychotics inhibit the activity of 5 HT2A  which leads us to believe that direct inhibition of 5 HT2A might work as an unconventional antipsychotic treatment At first glance  Pimavanserin now sounds incredible to investors  because an older  which implies  inferior  in some cases  compound like Aripiprazole has the capacity to generate  5 5 billion a year  ACADIA s market capitalization  being about  140 million  would probably be undervalued if Pimavanserin could manage just 3 or 4  of Abilify s sales  Unfortunately  looking at past examples  you can see that even small percentages of big pharma s market share in anti psychotics are very hard to grab  This is also assuming that Pimavanserin  or any other competing drug  would be approved by the FDA in the first place Even though the antipsychotic drug market has ballooned to an astounding  20  billion in annual sales this year  the presence of the big pharmaceutical companies  with their enormous marketing budgets  can prevent most competition from getting any profit whatsoever in the development of antipsychotics  Taking this obstacle into account  we are now looking at pimavanserin with healthy skepticism To add more perspective  we go back to pimavanserin s biggest blunder In 2009  pimavanserin failed to meet the primary endpoint in its first pivotal phase III trials which immediately sent shares of ACAD into a violent selloff  The primary endpoint for the study was a statistically significant change in the mean of SAPS  Scale for the Assessment of Positive Symptoms  scores from baseline  What wasn t really conveyed in the headline was the fact that the 40 mg pimavanserin arm  the group with the highest dose  did outperform on the SAPS  but it wasn t by enough The new phase III trial has been tweaked to highlight differences between the placebo and pimavanserin arms  and should address other issues that may have tampered with the trial s outcome  We are obviously expecting pimavanserin to meet its primary endpoint this time  In addition to that  we are going to see the conclusion of pimavanserin s phase III safety study in December 2012  which paves the way for an NDA submission in 2013 At this point  the big question we want to ask is whether or not pimavanserin is going to sell in the even that it does hit the market  Is there another  inverse 5 HT2A agonist  that would directly threaten pimavanserin I did find a few molecules that are blocking 5 HT2A receptor  but there aren t any other marketed  or developing  inverse agonists for 5 HT2a receptors other than an interesting molecule called Nelotanserin  which was a failed insomnia drug that was abandoned in 2008 by Arena Pharmaceuticals  NASDAQ  ARNA   and another failed sleeping pill called Ciltyri  eplivanserin  which was started and abandoned by Sanofi Aventis  NYSE  SNY   Pimavanserin  as an inverse agonist  which does a little more than inhibit its targeted receptor and actually triggers an  opposite response   could have some niche potential when it has to compete for the treatment of schizophrenia and Alzheimer s disease psychosis The most important aspect of pimavanserin s appeal  by far  is its potential as a treatment for Parkinson s disease psychosis  PDP   The Parkinson s Disease Foundation provides some eye popping incidence statistics for Parkinson s Disease  with estimates of 7 10 million affected worldwide and about 60 000 new diagnoses each year in the United States alone  If we take a very conservative chunk  maybe 500 000  and multiply by the NIH s 40  estimate of Parkinson s patients affected by PDP  instead of Acadia s looser 60  estimate   we have 200 000 To account for off label substitutes and untreated people  we ll cut that population  If the average Parkinson s patient spends about  2 500 a year on medication  we are looking at a fair  conservative estimate  250 million year market for medications  If pimavanserin can manage an FDA approval  that implies at least  5 share for ACAD in a rational market  After approval  if pimayanserin had the chance to saturate the broader PDP market while taking market share from off label usage of other antipsychotics  we d see plenty of room for additional upside ,2012-10-02,Myriad Equity,https://www.investing.com/analysis/investors-note-acadia-pharmaceuticals'-late-stage-progress-138421,138421
129821,351336,ACAD,ACADIA Investors Await Clinical Trial Results For Pimavanserin,opinion,Shares of Acadia Pharmaceuticals  ACAD  have recently given back a lot of the gains that were made earlier in the year   especially those from September  to bring total YTD gains to 99  With the gains made this year  ACAD has reached a market capitalization of  122 million  This jump in the valuation of the company is primarily based on the implied market potential of its flagship compound Pimavanserin  which is finishing phase III trials for the treatment of Parkinson s Disease Psychosis  PDP   and phase II trials for schizophrenia and Alzheimer s Disease Psychosis  ADP  Acadia has two other compounds in the clnical development stage called Adrenergic and Muscarinic  for the treatment of chronic pain and glaucoma  respectively  but since collaborator Allergan has the commercialization rights to these  Acadia is limited to milestone payments and royalty fees when if these drugs reach the market Pimavanserin works as an inhibitor of a specific serotonin receptor known as 5 HT2A  which has been associated with the altered brain chemistry in patients experiencing psychosis in certain studies  Contemporary studies have also noticed suppression of 5 HT2A related activity with traditional antipsychotic medications  which implies that there is an obvious link between this specific serotonin receptor and psychosis  This is why Acadia sees potential for Pimavanserin in a variety of patients that experience psychosis  There are no other 5 HT2A inhibitors being marketed or in development at this point  although there are failed compounds that targeted 5 HT2A A lot of investors were discouraged at the results of Pimavanserin after it failed its first phase III trial in 2009 for Parkinson s Disease Psychosis  although there seems to be a renewed hope that the upcoming phase III results  which are due before the end of the month  will finally prove the compound s efficacy and allow the drug to increase significantly in value The headline results from 2009 implied that pimavanserin s Parkinson s Disease Psychosis program was in big trouble  which was reflected adequately in the enormous selloff that followed the initial results of the trial   but there is some hope that the upcoming trial results will have a different outcome  The original results  from 2009  did imply that the 40 mg pimavanserin arm did outperform the placebo arm by the efficacy measure that was used   the Scale for the Assessment of Positive Symptoms  SAPS   but the improvement wasn t quite good enough to achieve a statistically significant p value  While the trial did technically fail  the results weren t completely negative or useless  According to Acadia s statements  the company also adjusted their recent phase III pimavanserin PDP trial to give the drug a better chance at achieving statistically significant improvement versus the placebo arm  Overall we believe that the optimized  020 study design has enabled sites to enroll patients with the desired clinical profile and should significantly improve the likelihood of achieving a successful outcome  Roger Mills  Acadia Pharmaceuticals Q3 Earnings Conference CallThe phase III results that are due before the end of this month  November  will be from something that the company refers to as the   020 study   although there are two others that will prove vital data towards pimavanserin s eventual NDA submission  Acadia is planning to put pimavanserin through a trial they re referring to as the   021  study  which will use results from the  020 study to optimize the trial design and find the best way to provide favorable results for pimavanserin s efficacy profile in PDP treatment  Another trial  known as the  015 study  will continue to build the safety profile of pimavanserin as it progresses towards an NDA submission for PDP Although investors may still worry about the old phase III results that the company presented in 2009  an event that Acadia still hasn t fully recovered from   there is enormous potential given that the drug can achieve FDA approval  With no approved treatments available for an estimated pool of 150 000 400 000 PDP patients  not including the rests of the  1 million Americans that have Parkinson s disease   there is enormous market potential for this drug given the huge number of people that could benefit from an effective treatment  Even more exciting is the unmet demand in Alzheimer s Disease  the most common neurodegenerative disease in the population   If Pimavanserin can demonstrate efficacy in PDP treatment in the upcoming results from the  020 trial  long term investors that haven t been following ACAD should give some attention to the stock for its appreciation potential as we wait for an NDA submission and potential FDA approval ,2012-11-27,Myriad Equity,https://www.investing.com/analysis/acadia-investors-await-clinical-trial-results-for-pimavanserin-145071,145071
129822,351337,ACAD,Acadia Rockets Into The Stratosphere On Clinical Trial Data,opinion,Yesterday morning we finally got to see the much anticipated data for ACADIA Pharmaceuticals   ACAD  phase III trial  which tested its flagship drug pimavanserin in the treatment of Parkinson s Disease Psychosis   Reacting to the news  ACAD stock rallied into the stratosphere and tacked on an incredible 136  by the closing bell   bringing the stock from  2 28 share to  5 43 share in a single trading session  This was a welcome relief for long term ACAD investors  who may have had positions decimated back in 2009 when pimavanserin failed its first phase III trial in the treatment of Parkinson s Disease Psychosis  ACAD stock briefly touched the speculative highs made back in 2009  but profit taking did cut down some of the enormous gains made in the stock yesterday   Pimavanserin s clinical trial met its primary endpoint with a large degree of confidence  p 0 001   The primary endpoint was based on improvement in the 9 item SAPS PD scale  a  Scale for the Assessment of Positive Symptoms  index   which is the same measurement scale that was used for pimavanserin in its failed trial from 2009  The secondary endpoint  which was based on measurements of motor function in Parkinson s patients that received pimavanserin  was also met with high levels of confidence  The study used the Unified Parkinson s Disease Rating Scale  UPDRS  to measure the motoric tolerability in PDP patients on pimavanserin  which showed that the drug was able to maintain stability in motor function relative to placebo   This endpoint was also strengthened with results gathered using something known as the CGI I scale  the Clinical Global Impression Improvement scale  which observes the overall illness of the patients  and implies some extra evidence of pimavanserin s overall safety efficacy profile   ACADIA stated that there were issues with the structure of the old phase III trial that could be addressed in the next trial  and it seems that they were right   The results were very good  and showed that pimavanserin is probably going to be the first true Parkinson s Disease Psychosis treatment  This will address the substantial unmet demand for a significant fraction of the  1 million that are affected by Parkinson s Disease  and also provides some hope for the drug in other indications as well  Pimavanserin is also being developed for the treatment of psychosis in Alzheimer s Disease  as well as schizophrenia   Pimavanserin s mechanism of action  MoA  is based on a specific serotonin receptor known as 5 HT2A which is suspected to play a vital component in all people that experience symptoms of psychosis  We now know that the drug works quite well for Parkinson s Disease Psychosis  If 5 HT2A is an equally good therapeutic target in Alzheimer s Disease Psychosis and Schizophrenia  we may see some stellar results from upcoming clinical trial for pimavanserin in the treatment of those diseases as well   The  020 study  the phase III trial for pimavanserin in PDP that released data yesterday  is a precursor to another phase III trial that Acadia plans to conduct to further build pimavanserin s efficacy profile  which will be referred to as the   021 study   and an additional safety study that the company refers to as the   015 study   These studies will be performed to solidify the chances of an FDA approval when the time comes for pimavanserin s first NDA submission  Although this means that investors will have to wait longer for pimavanserin s potential FDA approval  additional phase III trials with statistically significant data significantly improve the drug s chances since they establish a more elaborate efficacy and or safety profile for a drug   With its recent jump  Acadia has reached a market capitalization of  307 million  The market should slowly change its perspective on Acadia due to the recent results which prove that the drug actually works too  It s no longer a matter of whether or not pimavanserin works or not  but a matter of how valuable the Parkinson s Disease Psychosis market is  There is also a lot of potential for schizophrenia  and even greater potential in Alzheimer s Disease Psychosis  of course  Acadia investors who are in for the long haul realize this  and will probably hold on in anticipation of a higher valuation of the company  Traders  on the other hand  have a lot of incentive to take their outsized profits from yesterday s trading in the pursuit of other biotech catalysts on the horizon  While ACAD stock could see some immediate downward pressure due to this  the intrinsic value that was added by pimavanserin s latest clinical trial data remains ,2012-11-29,Myriad Equity,https://www.investing.com/analysis/acadia-rockets-into-the-stratosphere-on-clinical-trial-data-145407,145407
